Investigating the gasket function and perforin secretion of the natural killer cell immune synapse by Cartwright, Adam
 
 
 1 
 
 
Investigating the Gasket Function and 
Perforin Secretion of the Natural Killer 
Cell Immune Synapse 
 
Adam Cartwright 
 
 
Imperial College London 
Department of Cell and Molecular Biology 
Supervised by Professor Daniel M. Davis 
 
Submitted for the Degree of Doctor of Philosophy 
2014
 
 
 2 
Abstract 
 
 3 
Abstract 
 
Natural Killer (NK) cells interact with other cells through a structured interface, the 
immune synapse (IS). A balance of signals controls NK cell activity through ligation of 
activating and inhibitory receptors. If signaling favours activation, NK cells mediate 
the directed secretion of cytotoxic mediators, such as perforin (PFN). To test whether 
the IS also functions as a gasket to extracellular molecules, fluorescently labeled 
nanometer-scale dextrans of varying sizes were co-incubated with effector-target 
cell-cell conjugates. Quantitative fluorescence microscopy of synapses revealed that 
dextrans with hydrodynamic diameters ≥32 nm were excluded from activating 
synapses, whilst smaller dextrans could enter. Size-dependent exclusion required an 
intact filamentous actin scaffold, but not continuous reorganisation following synapse 
formation. Time-lapse microscopy further revealed that the synapse assembles in a 
zipper-like manner, clearing larger dextran from the synapse. In addition, monoclonal 
antibodies and low-density lipoproteins were also excluded from the IS, whereas 
smaller domain antibodies could penetrate. NK cells can lyse more than one target in 
series. Whilst it is known that, among other proteins, PFN is secreted to lyse 
diseased cells, the amount of PFN secreted by NK cells is currently unknown. To 
quantify PFN release following stimulation through NKG2D or CD16, NK cells were 
plated on protein-coated surfaces that could capture PFN. Quantification using 
fluorescence microscopy revealed that PFN secretion was analogue, varying with 
increased ligand density. Simulating serial killing, repeated stimulation decreased the 
amount of PFN secreted with sequential activation. Unexpectedly, CD16 stimulation 
following serial NKG2D ligation recovered this decrease in secretion, however a 
similar recovery was not seen under reciprocal conditions. These data show that the 
activating IS clears and excludes extracellular molecules, including antibodies, in a 
size-dependent manner. Further, NK cell PFN secretion is an analogue response that 
varies with both ligand density and the receptors ligated in series. 
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Chapter 1 – Introduction 
 
1.1 Natural Killer cells 
 
Human Natural Killer (NK) cells are large granular lymphocytes (1, 2), comprising 
between 2 – 18% of total peripheral blood cells and are phenotypically defined as 
CD56+, NKp46+ and CD3- (3-5). Considered part of the innate immune system, NK 
cells are activated via germ-line encoded receptors, exerting cytotoxicity without prior 
priming, and secrete cytokines that activate and stimulate other immune cells (6-8). 
NK cells, and indeed a variety of other immune cells, interact with target cells through 
an organised, structured interface termed the immune synapse (IS) (9, 10). Through 
these cell-cell contacts, NK cells can discriminate between healthy or diseased cells 
via a balance of activating or inhibitory signals, where the dominating signal 
determines the NK cell response (11, 12). Ligation of inhibitory ‘self molecules’ on 
healthy cells instructs the NK cell to not lyse its target, whereas ligation of activating 
‘stress-induced’ or ‘non-self’ ligands lead to cytolysis of the target cell (9, 13) (Figure 
1.1). In addition to the surveying of target cell health, regulatory functions can also be 
mediated through the IS, termed a regulatory synapse. NK cell interactions with other 
immune cells, such as T cells and dendritic cells (DC), can mediate cellular 
proliferation, differentiation and survival (14-16). 
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The IS forms as a result of the ligation of a combination of integrins and signalling 
proteins that accumulate at the cell-cell interface (17). NK cells participate in 
homeostasis by surveying the health of cells. They discriminate between healthy and 
diseased cells via the ligation of inhibitory ligands (expressed by healthy nucleated 
cells) and activating ligands (expressed by diseased cells). In the event of dominant 
activating signals, NK cells secrete a number of different cytotoxic mediators, 
including perforin (PFN) and granzymes (Gzms) (18, 19). NK cells transport these 
cytotoxic proteins to the synapse in lytic granules (LG) along microtubules (MT), 
which direct secretion towards and across the synapse (13, 20). NK cell 
A 
B 
C 
Figure 1.1. NK cell recognition of target cell health. (A) Inhibition – ‘Self-recognition’. 
Interaction between an NK cell and a healthy, autologous cell results in the ligation of inhibitory 
receptors with their cognate ligands. The NK cell receives inhibitory signals through its receptors, 
preventing activation and lysis of the target cell. (B) Activation – ‘Induced-self’. An upregulation of 
stress induced ligands on the target cell are a result of viral infection or transformation. Interaction 
with an NK cell enables the binding of these ligands to activating receptors. The balance of signals, 
activating versus inhibition, favours the former and the target cell is lysed. (C) Activation – 
‘Missing-self’. A target cell can internalise its inhibitory ligands, such as class I MHC molecules, 
upon viral infection or transformation. Contact with an NK cell results in the ligation of only activating 
receptors and lysis of the diseased target cell. Adapted from Orange (2008). 
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communication with other cells is almost wholly governed by receptors recruited to 
the immunological synapse, utilising a balance between germ-line DNA encoded 
receptors that activate, inhibit or regulate the response of NK cells (17, 21). 
Therefore, NK cell development is finely tuned and regulated to ensure that they are 
fully functional, delivering the correct response. 
                         
1.1.1 NK cell development and licensing 
 
NK cell development begins in the bone marrow (BM) microenvironment (22). Stage 
1 pro-NK cells, identified phenotypically as CD34+CD122-, are NK cell progenitors 
that give rise to stage 2 pre-NK cells. These second stage cells are sensitive to 
interleukin (IL)-15-induced differentiation (23), a hallmark characteristic of the pre-NK 
cells that are defined as CD34+, CD45RA+, CD117+ and CD94- (24). At this stage, 
pre-NK cells are not yet fully committed to the NK cell lineage, as bulk in vitro 
cultures of these cells can give rise to T cells and myeloid DC (24, 25). The presence 
of IL-15 drives the development of pre-NK cells into immature NK (iNK) cells, the 
third stage of NK cell development. These cells lack the plasticity to deviate to other 
lineages, and are fully committed to an NK cell fate (24). These iNK cells still lack two 
major features of mature NK cells: the ability to produce interferon gamma (IFN-γ) 
and to elicit PFN-dependent cytotoxicity against susceptible targets (24). iNK cells 
also lack expression of mature NK cell markers, including CD94, the receptor natural 
killer group 2 member D (NKG2D), CD16 and killer immunoglobulin-like receptors 
(KIR). However, iNK cells have been shown to express NKp44, a receptor 
responsive to IL-2 stimulation, which is also found uniformly on some mature NK cell 
subsets (24, 26, 27). The final stage of NK cell development, stage 4, is marked by 
the expression of CD94-NKG2A, which allows NK cells to detect non-diseased cells 
(28, 29).  Alongside this, CD117, CD33 and CD127 are downregulated, whilst 
activating receptors are upregulated (such as NKG2D, NKp46). Intracellular PFN 
stores accumulate and stage 4 NK cells develop the capacity for PFN- and Fas-
ligand-mediated killing, as well as IFN-γ production (24). The maturation of NK cells 
to stage 4 does not signify the end of their development. At this stage, NK cells can 
differentiate into two distinct subsets, based on their surface expression of CD56. 
The expression of CD56 gradually increases from stage 2 to 4 to form CD56bright cells 
(predominantly CD94+CD16–) that express high levels of CD56, compared to NK 
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cells that express lower levels of CD56 (CD56dim), which may represent a later, 
possibly fifth, stage of NK cell development (predominantly CD94+/–CD16+) (24, 30) 
(Figure 1.2). 
 
 
 
The control of NK cell development, as with all lymphocytes, is mediated by 
cytokines. The most significant cytokines involved in the development of NK cells are 
IL-2 and -15 (31), which not only drive lineage commitment of pre-NK cells, but also 
stimulate the development of later stage NK cells, such as CD56bright NK cells (26, 30, 
32, 33). IL-15 is regarded as the most critical cytokine involved in NK cell 
development, as demonstrated by a lack of NK cells in IL-15-deficient mice (34). 
Although soluble IL-15 can promote development of NK cells in vitro (32), it is also 
Figure 1.2. NK cell development. NK cell development begins in the bone marrow as 
haematopoietic stem cell progenitors. As the cells develop, the loss and gain of various surface 
proteins determines the stage of their development (Stage 1 – 5), as described in the text. Stages 1 
and 2 are pro- or pre-NK cells that have the potential to develop into NK cells, T cells or dendritic 
cells. At stage 3, NK cells are considered committed and will form mature NK cells. NK cells at 
stages 4 and 5 are fully functioning lymphocytes. Stage 4 CD56bright NK cells lack CD16 and produce 
significant amounts of cytokines, whereas stage 5 CD56dim NK cells up regulate CD16 expression 
and gain maximum cytotoxic function. 
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physiologically trans-presented by DCs on IL-15 receptors during regulatory synapse 
formation in the periphery (35). 
 
NK cell development and maturation occur in tissues that provide an environment 
with both a soluble and membrane-bound milieu of supportive and regulatory factors. 
Tissue-restricted development of NK cells can then occur without the threat of auto-
reactivity to the host. Current data suggests that initial development occurs in the 
BM, but NK cells undergo their final maturation within secondary lymphoid tissues 
(SLT) (25, 36). Within the SLT, populations of DCs interact with NK cells through 
regulatory synapses, driving their differentiation and development through trans-
presentation of IL-15 (37, 38). The migration of NK cells through various tissues 
provides a change in environments that facilitates their development into fully 
functional, mature cytotoxic lymphocytes.  
 
The development and maturation of NK cells is finely tuned due to the non-specific 
nature of NK cell cytolysis. For instance, uncontrolled signalling through IL-2/15 
receptor in vivo can result in the generation of NK cell leukaemia (39, 40) or over-
riding of their self-tolerance leads to a hyper-responsive population of cells (41). To 
ensure a tightly controlled response to target cell interactions, NK cells undergo 
licensing, or education. Licensing is the process in which NK cells use inhibitory 
receptors that recognize self major histocompatibility (MHC) class I (MHC-I) 
molecules on cell surfaces to license, educate or arm themselves for efficient and 
diseased-cell-selective cytotoxicity (42-45). For instance, NK cells that develop in the 
absence of MHC-I proteins are unable to kill MHC-I deficient tumour cells (42, 44). In 
parallel, NK cells lacking the receptors that can bind to MHC-I molecules are also 
hyporesponsive to in vitro stimulation. Therefore, expression and ligation of these 
MHC-I specific receptors act as a gateway for arming NK cells for effective killing 
potential (46-48). NK cell licensing requires critical signalling through inhibitory 
receptors, as mutations in their intracellular signalling domains render these NK cells 
hyporesponsive (48).  
 
Three major mechanisms have been described by which NK cells may be licensed: 
arming, disarming or affinity-induced. However, there is some debate as to which of 
these mechanisms are active in vivo. Arming is a mechanism by which primarily 
unresponsive NK cell inhibitory receptors engage MHC-I proteins, triggering the 
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initiation of an effector phenotype (48). During the process of disarming, NK cells 
mature as responsive effector cells but the absence of inhibitory receptors, or MHC-I 
ligands, the cells are rendered anergic (46) (Figure 1.3A). Affinity-induced licensing 
of NK cells is a process of fine-tuning effector function, controlled by inhibitory 
receptor affinity for MHC-I molecules, or the number of inhibitory receptor types 
expressed on the surface of the educating cell. This is governed by the genotype of 
the host, specifically by which inhibitory receptors (KIR) and ligand (MHC-I) genes 
they express (49). The affinity of NK cell inhibitory receptors for their ligands 
determines the responsiveness of the cell to ligation of activating receptors. This 
response is both qualitative and quantitative. For example, NK cells that possess two 
or more inhibitory receptor types respond more frequently and stronger than cells 
that possess just one type (49, 50) (Figure 1.3B).  This suggests that NK cell 
licensing determines effector function by the recognition and binding of MHC-I 
molecules. 
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Figure 1.3. NK cell licensing and education. NK cell effector function is mediated or fine-tuned 
through licensing/education. Licensing of NK cells enables the qualitative and quantitative determine 
of the eventual effector function of the NK cell. Ligation of MHC class I proteins on ‘educating cells’ 
determines the extent to which NK cells become fully competent effector cells. Three modes of 
licensing have been proposed: arming, disarming and affinity-induced. (A) Arming and disarming is 
the process by which NK cells develop as unresponsive cells. The ligation of MHC class I molecules 
on the surface of educating cells triggers development into competent effector cells (left cell). NK 
cells that lack KIR expression cannot bind MHC proteins and remain anergic (right cell). (B) Affinity-
induced licensing fine-tunes the NK cell effector response through quantitative ligation of high or low 
expressed/affinity MHC proteins on the educating cell. NK cells with higher expression of KIR 
receptors, or those that have a higher affinity to MHC proteins, become highly responsive cells (left 
cell). Low expression, or the expression of low affinity, KIR proteins renders NK cells poorly 
responsive (right cell). Adapted from Orr and Lewis (2010). 
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1.1.2 Bridging the gap between innate and adaptive immunity 
 
NK cells do not conform to the ‘textbook’ innate or adaptive bimodal description of 
the immune system. Classically, innate immunity derives from germ-line encoded 
receptors and can control, initiate and direct an adaptive immune response (51). The 
adaptive immune system has high specificity to foreign peptide sequences through 
somatic recombination (52), requiring various cytokines to initiate but also 
characterised by long-term ‘memory’ functions (53, 54).  
 
Innately, NK cells can recognise diseased or healthy cells through the binding of 
various combinations of germ-line encoded receptors (11). Following activation, NK 
cells secrete cytokines with inflammatory (55) or immunosuppressive functions (56), 
through interaction with other immune cells (15, 57, 58). NK cells are activated and 
elicit their cytotoxicity against target cells through ligation of two types of ligands, 
either ‘stress-induced’ proteins expressed on the surface of the target cell or the Fc 
portions of antibodies that have opsonised a target cell. NKG2D and receptors 
termed collectively as natural cytotoxicity receptors (NCR) (e.g. NKp46) interact with 
stress-induced ligands and, for example, specific influenza-derived haemagglutinin 
proteins (59) respectively. Antibody-dependent cellular cytotoxicity (ADCC) is 
initiated though engagement of the Fc receptor CD16 with the Fc portion of an 
antibody bound to the surface of a target cell (60). Most recently, NK cells have been 
shown to have a ‘memory-like’ function where they display clonal expansion, 
contraction, persistence and a secondary response to a particular antigen (54, 61), a 
function previously attributed only to T and B cells of the adaptive immune system.  
 
NK cells display characteristics of both the innate and adaptive immune system. This 
gives significant advantages to the body, providing responses to a wide variety of 
pathogens and transformed cells. The varied immunological functions of NK cells are 
initiated through cell-cell interaction with target cells via the IS. This can stimulate 
downstream responses within the host that affect other cells and systems in either 
direct contact or in a paracrine fashion. 
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1.2 The immune synapse 
 
The IS is an organised cell-cell interaction that forms between cells during direct 
interaction. Initially described as the site of directed cytokine secretion between T 
cells and antigen-presenting cells (APCs) (62), the IS is now known to be a 
micrometer-sized organisation of receptor clusters at the cell-cell interface (10), that 
can be formed by all lymphocytes. Classically, the structure of the IS was described 
as supramolecular activation clusters (SMAC) that form distinct rings in a ‘bull’s-eye’ 
pattern (Figure 1.4). Structured in concentric circles from the centroid of the synapse 
moving outwards, these are termed the central, peripheral and distal zones (c-, p- 
and dSMAC respectively) (63, 64). In brief, the activating/inhibitory receptors are 
located in distinct domains within the cSMAC, segregated from the larger integrins of 
the pSMAC. These zones are further segregated from glycoproteins, such as CD45, 
that are located in the dSMAC (65). Segregation of these receptors allows for 
effective signalling through different phosphatase or kinase cascade pathways 
following receptor ligation during contact with a target cell (10).  
 
 
 
  
Figure 1.4. The classical structure of the immune synapse. Immune synapses are structured 
into supramolecular activation clusters (SMAC) composed of distinct domains. These are formed by 
micro-clusters of similarly sized proteins. The central SMAC (cSMAC) contains activating and 
inhibitory receptors. The peripheral SMAC (pSMAC) contains mostly integrins. The distal SMAC 
(dSMAC) contains other large signalling molecules. 
dSMAC
cSMAC
pSMAC
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The organisation of receptor-ligand complexes at the NK cell IS does not always 
conform to the bull’s-eye structure of the T cell synapse. Whilst the NK cell IS 
contains regions of activating/inhibitory receptors segregated from integrins, these 
discrete domains are located throughout the synapse in a variety of configurations 
(66) (Figure 1.5). These differences may stem from receptor dynamics during the 
formation of the NK or T cell synapse. The NK cell synapse forms in distinct stages 
(13), as opposed to the continuous inward movement of the T cell receptors (TCR) 
towards the cSMAC (67). In brief, NK cell synapse formation consists of adhesion, 
organisation, polarisation/degranulation and termination.  
 
 
                      
Adhesion to the target cell 
Adhesion to the target cell is the first step in the formation of an IS. Adhesion 
molecules such as lymphocyte function-associated antigen (LFA)-1 (β1, β2-integrins, 
CD11a/CD18) bind integrins on the target cell, such as intercellular adhesion 
molecule (ICAM)-1 and -2 (68). In addition to mediating firm adhesion to the target 
cell, LFA-1 also plays a role in cellular signalling. The most notable consequence of 
integrin ligation is LFA-1-mediated polarisation (69, 70). Here, receptor-ligand binding 
leads to activation of a signalling cascade through PTK2B protein tyrosine kinase 2 
beta (Pyk2) and RACK1 (71-74). Pyk2 associates with Vav-1 and this signal further 
transduces through Ras-related C3 botulinum toxin substrate-1 (RAC1) and p21 
protein (Cdc-42/Rac)-activated kinase-1 (PAK1), ultimately leading to cytoskeletal 
rearrangement at the synapse (72, 75) (Figure 1.6). Stabilisation of adhesion 
molecules is facilitated by the subsequent rearrangement of the actin cytoskeleton 
Figure 1.5. The density of MHC class I protein determines its organisation at the NK cell 
synapse. Panels show 3D reconstructions of 221 target cell-expressed GFP-tagged HLA-C at the 
synapse formed with YTS cells (left panel) and a heat map colour-coded to the fluorescence 
intniesty of GFP, as shown in the colour scale. Cells were co-incubated for 45 minutes prior to 
imaging. Images are representative of between 46 and 84 conjugates. Adapted from Almeida and 
Davis (2006). 
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(13), which is essential for the formation and maintenance of the IS. Once firm 
adhesion to the target cell has been established, signalling receptors are recruited to 
the synapse where they bind their respective ligands, either activating or inhibitory 
(18). The local nature of signalling at the IS means that NK cells can mediate a range 
of responses to multiple cells simultaneously (76-79). During cell-cell contacts, NK 
cells can direct cytotoxic responses whilst secreting cytokines including IFNγ, 
TNFα/β and ILs (80-82).  
 
 
 
  
Figure 1.6. NK cell integrin signalling pathways. NK cell adhesion to its target cell is mediated by 
integrin ligation. Integrin ligation provides both adhesion and initial signalling, priming NK cells for 
target cell lysis. Once LFA-1 on the NK cell binds ICAM1 on the target cell, a kinase cascade is 
propagated, as described in the text. Signals result in both the rearrangement of actin at the synapse 
and polarisation of the MTOC. Adapted from Patsenker and Stickel (2011). 
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Receptor-ligand binding and subsequent downstream signalling control the response 
of the NK cell. However, irrespective of the number of synapses formed by one NK 
cell, at each synapse a balance of activating and inhibitory signals determine the fate 
of the target cell at that specific interaction. No one single receptor, activating or 
inhibitory, controls the NK cell response, rather dominance of signals from activating 
or inhibitory receptors will determine the outcome of the interaction (12). 
Furthermore, these responses are local, as opposed to global. NK cells in contact 
with two targets simultaneously can be inhibited at the contact site with a healthy cell, 
whilst delivering a cytotoxic response to a susceptible target (76). 
 
1.2.1 The inhibitory synapse 
 
NK cells contain pre-formed secretory lysosomes containing cytotoxic mediators that, 
upon ligation of germ-line encoded receptors, are rapidly released across the 
synapse, triggering apoptosis of the target cell. Inhibitory receptor ligation can quickly 
regulate interactions to prevent the inadvertent lysis of healthy cells. Upon contact 
with a healthy cell, inhibitory receptors bind MHC-I ligands expressed on all healthy, 
nucleated cells. These interactions form a micro-clustered structure, which was first 
identified and characterised between NK cells expressing the inhibitory receptor 
KIR2DL1 and Epstein-Barr virus (EBV)-transformed B cells expressing its cognate 
ligand, HLA-Cw6 (9). 
 
NK cells express a repertoire of inhibitory receptors that inhibit cytotoxicity by 
initiating a dominant inhibitory signalling cascade, preventing activating signalling 
and the release of cytotoxic proteins. KIR receptors recognise MHC-I molecules that 
are expressed on the surface of all healthy nucleated cells. In humans these are 
denoted as human leukocyte antigens (HLA). A complex of two non-covalently 
associated subunits forms MHC-I molecules. These are the polymorphic heavy chain 
α and the invariant β2-microglobulin (β2m) (83). These complexes are recognised by 
the extracellular domains of KIR receptors. Comprising either two or three 
immunoglobulin-like domain structural units, these mediate direct contact with the α1 
and α2 domains of the HLA-C molecules (84). There are different subsets of MHC-I 
molecules that are recognised by individual KIR receptors (85). For example, the KIR 
receptor KIR(2DL1) recognises, amongst others, the MHC-I proteins HLA-Cw4 and –
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Cw6, whilst KIR(2DL2) binds HLA-Cw3 and –Cw7. This has been shown by site-
directed mutagenesis (86, 87).  
 
Even though binding kinetics have been shown to be rapid (88), intercellular contact 
lasts for minutes (9). KIR receptors and their ligands accumulate within specific 
signalling domains, or clusters, that form interspersed within regions of adhesion 
between LFA-1 and ICAM-1 (78, 89-91). In addition to the KIR receptors, NK cells 
express a number of other inhibitory receptors that recognise various cognate 
ligands, summarised below in Table 1.1. 
 
Receptor Ligand(s) Reference 
KIR HLA-A, -B, and -C (92) 
(93) 
(94) 
CD94/NKG2A HLA-E (95) 
(96) 
LIR A number of MHC class I 
proteins 
(97) 
(98) 
CD66 Non-MHC ligands (99) 
TIGIT PVR 
PVR ligand 2 
(100) 
KLRG1 Cadherins (101) 
LAIR-1 Collagen (102) 
KLRB1A/NKRP1A/CD161 LLT-1 (103) 
Table 1.1. NK cell inhibitory receptors. KIR, Killer immunoglobulin receptor; HLA, human leukocyte 
antigen; NKG2A, natural killer group 2 member A; LIR, leukocyte immunoglobulin-like receptor; MHC, 
major histocompatibility complex; TIGIT, T cell immunoreceptor with Ig and ITIM domains; PVR, Polio 
virus receptor; KLRG1, Killer cell lectin-like receptor subfamily G member 1; LAIR, Leukocyte-associated 
immunoglobulin-like receptor; KLRB1A, Killer cell lectin-like receptor subfamily B member 1; LLT1, 
Lectin-like transcript-1 
 
Interactions between inhibitory receptors and their ligands do not require 
reorganisation of the actin cytoskeleton, downstream signalling or the engagement of 
integrins (9, 78, 104). Importantly, this interaction appears to be a thermodynamic 
process (9, 66, 90, 105). Rapid ligation of inhibitory ligands effectively overrides any 
activating signals present at the intercellular contact. Whilst activating receptors have 
been seen to accumulate at the inhibitory synapse, their proximity to the inhibitory 
receptors renders them ineffective, as inhibitory signalling is able to terminate 
activating signals (17). This occurs at a relatively early stage of synapse formation, 
demonstrated by the lack of cytoskeletal rearrangement, a process involving 
filamentous (F)-actin that is a hallmark of an activating synapse (106-108). 
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Inhibitory synapse formation occurs quickly to allow a rapid inhibition of any 
activating signals that would otherwise prepare the NK cell for a cytolytic attack (F-
actin reorganisation, polarisation, etc.). Clustering of the inhibitory receptors is ATP-
independent (9), yet requires the binding of zinc ions to an extracellular domain 
(109), which is also required for signal transduction (110). The importance of these 
ions in the formation of KIR receptor clusters was demonstrated by the loss of KIR 
function by inhibiting cluster formation, following the addition of metal-ion chelators 
(9). The micro-scale clusters provide signal-transduction through immunoreceptor 
tyrosine-based inhibition motifs (ITIM) in the KIR cytoplasmic tail, resulting in the 
recruitment of tyrosine phosphatases. It is these enzymes that inhibit kinase-
dependent phosphorylation of activating cytoplasmic motifs. The dephosphorylation 
of key activating signalling kinases prevents activating signalling cascades (89, 111-
113) and disrupts adhesion to the target cell (111). ITIM are bound by SHP-1 at their 
conserved sequence V/I/LxYxxL/V (amino acid letter code where x stands for any 
amino acid) (112). For example, following KIR2DL1 binding to HLA-Cw4/6, two ITIM 
(one membrane proximal and one distal) are tyrosine phosphorylated. The SH2 
domains of cytoplasmic tyrosine phosphatases, SHP-1 and SHP-2, subsequently 
bind these ITIM phosphotyrosines. The membrane proximal ITIM is sufficient to 
inhibit NK cell killing through SHP-1 recruitment, whereas the membrane distal ITIM 
acts in concert with the proximal ITIM to recruit SHP-2 and amplify the signal from 
SHP-1 (114). It is this SHP-mediated dephosphorylation of key activating signalling 
proteins, such as Vav1, that mediates the inhibition of NK cells (106) (Figure 1.7). 
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Inhibitory signalling is of a significant importance for regulatory synapses. The target 
cell must be protected from lysis whilst delivering its modulatory signals to the NK 
cell. The most well understood regulatory interaction is between NK cells and DC. 
During this interaction, integrins, inhibitory receptors and cytokine receptors 
accumulate at the synapse (15). During DC-NK cell interactions, both CD94/NKG2A 
and KIR2DL1/DL2 have been shown to enrich at the regulatory synapse (15). Most 
recently, the trans-presentation of IL-15, which is presented to the NK cell bound to 
the IL-15 receptor, has been reported to confer NK cell proliferation and survival. This 
is regarded as the mechanism by which NK cells can reach their full functional 
potential (15, 35, 115). The regulatory synapse has distinct similarities to the 
inhibitory IS, for instance the recruitment of inhibitory receptors that bind MHC-I 
proteins at the NK-DC interface, most likely to prevent the lysis of the DC (15). 
Therefore, the inhibitory synapse is not only essential for the protection of healthy 
cells during NK cell surveillance, but also has a functional role in facilitating effector 
functions above and beyond cytotoxicity.  
Figure 1.7. NK cell inhibitory signalling pathways. NK cells express inhibitory receptors (such as 
KIR) that bind MHC class I molecules expressed on healthy nucleated cells. Inhibitory receptors 
contain intracellular ITIM domains that are phosphorylated on membrane proximal and distal 
tyrosines following ligation. As described in the text, SHP-1 and -2 are recruited to these domains 
which then prevent the clearance of actin at the intercellular contact, and dephosphorylate proteins 
associated with NK cell activation, such as Vav1 and SLP76. This inhibits the activation of NK cells 
and arrests target cell lysis.  
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The ligation of inhibitory receptors provides NK cells with a fast and efficient 
response following cell-cell contact with healthy cells. The clustering of these 
inhibitory receptor-ligand complexes, in close proximity to activating complexes, 
facilitates the inhibition of activating kinase cascades. This tightly regulated control of 
effector functions means that NK cells are able to quickly discriminate the health 
status of a cell, in addition to mediating regulatory responses with other cells of the 
immune system. 
 
1.2.2 The activating synapse 
 
NK cell effector functions against diseased cells are crucial in maintaining 
homeostasis, preventing the persistence of viral infection and tumourgenesis (116). 
Following contact with a diseased cell expressing ligands for activating receptors, 
downstream signals result in the polarisation of cellular machinery, including LG, MT 
and mitochondria (68). Micro-scale clustering of activating receptors on the surface of 
NK cells (117) skews signaling in favour of activation, leading to the release of 
cytotoxic proteins onto the target cell. 
 
A diseased cell can be identified by the expression of a range of ‘stress-induced’ 
ligands. Therefore, NK cells have evolved to express a vast repertoire of activating 
receptors (118), summarised below in Table 1.2. Activating receptors are unable to 
signal intracellularly, instead they signal through immunoreceptor tyrosine-based 
activating motifs (ITAM) of recruited adaptor proteins. This triggers downstream 
signalling and results in secretion of cytotoxic proteins and cytokines (119-121). 
Ligation of activating receptors triggers a phosphorylative signalling cascade of ITAM 
and ITAM-like motifs encoded within the cytoplasmic domains of activating receptors, 
or associated adaptor proteins such as the DNAX activating proteins of 10 or 12 kDa 
(DAP10 and DAP12 respectively) (121). These adaptor proteins carry a negative 
charge allowing oligomerisation to a variety of receptors. This plasticity allows the 
same adaptor protein to trigger a response, based on the receptor-ligand complex 
formed (122-124).  
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Receptor Adapter Ligand References 
NKG2D DAP10 MICA/B, ULBP1-6 (125) 
 
NCRs 
NKp30 
NKp44 
NKp46 
NKp65 
NKp80 
 
FcRγ/CD3ζ 
DAP12 
FcRγ/CD3ζ 
- 
- 
 
B7-H6 
Viral haemagglutinins 
Viral haemagglutinins 
KACL 
AICL 
 
(126) 
(127) 
(128) 
(129) 
(130) 
2B4 SLP-76 
adapter 
protein (SAP) 
CD48 (131) 
 
DNAM-1 - PVR (CD155) 
Nectin-2 (CD226) and 
nectin-like molecules 
(132) 
 
CD16 FcRγ/CD3ζ Antibody Fc portion (133) 
CD2 CD2BP1 CD58 (134) 
CD44 SAP Hyaluronate (135) 
(136) 
BY55 
(CD169) 
DAP10 HLA-C (137) 
(138) 
CD28  CD80/86 (139) 
Table 1.2. NK cell activating receptors. NKG2D, natural killer group 2 member D; DAP10/12, DNAX 
activating protein of 10 or 12 kDa; MIC, MHC class I polypeptide-related sequence; ULBP, UL16 binding 
protein; NCR, natural cytotoxicity receptor; FcR, Fc receptor; KACL, keratinocyte-associated C-type 
lectin; AICL, activation-induced C-type lectin; DNAM-1, DNAX accessory molecule 1; PVR, polio virus 
receptor; CD2BP1, CD2 cytoplasmic tail-binding protein; HLA, Human leukocyte antigen 
 
One of the most widely studied activating receptors is the evolutionary conserved c-
type lectin receptor NKG2D (125). NKG2D is expressed on all NK cells and is fairly 
promiscuous, recognising as many as 8 ‘stress-inducible’ ligands, such as MICA/B 
and members of the UL-16 binding protein (ULBP) family (ULBP1-6) (140-143). 
These proteins are upregulated and expressed on the surface of cells in response to 
stresses such as UV-induced DNA damage, transformation or viral infection (140, 
144). NKG2D is a non-ITAM containing NK cell-activating receptor that is 
constitutively expressed with DAP10 (121). Ligation of NKG2D causes 
phosphorylation of the ITAM-like PI3K-binding motif (YxxM) in the cytoplasmic tail of 
DAP10, in a similar manner to the T cell co-stimulatory molecule CD28 (145), by the 
Src-kinase Lck (121, 146). This recruits two arms of the NKG2D signalling pathway 
via PI3K or growth factor receptor-bound protein 2 (Grb2)/Vav1. The importance of 
Vav1 in activating signalling was demonstrated by the recruitment of SHP-1 during 
inhibitory signalling, which specifically targets Vav-1, leading to its dephosphorylation 
and therefore inactivation (106). 
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In addition to binding cell-expressed ligands, NK cell activation and cytolytic activity 
can be mediated through ADCC (147). Most hematopoietic cells, except the majority 
of T cells, express Fcγ receptors (FcγR) (148). There are three types of FcγR and of 
these, NK cells express the activating low affinity FcγRIIIa (type III receptor for IgG; 
CD16), which mediates ADCC. This receptor is primarily expressed at high levels on 
the cytotoxic CD56dim CD16+ NK cell subset (149). ADCC is directed towards targets 
that have been opsonised with IgG1 and/or IgG3 antibodies. CD16 binding of Fc 
domains results in a strong activating signal that initiates cytotoxicity and cytokine 
release (147, 150). Moreover, co-engagement of other activating receptors has a 
synergistic effect, enhancing NK cell activation (8). 
 
CD16 also lacks ITAMs, signalling intracellularly through the accessory molecule 
CD3ζ, which contains the ITAM sequence YxxL(x)1-6YxxL (133). CD16 is thought to 
signal through the same pathway as some natural cytotoxicity receptors (NCR), such 
as NKp46 and NKp30 (151). Ligation of CD16, or NCR, recruits and activates the 
tyrosine kinase Syk and Zeta-chain-associated protein kinase of 70 kDa (ZAP70) 
(152). However, unlike other NK activating receptors (e.g. NKG2D, NKp46 and 
DNAM-1), specific engagement of CD16 is sufficient to elicit effective killing (8). 
Specifically, activating receptors such as NKG2D require the co-engagement of LFA-
1 and 2B4 to provide a cytotoxic response (153), whereas CD16 ligation alone is 
sufficient to activate NK cells. Moreover, CD16 is significantly stronger in concert with 
other receptors, such as NKG2D or 2B4, in resting NK cells (154). 
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Following ligation of activating receptors, downstream phosphorylation cascades 
converge through the SH2-domain containing leukocyte protein of 76 kDa (SLP-76), 
phosphoinosititide 3-kinase (PI3K), phospholipase C-γ (PLC-γ), Rho, Ras, p38 
mitogen-activated protein kinase (MAPK) and extracellular signal-regulated kinase 
(ERK) (122, 152, 155). Regardless of the specific activating receptor-ligand 
complexes formed at the synapse, activating kinase cascades lead to F-actin 
polymerisation at the NK-target cell contact site. Parallel polarisation of the 
microtubule-organising centre (MTOC) (156) prepares the NK cells for secretion of 
lytic granules containing PFN and granzyme B (GzmB). It is these proteins that enter 
the target cell and lead to target cell death (121) (Figure 1.8). However, some NK cell 
lines express and utilize non-classical activating receptors. YTS cells, an NK-like YT 
sub-clone, uses the activating receptor CD28, utilised by T cells and a small subset 
of NK cells (157), which signals through PI3K, ERK and JNK in orchestration with 
LFA-1 to initiate cytotoxic effector functions (20).  
 
 
Figure 1.8. NK cell activating signalling pathways. Upon viral infection or transformation, cells up 
regulate stress-induced ligands and internalise ‘self’ MHC class I molecules. Viral proteins are also 
presented on the target cell surface, which can be bound by antibodies. NK cells express activating 
receptors that recognise up regulated stress induced ligands as well as those that can bind the Fc 
portion of an IgG antibody. As described in the text, ligation of activating receptors to their cognate 
ligands results in the tyrosine phosphorylation of the intracellular ITAM on adapter proteins. These 
kinase cascades result in the activation of NK cells where its MTOC is polarised to the synapse as 
actin is cleared form the interface to allow the release of cytotoxic mediators. Adapted from Vivier et 
al (2004) 
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The IS is a highly responsive interaction, which utilises a wide range of receptors that 
allow NK cells to quickly and efficiently survey target cells. The formation of this 
complex, dynamic interface is crucial for the function and execution of NK cell 
interactions, directing cytolysis and mediating regulation. Through an array of 
activating and inhibitory receptors, NK cells are primed and prepared for a strong and 
efficient cytolytic response to infected or transformed cells. Despite the lack of 
somatic recombination of receptor genes, NK cells can effectively discriminate 
between ‘self’, ‘non-self’ and opsonised targets, resulting in signalling cascades to 
polarise and release cytotoxic mediators through the IS to diseased targets only. 
  
1.2.3 Polarisation and directed secretion at the immune synapse 
 
The polarisation of NK cells prior to degranulation is critical for the lysis of target cells 
(158). The mechanism by which NK cells polarise their LG to the synapse and 
release their cytolytic contents has been intensively investigated. The most critical 
factor in assembling a mature, cytolytic synapse and delivering a cytotoxic response 
is the proper functioning of the cytoskeleton (Figure 1.9). Numerous groups have 
dissected this through depletion/inhibition of proteins key to the cytoskeleton through 
knockdown (KD), knockout (KO) or pharmacological inhibition. 
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For instance, March and Long showed that by KD of paxillin, a signal transduction 
adapter protein known to be associated with LFA-1 signalling and actin regulatory 
functions (159), NK cell polarisation was significantly inhibited (160). Paxillin 
associates with Pyk2 (161), which is tyrosine phosphorylated downstream of LFA-1 
ligation. They conclude that by siRNA-mediated KD of paxillin, further signal 
transduction that localizes the MTOC to the synapse is lost, reducing NK cell 
cytotoxicity. In addition, Butler and Cooper demonstrated that following shDNA KD of 
Arp2/3, a protein complex required for actin nucleation, NK cells exhibited a reduced 
capacity to lyse target cells (162). Similarly, Mace et al. showed that the ligation of 
LFA-1 by NK cells from both talin- and Wiskott-Aldrich syndrome protein (WASp)-KO 
Figure 1.9. Polarisation and directed secretion at the NK cell immune synapse. Virally infected 
or transformed cells up regulate stress-induced ligands or are opsonised by antibodies. (A) NK cell 
contact with diseased cells engages activating ligands, where signals from activating receptors 
dominate over inhibitory signals. (B) Activating kinase cascades and signalling pathways cause 
polarisation of the MTOC (green) and its bound LG (purple), in addition to other cellular machinery, 
towards the synapse. (C) Once LG have reached the synapse, their membranes fuse with the cell 
membrane and release their cytolytic contents into the synaptic cleft. These trigger apoptosis in the 
target cell, identified by hallmarks such as membrane blebbing and DNA fragmentation. Adapted 
from Orange (2008). 
B 
A 
C 
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mice were unable to induce localised actin polymerisation (163). Talin and WASp are 
both signal transduction proteins, required for the organisation of actin at the 
cytoskeleton following LFA-1 ligation, and prerequisites for the reorientation of NK 
cells to dock LG at the synapse (70). Finally, the pharmacological inhibition of NK cell 
F-actin dynamics disrupts the accumulation of actin and the assembly of a functional 
IS. Actin targeting drugs, such as cytochalasin (164, 165), Latrunculin A (166), and 
Jasplakinolide (167), have all been shown to inhibit cytotoxicity. 
 
Cytoskeleton-dependent polarisation 
 
Polarisation of NK cells is critical for efficient target cell lysis (168). Prior to the 
movement of the MTOC, WASp facilitates F-actin rearrangement at the synapse. 
Following binding of the Rho GTPase Cdc42, Arp2/3 mediates the movement of actin 
in waves from the centroid of the synapse towards the periphery (169-171). This 
polymerisation and rearrangement of F-actin functions to stabilise the synapse, 
generating forces to tether the NK cell to its target, demonstrating the crucial role of 
integrin signaling for this process (166).  
 
Following the rearrangement of F-actin at the synapse, MT movement facilitates the 
reorientation of the MTOC – including its associated LG – towards the synapse. The 
relationship between F-actin reorganisation and movement of the MTOC has been 
demonstrated by the disruption of actin, causing the arrest and impairment of MTOC 
polarisation (172). Upon ligation of activating ligands, LG first rapidly move along MT 
towards the MTOC in a minus-end direction (173). LG interaction and movement 
along MT is facilitated by a combination of Rab7, vesicle-associated membrane 
protein (VAMP)-4 and VAMP7 expressed on the granule surfaces in both T cells and 
NK cells (174, 175).  
 
Studies using NK cells have shown that lysosomal-associated membrane protein 
(LAMP)-1 (CD107a) may also be a key factor in LG movement. Silencing CD107a 
impaired initial LG movement towards the MTOC, suggesting that proteins on the 
surface of granules are important in their trafficking (176). As LG move towards the 
MTOC, NK cells undergo a massive rearrangement of organelles required for 
cytolysis. The specific cell machinery for secretion (MTOC, Golgi apparatus, and 
mitochondria) moves towards the synapse, and those not required are trafficked 
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towards the posterior of the cell (177). A large number of factors are required for 
MTOC polarisation including Pky2, ERK2, CIP4 and Vav-1 (156, 172, 178). The 
major motor protein involved in the polarisation of NK cells is kinesin-1 that interacts 
with the small GTPase Arl8b (179). It is thought that the movement of the MTOC 
towards the synapse is facilitated by pushing and pulling forces generated by growth 
or shrinkage, respectively, at the sites where MT are anchored into the cortical actin 
(180, 181). At these junctions, IQ motif-containing GTPase-activating protein-1 
(IQGAP1) may act as a linker between CLIP-170 at the ends of the MT and the actin 
mesh (182). Once the MTOC has polarised to the synapse, LG are then trafficked 
along MT in a plus-end direction facilitated by WASp-interacting protein (WIP) (183). 
The physical docking of the MTOC at the synapse has been observed in T cells 
(184), but such close proximity has not been reported in NK cells. At this point, NK 
cells may simply traffic their LG along MT towards and onto the actin at the synapse 
for directed secretion into the synaptic cleft. 
 
Directed secretion 
 
NK cells use directed secretion to release potent cytotoxic mediators within the 
synaptic cleft onto their target. To facilitate this, in parallel with MTOC polarisation, F-
actin continues to undergo rearrangement at the synapse. This was originally thought 
to be a large-scale clearance of actin to permit the access of LG to the membrane 
(13, 185). However, recent advances in microscope techniques, primarily super-
resolution microscopy, have revealed that ligation of activating receptors creates a 
hypo-dense mesh of actin, punctuated with holes, or pores, that allow the passage of 
LG through to the membrane (117, 186, 187). The diameters of the holes within the 
mesh are sufficiently large to allow the passage of LG. Whilst LG appear to be 
polarised towards the vicinity of these holes, data from Mace et al. suggest that 
motor protein-based mechanisms (possibly through myosin IIA) could facilitate the 
final movement of LG along F-actin. Through this process, LG could migrate to, and 
through, these areas of increased periodicity for fusion with the NK cell membrane 
and the release of their cytotoxic contents (188). Conversely, inhibitory signalling 
does not produce an increased periodicity in the mesh and therefore may prevent the 
access of LG to the synapse (117). 
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The fusion of the cell and granule membranes to release the cytotoxic payload into 
the synaptic cleft is a multistep process, involving the initial vesicle tethering, 
membrane fusion and finally, the release of cytolytic contents. The N-ethylmaleimide-
sensitive protein attachment protein receptor (SNARE) proteins regulate the fusion of 
the LG with the NK cell membrane, directing the granules to the secretory zones of 
the synapse for intra-synaptic release. These regions are rich in proteins such as 
VAMP7, syntaxin-11 and Munc18-2. Interaction of these proteins drives membrane 
fusion for the release of cytotoxic contents (175) (158). Secretion occurs across the 
synaptic cleft, the gap formed between the effector and target cell, which varies 
between 15-55 nm (65, 189), focusing these cytotoxic mediators towards the target 
cell (190). 
 
It has been shown that degranulation occurs in two modes: complete and incomplete 
fusion (Figure 1.10). This was revealed by the use of a pH-sensitive fluorophore, 
pHluorin, where fluorescence is suppressed in acidic compartments, such as LG 
lumen. Firstly, LG were shown to fuse with the NK cell membrane in a slow 
(complete) manner. Upon contact and fusion of the LG and cell membranes, pHlurin 
entered a neutral pH and emitted fluorescence. This signal then dispersed across the 
cell membrane, away from the initial point of membrane fusion. This demonstrated 
that the LG, after releasing its contents, completely fused with the membrane. This 
mode of degranulation is also demonstrated, and used as an assay for NK cell 
degranulation, by the presence of the LG membrane protein CD107a on the NK cell 
surface (191). Fast (incomplete) fusion is the partial release of cytotoxic mediators, 
without complete fusion of the LG and NK cell membranes. This is thought to be via 
the formation of ‘fusion pores’ through which cytotoxic proteins are briefly released 
through areas of partial fusion. This is then followed by granule recession back into 
the NK cell cytoplasm. This was demonstrated by the appearance then 
disappearance of pHluorin fluorescence without any dispersion into the NK cell 
membrane (192). Based on the differential timing of these modes of degranulation, 
the mode of degranulation may depend on the signals received and the speed of kill 
required, however, the exact mechanisms that result in these modes of action have 
not been elucidated. 
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In contrast, a study by Bertrand et al. showed that polarisation of the MTOC in 
cytotoxic lymphocytes (CTL) does not necessarily precede LG secretion. In this 
setting, it was shown that the accumulation of LG at the synapse occurred before 
MTOC polarisation in up to 50% of cells (193). Furthermore, partial inhibition of 
MTOC polarisation using a PKCζ inhibitor did not impede secretion of cytotoxic 
mediators at the synapse. This indicates that there may be a separate mechanism 
employed by CTL that can facilitate the rapid secretion of cytotoxic mediators.  
  
Figure 1.10. Secretion at the NK cell immune synapse occurs in two modes: Complete and 
incomplete fusion. Following activation and polarisation of the MTOC to the intercellular contact. 
LG fuse with the cell membrane to release their cytolytic contents. Using pH-sensitive proteins, this 
has been shown to be achieved by either slow, complete fusion or fast, incomplete fusion. (A) 
Complete fusion occurs in three stages. (Left segment) LG (red) containing cytotoxic mediators 
(green) move towards the cell membrane (orange) at the synapse. (Central segment) The LG 
membrane fuses with the cell membrane and its contents are released. (Right segment) The LG 
completely fuses with the cell membrane, dissipating into the membrane.  (B) Incomplete fusion 
occurs in three stages. (Left segment) The LG containing cytotoxic mediators moves towards the cell 
membrane at the synapse. (Central segment) The LG membrane fuses with the cell membrane and 
some of its contents are released. (Right segment) The LG then recedes back into the cytosol, 
retaining some of its contents within the LG lumen. 
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1.2.4 The T cell synapse 
 
T cells are crucial players in the adaptive immune system, orchestrating immune 
responses by amplification (CD4+ T cells) and suppression (regulatory T cells; Treg) 
of immune responses or cytolysis of target cells bearing cognate antigens for 
antigen-specific receptors (CD8+ T cells). The T cell synapse was first described 
between T- and B-cells (194, 195) and has been demonstrated both in vitro (196) 
and in vivo (197-199). The T cell synapse is crucial for the proper functioning of T 
cells where antigen-specific TCR engage antigenic peptide fragments presented on 
the surface of APC by MHC-I or -II proteins (200, 201). 
 
The T cell synapse is organised in a spatio-temporal manner. The initial visualisation 
of the T cell synapse found that protein-protein complexes at the interface of a T cell 
and B cell were organised into segregated micrometer-scale domains, termed 
SMACs (196). T cells form synapses that are structured in SMACs, organised into 
concentric rings of receptors and adhesion proteins, determined by their extracellular 
domain length (10, 196), termed the mature T cell synapse (Figure 1.11). This is in 
contrast to the NK cell synapse, which conforms to a number of configurations 
consisting of punctate domains of activating/inhibitory receptors, surrounded by a 
mesh of integrin-ligand complexes (9, 66, 124).  
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The key receptors involved in T cell activation are located in the central region of the 
synapse or cSMAC. The somatic, multimeric TCR signals through Lck/ZAP70 and 
the co-stimulatory molecule CD28, which suppresses inhibitory E3 ubiquitin ligases 
(202) (Figure 1.12). A ring of LFA-1 adhesion molecules and talin, the pSMAC, 
surrounds this central region. Finally, larger molecules, such as CD43 and CD45, are 
segregated from the central and peripheral regions of the synapse, located in a distal 
region at the edge of the intercellular interface, the dSMAC (196, 203). The dynamic 
organisation of the T cell synapse was imaged in real-time using lipid bilayers 
incorporated with fluorescently labelled peptide-loaded MHC (pMHC) proteins (10). 
These studies showed that at the point of cell-cell contact, the TCR-pMHC 
complexes were first accumulated at a peripheral ring surrounding central integrin 
receptor-ligand complexes, termed the immature T cell synapse. Within a short 
space of time, in the order of a few minutes, the organisation of the synapse was 
reversed to form a mature synapse (10, 196, 203). More recently, improved imaging 
techniques have shown that the T cell synapse is formed with small aggregations of 
proteins within the interface, termed micro-clusters (204-206). The TCR mediates this 
initial signalling at the peripheral region of the synapse, migrating to the central zone, 
where signalling is terminated (205-207). This continuous dynamic movement of 
Figure 1.11. The structure and organisation of the mature T cell immune synapse. An en face 
view of the mature T cell immune synapse. The structure is characterised by its ‘bull’s eye’ pattern, 
comprised of the dSMAC (blue), pSMAC (green) and the cSMAC (red). The cSMAC contains 
signalling proteins such as the TCR and CD28. The pSMAC contains integrins and integrin-
associated proteins such as LFA_1 and Talin. The dSMAC contains larger signalling molecules such 
as CD45. 
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micro-clusters, of up to 100 TCR molecules (207), is critical for sustained TCR 
signalling (206) where the density of pMHC is proportionate to the micro-cluster size 
(207). 
 
 
 
The segregation and resulting dynamics of extracellular receptor-ligand complexes 
that control immune cell signalling are not controlled by receptor ligation alone. In 
synapses formed by both T cells and NK cells this has been consistently observed. 
Specifically, the extracellular domains of activating receptors of both cell types are of 
similar dimensions (84, 208-210), with the crystal structures of TCR-pMHC, NKG2D-
MICA and LFA-1-ICAM-1 receptor-ligand complexes already elucidated. The 
signalling receptor-ligand complexes of both T cells and NK cells are ~15 nm (84, 
208, 209, 211), whereas adhesion complexes are ~50 nm (212). This suggests that 
the receptor organisation is dependent on the extracellular span of the receptor-
ligand complexes that form and accumulate at the intercellular interface. 
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Figure 1.12. T cell activating signalling pathways. Upon engagement with an antigen presenting 
cell, TCR engagement of specific peptides presented on MHC proteins triggers activating signalling 
pathways. Initially bound at the periphery of the synapse, the TCR moves into the central region as 
the synapse matures. As the TCR moves centrally, phosphorylation cascades, as described in the 
text, initiate gene activation and transcription. These pathways result in the secretion of cytokines 
and/or cytotoxic proteins, activating other branches of the adaptive immune system or lysing their 
target, respectively. Adapted from Fathman and Lineberry (2007). 
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1.2.5 The size-dependent kinetic segregation model 
 
The kinetic segregation (KS) model proposes that receptors at the IS are 
spontaneously segregated according to their extracellular domain lengths (213). 
Described as early as 1992 (214), it has been thought, specifically for T cell-APC 
interactions, that extracellular domain size is a major contributor in the final outcome 
of signalling at the IS. This size-dependent segregation has also been confirmed for 
NK cell synapses (65, 124, 189). 
 
The extracellular domains of activating and integrin receptor-ligand complexes have 
been shown to be around 15 – 25 nm and 45 – 50 nm, respectively (65). The 
difference in extracellular length of proteins within such close cell-cell interactions 
would result in a significant bending of the cell membrane, which would be at a high 
energy cost to the cell (189). To overcome this, immune cells segregate their 
receptors according to size (215) (Figure 1.13). Larger integrins are segregated from 
the smaller activating and inhibitory signalling receptor-ligand complexes. Recently in 
NK cell systems, both experimental data and mathematical modelling have 
addressed this segregation in accordance with the KS model.  
 
 
 
  
Figure 1.13. Size-dependent segregation at the immune synapse. Receptor-ligand complexes 
are segregated at the synapse depending on their size. Smaller signalling proteins (NKG2D-MICA 
(red and purple), KIR-HLA (Blue and yellow) and CD16-Fc fragment (purple and pink)), around 15 – 
25 nm, are clustered between complexes of larger span, around 45 – 50 nm, such as LFA1-ICAM1 
(green and yellow). The segregation of these proteins is known as the kinetic segregation model. 
Diagram not to scale. 
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Köhler et al. demonstrated that elongation of the extracellular domains of MICA or 
HLA-Cw6 drove segregation of differently sized proteins within the synapse. The 
addition of 2, 3, or 4 Ig domains into the extracellular portion of the protein 
segregated receptor-ligand complexes from the shorter wild-type (WT) form. 
However, matched sizes, either long (4 additional Ig domains) or short forms (no 
additional domains), were clustered together within the synapse. Secondly, they 
showed that elongation of MICA decreased NK cell-mediated lysis, but the co-
expression of a shorter Cw6 protein did not decrease killing any further. Only the 
expression of a matched-size inhibitory receptor had any further effect. Pearson’s co-
localisation analyses confirmed that only matched sizes are able to cluster together 
in the synapse (r ≥ 0.5), whereas mismatched sizes were segregated (r ≤ 0). This is 
most likely due to the inability of the receptors to co-localise within the synapse. 
Functionally, this lack of co-localisation abrogated the ability of inhibitory receptors to 
efficiently dephosphorylate the activating receptors, resulting in the diminished 
signalling reported (124). 
 
To address size segregation at the synapse by a different means, Alakoskela et al. 
inserted lipid anchors into NK cell membranes that could bind quantum dots (QD) of 
a range of sizes via a biotin-streptavidin bond. These data demonstrated that the 
exclusion of QD was proportional to their size. Those of diameter below the span of 
signalling receptor-ligand complexes were included within the central regions of the 
synapse, whereas those larger were excluded to the periphery (189). 
 
Together, these studies show the importance of extracellular domain size at the IS, 
influencing both the organisation and proper function of the synapse. More 
importantly, the extracellular dimensions of these receptors will have a profound 
effect on the cell-cell membrane proximity, thus influencing where cell-bound proteins 
are located within the synapse. Whilst these studies do not address the effect size 
has on extracellular proteins, they confirm the importance of size at the IS. 
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1.3 Cytotoxic mediators and target cell death 
 
Cytotoxic proteins, stored in pre-formed LG, facilitate NK cell-mediated cytolysis. 
These lysosome-like organelles are polarised to the IS and their cytotoxic contents 
are secreted across the synaptic cleft following activating signal cascades. The 
polarisation and release of these mediators activates various pathways that induce 
apoptosis of the target cell. The major proteins expressed by NK cells that are 
involved in cytolysis are PFN (216-218) and Gzms (219-222).  
 
1.3.1 Lytic Granules 
 
LG are considered to be ‘secretory lysosomes’ based on their similarities to 
conventional lysosomes (223-225). They are classed as ‘dual-functional’ organelles, 
exhibiting both degradative activity, as well as trafficking and membrane fusion, 
which facilitates release of granule contents during secretion (226). A lipid bilayer 
separates LG contents from the cytoplasm. This membrane also contains various 
proteins required for transport within the NK cell (227).  
 
Mature LG membranes contain a number of proteins required for fusion, trafficking 
and secretion, including CD63, the LAMP family of proteins (LAMP-1, -2 and -3), 
Munc13-4 and Synaptobrevin-2, a vesicular SNARE protein (223, 228, 229). 
Diseases associated with the loss of function of these molecules demonstrate the 
importance of the surface proteins required for LG trafficking and secretion. For 
example, individuals suffering from diseases such as Chédaik-Higashi syndrome and 
Griscelli syndrome have impaired secretory lysosome function. This is due to a 
mutation in the gene LYST, which encodes the protein lysosomal trafficking regulator 
(230-232). These diseases are associated with both severe immunodeficiencies, due 
to a lack of LG secretion, as well as hypopigmentation, caused by defects in the 
melanosome formation. These findings show that LG are an integral part of a system 
that is employed by a range of cells in the human body to release proteins in a 
secretory manner (233). Similarly, familial heamophagocytic lymphohistocytosis type 
3 (FHL3) manifests in patients with defects in the gene UNC13D, which encodes 
Munc13-4. This leads to a disruption in LG exocytosis and abrogation of cell-
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mediated cytolysis, demonstrating the essential requirement for exocytosis in NK 
cell-mediated effector function (234). 
 
Whilst diseases such as these have highlighted proteins critical for correct sorting 
and trafficking of LG, the exact mechanisms behind these processes are currently 
unknown (226). Traces of proteins from LG can be found across the rough 
endoplasmic reticulum and trans-Golgi network (TGN), but not of endosomal 
compartments, which indicate that the dense cores of LG are derived directly from 
the TGN, with little or no involvement of endosomes (235, 236). Previous groups 
have attempted to characterise LG, detailing their formation through fusion of 
multivesicular bodies (223). However, recent EM cryosections, which preserve 
intracellular organelles, have identified that there are a number of different structures 
that resemble LG. This makes following the maturation of LG and their identification 
particularly difficult (237). 
 
The LG lumen contains an array of unique enzymes and those typical of lysosomes. 
These unique proteins include PFN, Gzms, Fas ligand (FasL; CD178), TNF-related 
apoptosis-inducing ligand (TRAIL; CD253), and granulysin (223, 238). The 
identification of PFN and Gzms within the LG lumen is currently the most reliable 
indicator of a mature LG (224). Within the multivesicular bodies of fully developed 
LG, cathespins and other lysosomal hydrolases (e.g. acid phosphatase) exist in 
areas devoid of cytotoxic enzymes. The dense cores of LG are where cytotoxic 
proteins (such as PFN and Gzms) are held in lattices by a chondroitin-sulfate 
proteoglycan, serglycin (SG) (223). Furthermore, the deficiency of SG in CTL has 
been shown to affect the maturation and storage of GzmB, suggesting a critical role 
in LG formation and processing of granule contents (239). 
 
1.3.2 Perforin 
 
PFN is the major cytotoxic protein expressed by CTL and has been the subject of 
many studies since its discovery in LG (240, 241). PFN is a multi-domain protein, 
named for its ability to form pores within a membrane. It is constitutively expressed in 
NK cells (at greater levels in CD56dim compared to CD56bright) (242-245). PFN is 
transcribed as a 65 kDa protein that consists of a 21 amino acid signalling peptide, a 
highly conserved membrane attack complex/PFN (MACPF) domain (246), a four-
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stranded β-sheet flanked by two clusters of α-helices (CH1 and CH2) (247), an 
epidermal growth factor (EGF)-like domain and a C2 domain at its extreme C-
terminal end (248) (Figure 1.14A and B). The MACPF domain has homology with 
many other pore-forming proteins such as complement C9 (249, 250) and distinct 
functional similarities to bacterial pore-forming toxins (251). Once transcribed, PFN is 
transported from the ER to the Golgi apparatus via its C2 domain, then via N-
glycosylation sites to the LG (252). Whilst these trafficking mechanisms have not 
been fully elucidated, the mannose-6-phosphate receptor (M6PR) pathway is thought 
to be involved, similar to neuraminidase transport to lysosomes (253). Once located 
within LG, PFN is modified by cathespin-L, undergoing proteolytic cleavage to 
remove the signal peptide at the N-terminal, resulting in a mature, active PFN protein 
(254). Once active, PFN activity is controlled and inhibited by a combination of the 
acidic LG lumen, calreticulin/calreticulin-mediated resistance to lysis and interaction 
with SG (255, 256). 
 
 
 
  
Figure 1.14. The structure and pore formation of perforin. The structure and domains of 
perforin facilitate its membrane binding and insertion, and pore-formation. (A) Crystal 
structures of perforin monomers show a ‘key-shaped’ protein containing a MACPF domain 
with a central β-sheet (blue and red respectively), amphipathic CH1 and CH2 domains 
(orange), an EGF-like domain (green) and a C2 domain (yellow). (B) Once in a neutral pH, 
perforin can extend its CH1/CH2 domains into β-hairpins that facilitate membrane insertion. 
(C) Surface and (D) cut-away views of a cryo-electron microscopy reconstruction of a perforin 
pore with 20-fold symmetry. The cut away image is rainbow coloured by density, where red to 
green represent high- to low-density regions, respectively. Images taken from Law et al. 
(2010) 
A B 
C D 
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Even a small decrease in PFN expression can have an impact on the cytolytic 
capacity of NK cells (257). Studies using NK cells or CTL cells from PFN (258, 259) 
or Gzm (260) KO mice have shown that PFN is critical for GzmB-mediated apoptosis. 
PFN alone is insufficient to mediate effective cytolysis, demonstrated in KO mouse 
studies and using in vitro cell cultures with the addition of PFN in the presence or 
absence of Gzms (258, 261). A later study by Smyth et al. investigated the lytic ability 
of in vivo NK cells from WT and PFN KO mice to clear tumour cells (222). The 
absence of PFN markedly reduced, or abolished, NK cell-mediated lysis. 
Furthermore, PFN-deficient NK cells have been shown to lack lytic capacity following 
activation by IL-2 or polyI:C (258). These studies demonstrate the essential role of 
PFN in NK cell-mediated lysis. In a more recent study, Krzewski et al demonstrated 
that depletion of LAMP1, a surface protein expressed on the surface of PFN-
containing LG, inhibited both the trafficking of PFN to the LG and the fusion of LG 
with the cell membrane, ablating the cytotoxicity of NK cells. (176). These findings 
further highlight the critical role of PFN in NK cell-mediated lysis. However, the 
amounts of PFN that are secreted by NK cells remain unknown.  
 
The critical role of PFN in immune regulation of tumour cells is demonstrated by the 
increased susceptibility to tumourgenesis in PFN KO mouse models (262). Whilst 
there have been significant advancements in our understanding of the modes of 
action of these proteins, the physiological amounts secreted and the exact 
mechanism of entry are contentious. Indeed, if a sufficient amount of PFN is added to 
an in vitro cell culture, cell death is initiated, however in the absence of GzmB, cells 
undergo necrotic cell death rather than apoptosis (248, 261). These studies are not 
representative of the physiological secretion of PFN, which is secreted by CTL into a 
micrometer-sized cleft. These in vitro studies involved the addition of extracted or 
recombinant protein to culture medium. Moreover, amount of PFN capable of 
initiating 50% lysis of cells in culture varied by an order of magnitude – 175 pM and 
1.27 nM. This could well have been due to cell types or the source of PFN 
(recombinant or extracted from granules). These experiments did not take into 
account the effect that PFN has over the entire surface of the cell body, which may 
require more or less PFN than is released across the synapse. Therefore, the 
physiological amounts of PFN released by CTL to initiate cytolysis remain unknown.  
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1.3.3 Granzymes 
 
Gzms are a group of five serine proteases that are constitutively expressed in NK 
cells (245, 263) and are classified based on the residues at which they cleave their 
substrates (263-266), as summarised below in Table 1.3. Gzms are synthesised as 
pro-enzymes and are transported to LG through the M6PR pathway (267). Once 
within LG, Gzms are processed into an active form by cathespin-C (Gzms A, H, K 
and M) or -H (GzmB) (222, 268, 269) and packaged in complexes with SG and PFN 
(256, 270). Studies in SG-deficient mice demonstrate that CTL have significantly 
lower intracellular levels of GzmB, but not GzmA, compared to WT mice, suggesting 
that whilst these proteases are required for effective induction of apoptosis, they use 
distinct transport mechanisms to traffic from the Golgi to the LG (239). 
 
Granzyme Enzyme Type Substrate cleavage Reference 
A Tryptase After arginine or lysine 
residues 
(266) 
 
B Asp-ase After aspartic acid 
residue 
(264) 
 
H Chymase At hydrophobic 
residues – Phe, Tyr or 
Trp) 
(265) 
K Tryptase After arginine or lysine 
residues 
(263) 
M Met-ase At methionine or leucine 
residues 
(263) 
Table 1.3. Gzms expressed within NK cells, their enzyme type and substrates. 
 
One of the most widely studied Gzms is GzmB. This protein has been shown to 
initiate apoptosis via two mechanisms: caspase-dependent or caspase independent 
pathways (271) (Figure 1.15). The key features of granule-mediated apoptosis are 
DNA fragmentation, phosphatidylserine (PS) externalization, cytoskeletal breakdown 
and the loss of inner mitochondrial transmembrane potential (ΔΨm) resulting in the 
release of cytochrome c (272). 
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Caspase-dependent pathway (Caspase-3) 
 
Caspase-dependent cell death is induced through activation of caspase-3 (273), 
demonstrated in GzmB deficient murine cells, where DNA fragmentation in target 
cells was significantly reduced during in vitro assays of cytolysis (274). Caspases 6 – 
10 are also substrates for GzmB, but caspase-3 appears to be the most important 
(275). Activation of caspase-3 leads to the cleavage of gelsolin, a cytoskeletal 
maintenance protein and an inhibitor of caspase-activated DNase, inducing 
apoptosis in target cells. Cell death is demonstrated by the hallmark cellular changes, 
such as cytoskeleton breakdown and DNA fragmentation (276, 277). However, other 
Figure 1.15. Granzyme B initiates apoptosis through both caspase-dependent and caspase-
independent pathways. (A) Upon entry into the target cell cytosol, Granzyme B cleaves and 
activates caspases 3 and 6 – 10. These activated caspases then deactivates gelsolin, a protein 
that maintains cytoskeletal repair and inhibits DNase. Uninhibited DNase moves into the nucleus 
and fragments the DNA. (B) In the absence of caspases (e.g. following inactivation of caspases 
through transcribed viral proteins), granzyme B can initiate apoptosis independently. Cleavage and 
truncation of Bid, which moves to the mitochondrial membrane, recruits Bax. These proteins form 
pores within the outer mitochondrial membrane, resulting in the release of cytochrome c. 
Cytochrome c both inhibits DNA repair mechanisms and activates the SET complex that performs 
single-stranded DNA damage. 
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studies have demonstrated that in addition to caspases, there are additional 
substrates for GzmB activity (278).  
 
Caspase-independent pathway (Bid) 
 
Whilst caspase inhibition was able to inhibit DNA fragmentation, the loss of ΔΨm and 
cytochrome c release still occurred. This resulted in the necrosis of target cells as 
opposed to regulated cell death via apoptosis (272). This may be an evolutionary 
advantage so that viral inhibition of caspases would not prevent the death of infected 
cells. The loss of ΔΨm has been demonstrated to be a result of GzmB-mediated Bid 
cleavage, which translocates to the mitochondria upon truncation (279). The 
truncated Bid protein recruits the pro-apoptotic B-cell lymphoma protein (Bcl)-2 family 
member, Bax, to the membrane of the mitochondria, forming pores in the outer 
mitochondrial membrane and causing the release of cytochrome c (280). In addition, 
Gzms B and K abrogate DNA repair and spindle stabilisation by inhibiting proteins 
essential for these processes (poly APD ribose polymerase (PARP), DNA-PKc, 
nuclear mitotic apparatus (NuMA) and Ku70 (278, 281, 282). In addition, these Gzms 
activate nucleases that induce single-stranded DNA damage, such as the SET 
complex (283). In concert, the cleavage of DNA related enzymes and the loss of 
mitochondrial membrane integrity prevent the repair of the target cell and increase 
the amplitude of the pro-apoptotic effect of Gzms. 
 
1.3.4 Target cell death by cytotoxic mediators 
 
Target cell lysis, mediated through apoptosis, is initiated by a combination of pore-
forming PFN and the apoptosis-triggering factors, Gzms. Once released into the 
synaptic cleft, physiological calcium (Ca2+) levels and a neutral pH facilitate PFN 
membrane binding via the calmodulin-based C-terminal C2 domain (248). Up to 4 
Ca2+ ions bind the C2 domain within Ca2+-binding loops, possibly via lipid head 
groups (284, 285). Once bound to the target cell membrane, extension of the 
amphipathic CH1 and CH2 regions facilitate insertion into the membrane. These PFN 
monomers then oligomerise to form pores within the target cell membrane (Figure 
1.14C and D). PFN pore diameters range between 5 – 30 nm, with most formed of 19 
– 24 subunits corresponding to lumen diameters 13 – 20 nm (286). These diameters 
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are of sufficient dimensions to allow typical GzmB monomers or dimers (5 and 9 nm 
in their longest dimensions respectively (286)) to pass through the lumen into the 
target cell cytosol. However, it has been shown that they are unable to enter the 
target cell cytosol by diffusion alone (261, 287). Gzms are held within complexes 
formed with SG and PFN. This may impede their diffusion through the PFN pore 
lumen as these complexes can consist of up to 20 GzmB molecules interacting with a 
single SG (256). Instead, Gzms require mechanisms that are initiated by PFN to 
enter the target cell (256). Insertion of the PFN-SG-GzmB complexes into the target 
cell membrane form invaginations and facilitate GzmB entry. Studies have shown 
that in concert with PFN-SG, GzmB delivery to cells was markedly improved, when 
compared to PFN proteins alone, suggesting that this complex enhances the entry of 
Gzms into the target cell (256). GzmB is thought to enter cells through one of two 
mechanisms: diffusion or endosomal uptake.  
 
Diffusion of GzmB into the target cell cytosol may require PFN-generated pores 
within the membrane that allow the diffusion of Gzms into the cytosol (242, 288, 289). 
Studies have demonstrated that PFN added to in vitro cell cultures with and without 
GzmB can induce cytolysis. Whilst PFN alone induces necrosis, the addition of 
GzmB facilitates the initiation of apoptotic cell death. In addition, a study by Gross et 
al. demonstrated a PFN-independent entry of GzmB into the cytosol. Heat shock 
protein (HSP)-70, expressed by a human colon carcinoma cell line, was shown to 
facilitate the uptake of GzmB into the cells (290). Whilst this uptake indeed induced 
apoptosis in the cells, the effect was observed over a 24-hour period of GzmB 
exposure to the cells. An unexpected finding of this study was that the high 
expression of HSP-70 on the surface of cancer cells increased cell-mediated lysis. 
This demonstrates that there are proteins, in addition to PFN, that can facilitate the 
entry of GzmB into the target cell. 
 
The endosomal route of PFN, Gzms and SG uptake is a mechanism facilitated via 
invagination and disruption of the target cell membrane, demonstrated by a number 
of groups (261, 287, 288) (Figure 1.16). Collectively, these studies have shown that 
the binding of PFN to the target cell membrane caused ruptures that allowed Ca2+ 
entry into the cytosol (291). This triggered a membrane repair response (MRR) 
mechanism, by which the damaged membrane was endocytosed in a clathrin- and 
dynamin-dependent manner (261, 265, 292, 293). As a result, PFN-GzmB-SG 
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complexes bound to the target cell membrane via PFN were endocytosed into the 
target cell in a number of early endosomal antigen (EEA)-1 positive endosomes. The 
fusion of these endosomes forms larger vesicles, termed gigantosomes (294). The 
neutral pH within the lumen of these gigantosomes causes the gradual dissociation 
of PFN-GzmB-SG complexes. PFN monomers insert into the gigantosome 
membrane, oligomerise into pores, and disrupt the structural integrity of the 
membrane. PFN-mediated pore-formation at this stage facilitates the gradual release 
of free Gzms into the cytosol until the collapse of the gigantosome, providing the full 
release of GzmB, and the death of the target cell. This growing body of evidence 
suggests that it is most likely that this mechanism is used by GzmB to access the 
target cell cytosol. These findings demonstrate the necessary role of both PFN and 
GzmB to act in concert to initiate apoptosis, driving cytolytic effector functions. 
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Figure 1.16. Calcium-dependent endosomal uptake of granzyme B into the target cell. 
Recent data suggests that granzyme B enters the target cell through endosomal uptake. (A) 
Perforin (red) binds to the cell membrane (brown), creating small pores that allow the influx of 
calcium ions (green). (B) Calcium ions within the target cell trigger the membrane repair response, 
a mechanism by which the cell tries to repair damage via endocytosis of the damaged membrane. 
(C) Endosomal uptake of the damage membrane internalises perforin, granzyme B (orange) and 
serglycin (purple) complexes. Under neutral pH, perforin dissociates from the complex, creating 
pores within the endosome. Granzyme B gradually leaks out of the endosome until sufficient pores 
cause a collapse of the endosomal and a full release of granzyme B and perforin initiate apoptosis. 
Cell death is mediated through binding to the mitochondria (black) and fragmenting DNA within the 
nucleus (red). 
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1.4 NK cells and disease 
 
A significant proportion of NK cell research is focused towards their ability to lyse 
virally infected or transformed cells. As a result, therapies to increase NK cell lytic 
capacity against tumours have been extensively researched and there are various 
therapies emerging that employ redirected lysis to aid the clearance of transformed 
cells. However, research into the role of NK cells in autoimmunity has not been 
widely studied and hence, few therapies are available to modulate their role in these 
diseases. 
 
1.4.1 Anti-tumour therapies 
 
Despite the evolution of a range of receptors to recognise and exert cytotoxic function 
towards transformed or infected cells, flaws in the system, mostly due to immune 
escape or evasion, can lead to the development of long-term, terminal cancers (295-
297) or persistent viral infections (298-300). Therefore, therapeutic manipulation of 
NK cells, both in vitro and in vivo, to augment the clearance of pathogenic agents 
within the body is an area of ongoing research.  
 
There have been a number of methods developed to enhance NK cell-mediated 
cytolytic functions against tumours. The first trials in humans made use of ex vivo IL-
2 expanded NK cells. Recent work using such methods have shown NK cell cytolytic 
capacity to increase 5-fold and resulted in remission in a number of patients treated 
(301). More recently, ex vivo NK cells have been expanded with other cytokines such 
as IL-15, or EBV-transformed lymphoblastoid feeder cells. These studies have both 
shown promising results. IL-15 expansion of NK cells increased cytotoxicity by 40-
fold, prolonging one- and two-year patient survival rates by 20% and 30% 
respectively (302). EBV-transformed feeder cells have been shown to increase 
NKG2D expression on NK cells, in addition to increasing cytotoxic capacity and 
expanding cell numbers up to 850-fold over three weeks (303). In addition to the ex 
vivo expansion of NK cells, clinical researchers are using novel methods of 
amplifying the NK cell response against tumour cells. In a very recent trial by Guma 
et al., IL-2 in an aerosol form was administered intranasally (304). They reported an 
increase in the numbers of NK cells in metastatic nodules, but not in other organs. 
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Encouragingly, the application of aerosol IL-2 decreased nodule size in the lung and 
the further addition of expanded NK cells was able to decrease the number of lung 
nodules by up to 6-fold. 
 
Unfortunately, such therapies are not all successful in the long term. This is due to 
numerous factors including autologous inhibition by MHC-I and immunosuppression 
by tumour-derived factors and regulatory T cells (Treg). To overcome this, the 
transfer of tissue-typed NK cells from healthy related donors was trialled (305). A 
number of factors must be considered prior to the allogenic transfer of NK cells. 
These include KIR/HLA expression profiles of both the donor and recipient to ensure 
tissue compatibility and to improve the outcomes of adoptive transfer-based 
therapies (306-308). Nonetheless, IL-2-activated-NK-cell transfer resulted in 
successful expansion of NK cells and up to 66% of patients cleared leukaemias – 
significantly more than patients whose NK cell transfers failed to expand. 
Unfortunately, despite this success, IL-2 expansion of NK cells can also be 
associated with life-threatening toxicity (309), as well as an increase in NK cell 
susceptibility to apoptosis following contact with vascular endothelium (310).  
 
The expansion of NK cells using IL-15, a cytokine paramount to NK cell 
development, is possible without some of the caveats of IL-2 activation (32, 310, 
311). IL-15 has been shown to be more efficient than IL-2 for expanding NK cells, 
promoting their survival and protecting them from IL-2 associated-induced cell death 
(AICD) (310, 311). The limitation of this therapy is that large quantities of IL-15 are 
required to provide a significant effect. For this reason, the use of DC-mediated IL-15 
trans-presentation has been proposed (312). Further studies have also focused on 
the use of IL-12 and IL-18 for augmentation of NK cell function. Aside from increased 
cytotoxicity and lysis of tumour cells, both IL-12 and IL-18 have been shown to 
increase IFNγ production from NK cells through the upregulation of the IL-12 receptor 
in response to IL-18 (38, 313-316). This enhanced IFNγ production promotes a type I 
immune response that can counteract the immune escape mechanisms employed by 
tumour cells or immune suppression mediated by Tregs (317-319). These findings 
show that NK cell-based immunotherapies can be used to efficiently modulate 
cytolysis, improving the eradication of tumour cells.  
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Another NK cell-based therapy that has been trailled is use of antibodies to direct 
ADCC against transformed cells (320). A successful and well-studied example is 
Rituximab. Rituximab is a monoclonal IgG antibody against CD20, expressed on 
mature B cells, and is currently used to treat non-Hodgkin’s lymphoma (321, 322). 
Increased efficacy of this antibody has been attributed to both the high affinity CD16 
F/F genotype (a homozygous polymorphism at position 158 of Phe instead of Val) 
(323) and the alteration of the phenotype of the B cell itself (CD20 capping), 
increasing its susceptibility to killing (324). The use of antibodies to target NK cells 
towards tumours provides a useful tool for combating tumour cell growth. Other 
monoclonal antibodies that promote NK cell ADCC have been successful, including 
Trastuzumab (breast cancer) (325), Alemtuzumab (chronic lymphoid leukaemia) 
(326) and Cetuximab (colorectal cancer) (327).  
 
In combination with therapies promoting ADCC, blocking antibodies against the KIR 
inhibitory receptors have also been developed. Specifically, an antibody that targets 
KIR2DL1/2/3 has been shown to increase the lysis of acute myeloid leukaemia cells 
and clinical trials are currently underway (328). Finally, antibodies to promote 
cytokine secretion and cell-mediated cytolysis have also been developed. 
Trastuzumab-mediated ADCC was found to upregulate CD137 on the NK cell 
surface. CD137, a co-stimulatory molecule of the TNF receptor family, is normally 
expressed at low levels on NK cells prior to CD16 ligation. Whilst the mechanism is 
unknown, the addition of anti-CD137 antibodies along with Trastuzumab increased 
both IFNγ and ADCC-mediated cytolysis of HER2+ breast cancer cells, both in vitro 
and in vivo (325). Antibodies against CD137 have been used in combination with 
Rituximab and increased both NK cell degranulation and IFNγ production. Other 
treatments include the co-administration of antibody-based therapies that target 
cancer cells or NK cell receptors with drugs. One such drug is Lenolidamide that 
enhances ADCC in the treatment of multiple myelomas (329). In addition, cytokine-
based stimulation (IL-2, -12, -15, and -21) has also been shown to increase NK cell-
mediated ADCC against tumour cells (330-333).  
 
These findings demonstrate that there is a vast amount of work focused on 
enhancing NK cell-mediated tumouricidal functions. The expansion, manipulation, 
and direction of the immune system towards evasive targets have shown promising 
results. Whilst the exact mechanisms of some therapies remain unknown, it is clear 
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that NK cells play a pivotal role in protection against virally infected and transformed 
cells.  
 
1.4.2 Dysregulation and auto-immunity 
 
Autoimmune diseases can be divided into two types: tissue-specific (e.g. diabetes 
mellitus (DM) or multiple sclerosis (MS)) or systemic (e.g. systemic lupus 
erythematous (SLE)) (334). The majority of studies on autoimmune diseases have 
focused on inappropriate T- and B-cell-mediated reactions to ‘self’, which can be a 
multi-step process over a number of years (335). The inclusion of NK cells to 
autoimmune studies most commonly arises following the onset of symptoms and 
thus their contribution to autoimmune diseases remains poorly investigated (334). 
 
Several studies have shown an elevated number of NK cells in tissues affected by 
autoimmune diseases, such as the pancreas of type 1 DM patients (336), the hair 
follicles of alopecia areata patients (337) and the muscle tissues of jeuvenile 
dermatomytosis affected individuals (338). The roles of NK cells in the progression of 
these diseases is not fully understood, but studies in both mouse models and human 
patients have shown that increased numbers of NK cells are located within the islets 
of Langerhans during the early stages of type 1 DM, whereas late-term diseased 
tissues show a reduced number (336, 339). Other studies have shown a role of 
ADCC in SLE nephritis. The high expression of CD16 by NK cells, in combination 
with a high-affinity F/F homozygous polymorphism, renders the patient susceptible to 
severe cytolysis of kidney tissue (340) following the production auto-reactive 
antibodies by plasma cells (341). These findings suggest that NK cells may 
contribute to the onset and initial progression of autoimmune conditions, whereas 
later stages of disease may not involve NK cells.  
 
Conversely, in some autoimmune diseases, NK cell numbers are severely reduced 
and those that are present lack cytolytic capacity (342-344). Various studies have 
shown that NK cell involvement in autoimmunity can be tissue specific, a reflection of 
their varied functions within different tissues (345). For instance, rheumatoid arthritis 
(RA) patients have been shown to elevate levels of IFNγ-producing CD56bright NK 
cells in their joint synovia (343, 346), whilst peripheral blood NK cells are depleted 
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and those remaining have a reduced function. Functionally, the increased production 
of IFNγ by NK cells has a direct effect on DCs, promoting disease progression in this 
setting (343, 344).  
 
NK cells have been shown to have simultaneously exacerbating and ameliorating 
roles in a range of autoimmune diseases. This dichotomy may depend on NK cell 
interactions with other immune cells. MS, an inflammatory disease that affects the 
central nervous system (CNS), is thought to be a case where NK cells have bi-modal 
roles. An immunoregulatory role has been demonstrated by lysis of alloreactive T 
cells by NK cells (347). In contrast, oligodendrocytes, astrocytes and microglia in the 
CNS are directly lysed through the recognition of NKG2D ligands (348, 349). 
However, monoclonal antibody therapies, such as daclizumab (a humanized anti IL-
2Rα antibody), significantly increase the number of CD56bright NK cells leading to a 
decrease of infiltrating CD4+ T cells in the CNS (350, 351). This demonstrates that 
whilst NK cells may well play a role in disease progression, NK cell directed 
therapeutics may increase their capacity for an immunoregulatory, protective role.  
 
Studies of SLE, a disease associated with immune complex-mediated destruction 
and dysfunction of a number of organs, have indicated that NK cells may inhibit the 
development of B-cell-derived autoantibodies, a hallmark of SLE (352). Specifically, 
NK cell depletion leads to the development of autoantibody-secreting B cells, whilst 
adoptive transfer of NK cells delayed the onset of antibody production (353). 
Furthermore, in vitro differentiation of haematopoietic stem cells (HSC) taken from 
SLE patients generated lower proportions of NK cells that expressed reduced 
amounts of PFN (344). These findings suggest that NK cells have both ‘central’ and 
‘peripheral’ roles in the development of SLE. Further, NK cells in SLE are CD56bright, 
producing excess amounts of IFNγ. This results in a severe dysregulation of the 
adaptive immune system (354). There also appears to be a genetic component to the 
role of NK cells in SLE. Studies have shown that the CD16 F/F genotype, as 
discussed above, has been strongly correlated with increased IgG1 binding. This 
leads to improved ADCC, but increased pathogenicity of nephritic SLE (341). 
Potentially, this could result in a greater capacity for NK cell-mediated lysis. This 
double-edged sword could predispose NK cells to more efficient clearance of 
opsonised targets, but may also have the consequence of increased lysis of healthy 
cells in autoimmune diseases. 
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As of yet, NK cells are not direct therapeutic targets for autoimmune conditions (334). 
This is primarily due to a lack of knowledge of the specific roles of NK cells within 
each disease setting. The studies detailed above have demonstrated that NK cell 
depletion or loss/gain of functions could be associated with the development of some 
autoimmune diseases. NK cells have various roles within the development of 
autoimmune disorders, associated with both cell-mediated lysis and cytokine 
production. The treatment of the immune dysregulation associated with autoimmunity 
is currently confined to targeting proteins expressed on cell surfaces or secreted into 
the serum. However, dysregulation of the immune system can also occur at the cell-
cell level, mediated by intercellular contacts like the IS (355). Currently, no therapies 
that target proteins secreted across the IS have been developed, possibly because 
antibodies targeting these molecules are unable to penetrate the interface formed 
between interacting cells. Therefore, the development of antibody-based therapies 
capable of penetrating the IS may provide novel methods to augment or inhibit the 
immune response.  
 
1.5 The immune synapse gasket 
 
A relatively unexplored function of the IS is to form a gasket, or seal, around its 
secretory domains. This may be formed by both inhibitory, e.g. KIR-HLA, and 
activating, e.g. NKG2D-MICA, complexes that possess small extracellular domains, 
spanning only ~15 nm. This has been confirmed by receptor-ligand crystal structure 
analysis (356, 357) and electron microscopy of the IS (65). These complexes 
segregate within the IS away from the larger, ~50 nm, LFA-1-ICAM-1 complexes (65, 
124, 189). Molecular ruling with QD of known diameters has also confirmed the 
distance of the inter-membrane span at the IS. These QD were sized to match or 
exceed extracellular receptor-ligand complex dimensions, and as a result were 
included or excluded from the synapse, respectively (189). As signalling is achieved 
by tyrosine-phosphorylation, similar receptor sizes allow clustering (9, 66) and co-
localisation of the receptors within the IS (124) along with associated adaptor 
proteins such as DAP10, DAP12 and CD3ζ (17). These data have conclusively 
shown that receptor size is crucial at the IS, however, how soluble extracellular 
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molecules are affected by this, or indeed could affect synapse formation, has not yet 
been investigated, 
 
The structure of the synapse, specifically with respect to the extracellular domains of 
receptor-ligand complexes, results in NK and target cell membranes coming into 
extremely close contact, within tens of nanometers. Following the binding of 
activating receptors, PFN and Gzms are released across the IS cleft – yet no 
bystander-cell death occurs (358). It has been hypothesised that this is due to the 
structure of the IS forming a gasket, or seal, around the signalling and secretory 
domains (68, 359-364). This gasket may consist of membrane ruffles (123, 363), 
adhesion molecules (365), activating and inhibitory complexes (19, 90) and distal 
CD45 (65). The crystal structures of ICAM-1 (356) and LFA-1 (212) suggest that the 
extracellular receptor contours would be unable to perfectly align, resulting in small 
nanometer spaces around the receptor-ligand complexes. Whilst this may prevent 
receptors forming a tight seal as they accumulate at the synapse, the close proximity 
of the cell membranes may contribute to forming this gasket.  
 
To function as a gasket, the extracellular domains of the receptors at the synapse 
may cause both the inclusion of secreted proteins and the exclusion of extracellular 
molecules from the synapse. Should PFN and Gzms leak from the synapse, this 
could lead to collateral damage to neighbouring cells. Gasket formation may act to 
prevent leakage of cytotoxic mediators at the synapse. In addition, the inclusion of 
extracellular molecules within the synapse could affect the efficacy of cytotoxic 
proteins secreted by NK cells, either interfering directly with their function or 
decreasing PFN/Gzm concentration within the synapse. Studies using monoclonal 
IgG antibodies demonstrated the inability of these large molecules to block proteins, 
either cytotoxic mediators or cytokines, secreted at the synapse (366) (367). This 
suggests that the IS is able to restrict the entry of molecules into the synapse, but the 
extent to which this occurs, specifically regarding a range of molecular sizes, and 
whether this is directly determined by molecule size alone, has not been investigated. 
 
A gasket function of the IS would be beneficial to the immune system, maintaining 
cytolytic proteins within the synaptic cleft to provide the most efficient response. 
However, exclusion of molecules from the synapse may also restrict the ability to 
target these proteins and influence their function for therapeutic purposes. Most 
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importantly, many autoimmune diseases are associated with dysregulation at the 
synapse, either from signalling or secretion of cytotoxic proteins and cytokines (368). 
Any dysregulation at the synapse may lead to unnecessary attack on the body’s 
healthy cells. This can ultimately result in a range of diseases that are, at present, 
difficult to treat. Therefore, to determine whether – or to what extent – the IS 
functions as a gasket to exclude extracellular molecules, would provide a basis for 
the engineering of novel antibody-based therapies. Subversion of this gasket by 
antibody-based therapies could allow targeting of secreted proteins that are currently 
inaccessible to existing therapeutics. This could provide a novel treatment for 
autoimmune disorders. 
 
1.6 Fluorescence Microscopy 
 
Many major discoveries regarding dynamics and functions of the IS have been 
revealed using fluorescence microscopy. Our understanding of IS structure, such as 
the identification of protein segregation (10) (9) (369), and the dynamics of receptors 
(196) (13) and signalling proteins (370) (203) (371), is entirely dependent on this 
technique. Fluorescence microscopy is now an essential tool to study cellular 
structures and functions – including at the IS – in real-time. The ability of this 
technique to accurately visualise fluorescent labels, tags and proteins enables 
biologists to watch cell functions unfold before them. Furthermore, the quantification 
of images allows the generation of readable information that can describe, in detail, 
numerous cellular processes. Most importantly, fluorescence microscopy facilitates 
the study of processes and mechanisms, such as the IS, that cannot be visualised or 
investigated by other means.  
 
1.6.1 Basic principles of confocal microscopy 
 
Confocal microscopy is an imaging technique that is based on wide-field 
fluorescence microscopy. In this technique, the entire sample is illuminated and all 
photons emitted are collected at the same time to create an image. As the same lens 
is used for illumination of the entire sample and signal collection, this results in a 
significant amount of background noise from out-of-focus light reflected from the 
sample (Figure 1.17). 
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This was overcome by optically sectioning the sample, building up an image from 
multiple images taken horizontally along the xy-axis and vertically through the z-axis. 
This led to the development of the laser scanning confocal microscope (372), 
providing an increase in optical resolution and contrast. This technique uses a laser 
that is passed through a light source aperture and is then focused by an objective 
lens into a small focal volume, either within or on the surface of the sample. As the 
light reflects off the sample, a beam splitter separates a portion of light and a pinhole 
is used to prevent any out-of-focus light from reaching the photo-detection device 
(Figure 1.18). Detectors are usually a photomultiplier tube (PMT), avalanche 
photodiode (APD) or a combination of both, termed Hybrid Detectors (HyD) (373).  
 
Figure 1.17. Schematic diagram of a fluorescence wide-field microscope.  A wide-field 
microscope uniformly illuminates the sample at a specific wavelength (purple). The light emitted 
from the sample (green) is collected on a wide-field detector, producing an image of the entire 
sample. 
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PMT detectors consist of a vacuum tube that detects low amounts of photons, 
converting the signal into an analogue electron flow. The electron flow is then 
amplified over a series of dynodes before arriving at the anode. This continuous 
signal is sampled at separate time points and then digitised into a discrete signal by 
an image processor, pixel-by-pixel, into the image displayed by a computer. If signals 
are fast enough, PMT can measure single photons as electric pulses. However, due 
to the nature of electron amplification employed by PMT, images produced can 
contain a significant level of noise (Figure 19A).  
 
APD are highly sensitive semiconductor devices that use the photoelectric effect to 
convert light into an electrical signal. These detectors use a voltage to drive an 
avalanche amplification of electron signals. Starting from electron pairs, waves of 
electrons move through a multiplication zone where they are amplified by impact 
ionisation. The amplification of signals within an APD allows the signal to be 
Detector
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Laser
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or
Figure 1.18. Schematic diagram of a laser scanning confocal microscope. A laser beam at a 
specific excitation wavelength (purple) is focused onto the sample. This creates an excitation spot   
across a specific plane of the sample (red dotted). The emitted light is focused through a pinhole 
towards the detector. In-focus light (red) is captured by the detector, and out-of-focus light (blue) is 
blocked around the periphery of the pinhole. The laser line is then scanned across the sample to 
generate an image. The focal plane of the microscope can be adjusted throughout the sample 
(along the z-axis) to generate multiple slices and a computer can reconstruct these into a 3D 
image. 
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measured without additional circuitry, resulting in very low noise. Despite a low 
dynamic range, APD provide a better sensitivity in the red range of wavelengths. 
(Figure 19B).  
 
HyD are a combination of both PMT and APD detectors, allowing precise and fast 
measurements over a wide dynamic range. HyD use a photocathode for light 
conversion, similar to the PMT. Electrons within the PMT component are accelerated 
by a high voltage, which is dissipated in a semiconductor almost instantly. The initial 
high voltage acceleration increases the signal 500-fold and the straight movement of 
the accelerated photon means that there is no variation in the time that the individual 
electrons hit the semiconductor. This provides a higher frequency of photon counting, 
which directly translates into a higher dynamic range. This also reduces the 
instrument time constant, improving the lifetime of the detector. Once electrons have 
reached the semiconductor, avalanche gain increases the count and they are 
converted to an electronic digital signal (Figure 19C). 
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The laser beam of a confocal microscope can be focused throughout the sample, 
which enables the imaging of a number of confocal planes, which can then be 
reconstructed into a three-dimensional (3D) image. This technique provides a 
method for studying biological structures, either live or following fixation, in details 
that surpass previous microscope techniques (374). 
Lasers of specific wavelengths can be used to illuminate the sample. This allows the 
use of fluorophores that are bound to individually dyed or labelled samples. Use of 
Figure 1.19. Schematic diagrams of confocal microscope detectors. Confocal microscopes 
use a number of detectors to convert light energy into an electrical signal. Each detector type has 
advantages and limitations, as described in the text. (A) A photomultiplier tube (PMT) detector 
converts photon energy into accelerated electrons at the photocathode. Subsequent collisions with 
dynodes multiply the photoelectrons by secondary emission. The potential difference between the 
dynodes determines the multiplication of photons. (B) An avalanche photodiode (APD) absorps 
photons in an intrinsic layer, where an electron-hole pair is generated. Within a multiplication zone, 
an electron avalanche is created by impact ionisation. (C) A hybrid detector (HyD) is a combination 
of PMT and APD detectors. HyD firstly uses PMT technology to accelerate the electrons through a 
vacuum, the accelerated electrons then strike an APD where the electron signal multiplies. 
Adapted from Borlinghaus, Birk and Schreiber (2012). 
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fluorophores enables identification or localisation of specific proteins or structures 
throughout a sample. Fluorophores are molecules that are excited by a particular 
wavelength, providing energy that moves electrons to a higher energy state. A loss of 
energy through a nonradiative transition (internal conversion) then occurs due to a 
relaxation of the molecule to its lowest vibrational level (termed vibrational 
relaxation), a process involving dissipation of the electron’s energy to its 
surroundings. This is followed by the loss of energy that is then emitted as light (a 
photon) at a longer wavelength than that used for excitation, specifically the 
difference in energy between the first excited state and the internal conversion. 
These photons can then be collected to image labelled areas within a sample (Figure 
1.20). Following the identification of the genetic sequence for fluorescent proteins, 
such as green fluorescent protein (GFP) (375), this allowed for endogenous proteins 
within cells (or whole organisms) to be fused in tandem at the C- or N-terminal with 
GFP. These constructs can be used to identify specific protein locations, interactions 
and dynamics in real-time. 
 
 
 
  
Figure 1.20. Electronic states of fluorophore excitation and emission. Molecule electrons can 
emit energy as a photon. This occurs though excitation and relaxation (gain and loss of energy) 
across higher energetic vibrations states (S0–3). The electrons of a resting fluorophore populate the 
ground state (S0). When excited by light of the appropriate wavelength, the fluorophore will absorb 
the photon and be promoted to a higher energy and vibrational state (S3) (purple arrow). A loss of 
energy through internal conversion (black arrow) dissipates the electron’s energy into its 
surroundings, termed vibrational relaxation. Finally, the further loss of energy is then emitted as a 
photon at a longer wavelength than used for excitation – the difference between the energy of the 
excited state and the internal conversion (green arrow). 
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1.6.2 Limitations of confocal microscopy 
 
Despite the vast improvements of confocal microscopy over previous imaging 
techniques, there still remain some limitations. For instance, when imaging smaller 
structures (at the micro- or nanometer scale), resolution and diffraction become 
limiting factors on the size of structures that the microscope can discriminate 
between. Optical resolution is defined as the minimal distance at which two separate 
structures can be identified as individual objects. This is heavily dependent on the 
signal-to-noise (SNR) ratio and the point spread function (PSF) of the microscope. 
SNR is the ratio at which the signal strength from the sample can be measured over 
the background levels. This can be affected by the fluorophore brightness, density or 
specificity within a sample. SNR can also be exacerbated by increased laser power 
but ameliorated by reducing the size of the pinhole through which photons reach the 
detector. However, this reduction in photon numbers produces a dimmer image. This 
can be partially corrected by altering the gain (based on the voltage) of the detector.  
Extremely high or low values of gain, however, result in a non-linear increase or 
decrease of signal, affecting quantitative analysis of the image. The PSF is the 
response of an imaging system to a point source or object. This is usually a spatial 
domain that is occupied by each fluorophore and is determined by the imaging 
system (Figure 1.21). The PSF plays a key role in optical resolution as the overlap of 
two adjacent fluorophores prevents the resolution of those two independent objects. 
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Diffraction is the consequence of varying refractive indexes (the ratio of the speed of 
light in a vacuum to the speed of light within a substance) on the path of a wave. 
Some diffraction is overcome by the use of a medium, usually water or oil, between 
the objective lens and the cover glass. The refractive index of the medium is matched 
to the lens and cover glass so that when the light exits the objective, the diffraction is 
almost entirely eliminated, as compared to if it was passing through air. However, as 
light travels through a sample, there are numerous refractive indexes (a change of 
sample composition, proteins, etc.), which diffract the light. This can limit the detail of 
cellular structures, proteins and imaging dynamics when using confocal microscopy.  
 
  
Figure 1.21. The point spread function (PSF) of a microscope. The PSF is the response of a 
microscope system to a point object. This is the smallest representation of a single object that the 
imaging system can achieve. The PSF can be measured in the (A) xy-axis, averaging around 250 
nm, and the (B) xz-axis, averaging around 1 μm. The PSF can vary depending on the microscope 
system and the fluorophore. 
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1.6.3 Basic principles of total internal reflection fluorescence 
microscopy 
 
Total internal reflection fluorescence (TIRF) microscopy is based on conventional 
wide-field techniques, similarly to confocal microscopy. This technique is able to 
selectively excite fluorophores within a small (~100 nm) region adjacent to the 
coverglass, known as the evanescent field, minimizing the background fluorescence 
from the intracellular regions. For this reason, TIRF microscopy as also known as 
evanescent wave or evanescent field microscopy. 
 
TIRF microscopy takes advantage of the effect of total internal reflection. When the 
incidence angle of the light source is irradiated at above the ‘critical angle’, almost all 
photons are reflected from the surface at the same angle. Instead of directly 
illuminating the sample, an evanescent wave is created on the opposite side of the 
coverglass, penetrating approximately 100 nm into the sample. This allows improved 
sample sectioning compared to confocal microscopy. Only fluorophores within the 
range of this evanescent field, which decays exponentially into the sample, are 
excited. This minimises the background fluorescence and creates an image of the 
sample immediately in contact with the coverglass surface (Figure 1.22). Optimal 
TIRF is achieved by creating a uniform angle of illumination. This is achieved by 
focusing the laser beam on the back focal plane of the objective. Here, the light is 
collimated and exits the objective in a coherent beam, all rays parallel, at the same 
angle, and in phase. Practically, the illumination angle of a TIRF microscope cannot 
be ‘set’ at a predefined angle, but rather evaluated for each sample type, as the 
critical angle will change depending on the refractive index of the sample.  
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TIRF microscopy has both advantages and disadvantages compared to confocal 
microscopy. Whilst confocal microscopy provides optical sections from almost any 
plane within a specimen, unlike the narrow ~100 nm imaging depth of TIRF 
microscopy, the optical sections generated by a confocal microscope can be 6-fold 
greater in depth. Consequently, the application of either technique is governed by the 
experiment and exactly what is being imaged. TIRF microscopy has been utilised for 
a wide range of studies investigating processes close to the cell-slide interface, 
including cytoskeleton structure and dynamics, endocytosis, cell-substrate contact 
regions and intracellular signalling (376). A number of significant membrane-proximal 
events regarding the IS have been revealed and studied using TIRF microscopy with 
the addition of tools such as supported planar bilayers (377). TIRF microscopy is 
therefore an extremely powerful technique for imaging samples at or within extremely 
close proximity to the coverglass. 
 
Fluorescence microscope offers insights into biological functions that cannot be 
addressed by other means. The dynamic movement of molecules, the organisation of 
cellular structures, and mechanisms of cellular functions has all been revealed 
through this technique. There remain many questions regarding NK cell function, but 
microscopy promises to be an indispensible tool to address these issues. 
Figure 1.22. Schematic diagram of total internal reflection fluorescence (TIRF) microscopy. 
A laser beam at a specific excitation wavelength (purple) is focused onto the sample above the 
critical angle to give total internal reflection. This creates an evanescent wave (red) that decays 
exponentially from the sample-slide interface, selectively exciting fluorophores within a restricted 
region of the sample adjacent to the coverglass (black). The microscope optics then collect the light 
from these excited fluorophores (green) creating an image with a z-axial depth of ~100nm. 
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1.7 Aims and hypothesis  
 
The IS is a complex, ordered and dense meshwork of protein-protein interactions 
comprised of integrin, activating and inhibitory receptor-ligand complexes. A balance 
of signals in favour of activation results in NK cells directly secreting cytotoxic 
mediators, primarily PFN and Gzms, across the synapse to initiate apoptosis and 
clearance of diseased cells.  
 
Close, but variable, proximity of the NK and target cell membranes occurs at the IS. 
This results in not only the size-dependent segregation of receptor-ligand complexes, 
but may also form a gasket, or seal, around the synapse. This gasket could prevent 
both the leakage of cytotoxic mediators but could also limit the entry of extracellular 
proteins, including antibody-based therapies. Some anecdotal evidence exists that 
supports this theory, however, it has not been directly tested. This may explain why 
there are currently no antibody-based therapies that target these secreted proteins. 
Development of an appropriately sized antibody may be able to access the synapse 
and block secreted proteins.  
 
Much is still unknown about the nature of the cytolytic response initiated by NK cells 
across the IS. Before the development of therapies to block NK cell effector proteins 
can occur, the concentrations at which they are released across the synapse must be 
elucidated. Given that any cytolytic activity of Gzms is wholly dependent on the 
presence of PFN, a better understanding of the nature of the PFN response is 
crucial. In particular, NK cells recognise a number of ligands, yet the effects of these 
different ligands and their density on the amount of PFN secreted have not yet been 
directly investigated. Further to this, the impact of serial stimulation of NK cells by 
activating ligands has not been addressed, with regards to the effect on PFN 
secretion.  
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The aims of this thesis were to establish to what extent the IS functions as a gasket 
to extracellular molecules and to quantify PFN secretion at the synapse.  
 
The specific objectives of this thesis were: 
 
1. To investigate the extent to which the IS functions as a gasket to various 
nanometer-scale sized molecules (Chapter 3) 
 
2. To investigate the extent to which the NK cell IS acts as a gasket against 
functional proteins (Chapter 4) 
 
3. To quantify the amount of PFN secreted by NK cells following activation and 
degranulation (Chapter 5). 
 
To address these aims, fluorescence microscopy was utilised. In addition, cell 
responses were measured using flow cytometry, molecular biology techniques and 
other cell assays. 
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Chapter 2 – Materials and Methods 
 
2.1 Cells and cell culture 
 
2.1.1 Immortalised cell lines 
 
A variety of immortalised cell lines were used throughout this study. All cell lines were 
maintained in RPMI-1640 supplemented with 10% heat-inactivated foetal calf serum 
(FCS), 2 mM L-glutamine, and 1 mM penicillin/streptomycin (hereon referred to as 
R10) (all Gibco, Life Technologies, USA). Cells were incubated at 37ºC in a 5% 
(vol/vol) CO2 atmosphere. 
 
Effector cell lines 
 
Effector cell lines used in this study were the YT sub-clone, YTS (378), and the 
leukaemic T cell line, Jurkat (379). To form inhibitory synapses, YTS cells expressing 
KIR2DL1 (YTS/KIR) (380) were available in the lab.  
 
Target cell lines 
 
The target cell lines used in this study were as follows. The human EBV-transformed 
B cell line 721.221 (hereon referred to as 221), which lacks endogenous class I HLA-
A/B/C, was used as the main NK cell target (381). This was due to their specific lysis 
by both YTS and primary NK cells. For inhibitory synapse studies, 221 cells 
transfected with HLA-Cw6 (221/Cw6), the cognate ligand for KIR2DL1, were 
available in the lab (89). In addition, the B cell lymphoblastic cell line, Daudi (382) 
and the myeloid leukaemia cell line, K562 (383), were used as additional targets for 
primary NK cells. To study the T cell synapse, Raji cells (384) were loaded with 
superantigen Enterotoxin E (SEE) from Staphylococcus aureus (Sigma Aldrich, UK). 
To load Raji cells, 5 x 106 cells were centrifuged (353 g, 5 minutes) and resuspended 
in 1 mL R10. One microlitre of SEE was added to the suspension to a final 
concentration of 10 ng/mL and incubated at 37ºC 5% (vol/vol) CO2 for 1 hour. Cells 
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were then washed 3 times with conjugation medium (0.5% FCS in RPMI-1640) by 
centrifugation (353 g, 5 minutes) and resuspended in 1 mL R10.  
 
2.1.2 Primary human NK cells 
 
Primary human NK (pNK) cells were isolated from peripheral blood mononuclear 
cells (PBMC) from normal healthy donors by negative selection using an NK isolation 
kit (Mitlenyi Biotec, Germany) as previously described (90). Briefly, human blood 
from a leukocyte cone was poured in to a 250 mL flask and 50 mL RPMI 160 
(equilibrated to room temperature) was then added (Sigma-Aldrich). In 50 mL tubes, 
15 mL Ficoll-Pacque (GE Healthcare) was added and an equal amount of the 
blood/RPMI 1640 mixture was added drop by drop. This was then centrifuged at 535 
g for 40 minutes at 20ºC without a brake applied. Using a sterile plastic Pasteur 
pipette, the lymphocyte layer (second from top) was removed and placed into 50 mL 
tubes. The cells were then washed twice, adding RPMI 1640 to the lymphocytes to a 
final volume of 50 mL and centrifuged at 301 g for 10 minutes at room temperature. 
The supernatant was then decanted and cells were resuspended in 10 mL RPMI 
1640, counted, and 108 cells were taken and RPMI 1640 added to a final volume of 5 
mL. Tubes were then centrifuged at 301 g for 10 minutes at 4ºC and the supernatant 
removed completely. The pellet was then resuspended in 400 μL MACS buffer (PBS, 
2mM EDTA (Sigma) and 0.5% BSA (Sigma); sterile filtered) and to this, 100 μL 
biotin-antibody cocktail (Product code: 130-092-657; Miltenyi Biotec) was added, 
mixed, and incubated for 5 minutes at 4ºC. After incubation, 300 μL MACS buffer and 
200 μL anti-biotin microbeads (Miltenyi Biotec) were added, mixed and incubated for 
10 minutes at 4ºC. Cells were then washed by centrifugation at 301 g for 10 minutes 
at 4ºC and the supernatant removed. Cells were then resuspended in 500 μL MACS 
buffer and placed in a prepared (rinsed with 3 mL MACS buffer, placed in a magnetic 
stand (Miltenyi Biotec)) LS column (Product code: 130-042-401; Miltenyi Biotec) over 
15 mL tubes. The column was then washed 3 times with 3 mL MACS buffer, allowing 
column to dry between each wash. The cells were then counted, pelleted by 
centrifugation at 301 g, 4ºC and resuspended in clone medium (described below) to a 
final cell density of 106/mL. 
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Human biological samples were sourced ethically and their research use was in 
accord with the terms of the informed consents. Blood collection approved for 
Imperial College London by the Riverside Research ethics committee 
(05/Q0401/108) and for the University of Manchester by the University Research 
Ethics Committee (12295). 
 
Primary NK cells were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) 
supplemented with 10% human serum, 2mM L-glutamine, 1mM sodium pyruvate, 
1mM penicillin/streptomycin and 1 mM non-essential amino acids (all from Gibco, 
Life Technologies, USA) (hereon referred to as clone medium). Cells were incubated 
at 37ºC in a 5% (vol/vol) CO2 atmosphere. Following isolation, pNK cells were 
expanded using 150 U/mL recombinant interleukin (IL)-2 and 6 day rested prior to 
use. 
 
2.2 Dextran 
 
Dextran (Molecular Probes, Life Technologies, USA) is a hydrophilic, complex 
branched glucan (a polysaccharide comprised of glucose molecules). Molecules of 
varying molecular weights are synthesised from sucrose by certain lactic-acid 
bacteria (385). Dextran can be bound to different fluorophore dyes to allow 
visualisation using a fluorescence microscope. Dextran has been previously 
measured by dynamic light scattering to give nominal values of the hydrodynamic 
radii for each molecular weight available (386, 387). The dextrans used in this study 
including molecular weights, hydrodynamic radii, fluorophore conjugations, excitation 
and emission maxima and working concentrations are detailed in Table 2.1 below. 
Stock solutions were prepared in phosphate buffered saline (PBS) to maintain 
physiological salt concentrations. Working concentrations were prepared by further 
dilution of stock solutions in R10 medium. 
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Molecular 
Weight 
(kDa) 
Hydrodyna
mic 
Diameter 
(nm) 
Fluorophore λex, 
λem 
(nm) 
Working 
Concentration 
(μM) 
Reference 
3 000 3 Fluorescein 494/
521 
50 (387) 
10 000 4 Biotin 
Fluorescein 
 
Texas Red 
 
Alexa Fluor 
647 
N/A 
494/
521 
595/
615 
650/
668 
50 (386) 
 
40 000 10 Fluorescein 494/
521 
50 (386) 
70 000 13 Fluorescein 494/
521 
50 (386) 
500 000 32 Biotin 
Fluorescein 
N/A 
494/
521 
20 (386) 
2 000 000 54 Fluorescein 494/
521 
2.5 (386) 
Table 2.1. Dextran molecular weights, hydrodynamic diameters, fluorophores, 
excitation/emission maxima, and working concentrations.  
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2.3 Antibodies and proteins 
 
2.3.1 Monoclonal antibodies 
 
The monoclonal antibodies used in this study are summarised in Table 2.2. Specific 
methods are outlined below in the relevant experimental procedures.  
 
Antigen Clone or 
Product No. 
Host Isotype Fluorophore Source 
Murine IgG A-11001 Goat (H + L) Alexa Fluor 
488 
Molecular Probes, 
USA 
Human CE2.10 Mouse IgG2a Unconjugated Abcam, UK 
Human dG9 Mouse IgG2b, κ Alexa Fluor 
488 
Biolegend, USA 
CD16 3G8 Mouse IgG1, κ Purified BD Pharmingen, 
UK 
HLA Class 
I 
W6/32 Mouse IgG2A Alexa Fluor 
488 
R&D Systems, 
UK 
KIR2DL1 143211 Mouse IgG1 FITC R&D Systems, 
UK 
Isotype 
Control 
20102 Mouse IgG2A Alexa Fluor 
488 
R&D Systems, 
UK 
Isotype 
Control 
11711 Mouse IgG1 FITC R&D Systems, 
UK 
CD56 B159 Mouse IgG1, κ Alexa Fluor 
488 
BD Biosciences, 
USA 
CD3 SP34-2 Mouse IgG1, λ PE-Cy7 BD Biosciences, 
USA 
NKG2D 1D11 Mouse IgG1, κ BV510 BD Biosciences, 
USA 
CD16 B73.1 Mouse IgG1, κ APC BD Biosciences, 
USA 
Table 2.2. Antibodies used for the analysis of size exclusion and receptor expression and for NK 
cell activation.  
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2.3.2 F(ab’)2 fragments 
 
Antibody fragments can be generated by digestion of IgG molecules (388). To study 
access of the immune synapse by antibody fragments, F(ab’)2 fragments conjugated 
to Alexa Fluor 488 were used (A-11070, Life Technologies). The fragments were 
generated from a goat anti-rabbit IgG that contained both heavy and light chains. The 
F(ab’)2 fragment was supplied at 2 mg/mL and used as described in the relevant 
methods section. 
 
2.3.3 Domain antibodies 
 
Domain antibodies (dAb) are single domain antibody fragments that comprise of a 
single monomeric variable heavy chain antibody domain (389). To investigate the 
ability of dAb to penetrate the immune synapse, a previously published dAb against 
glycoprotein VI (GPVI) was produced (390). HB2151 E. coli were electroporated to 
take up a pDOM5 expression vector containing the sequence for the BLO8-1dAb and 
a 5ml starter culture was grown in LB broth supplemented with 100 μg/mL 
carbenicillin (Sigma), incubated at 37ºC with 220 RPM shaking overnight. Then, 1 mL 
of the starter culture was used to inoculate a 1 L ONEX media broth culture (Merck 
Millipore, Germany) supplemented with 100 μg/mL carbenicillin and incubated at 
37ºC with 220 RPM shaking overnight. The culture supernatant was harvested by 
centrifugation in a bench-top centrifuge for 30 minutes at 6800 g and decanted into 
fresh flasks. To the supernatant, 20 mL of PBS washed sedimented protein L (Life 
Technologies), a bacterial protein that binds immunoglobulin, was added and rotated 
at 4ºC overnight. The solution was allowed to settle and the supernatant was 
removed (leaving about 20 mL for resuspension of the protein L). The solution was 
transferred to a PD10 column (GE Healthcare, UK) and washed, twice using 3 resin 
bed volumes of PBS and twice using 2 resin bed volumes of 10 mM Tris pH 7.4, to 
remove any remaining salts and precipitation. The dAb was then eluted from the 
matrix using 2 rounds of 2 resin bed volumes of 0.1 M glycine pH 2. Neutralisation of 
the elution buffer was performed using 0.2 volumes of 1 M Tris pH 8. Precipitation 
was removed by centrifugation at 6800 g for 2 minutes. Once precipitates had been 
removed, the dAb was concentrated using an ultra centrifugal filter (Millipore, USA) 
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by centrifugation at 6800 g for 10 minutes. Spins were repeated (times adjusted 
accordingly) until 1 mL of solution was remaining. 
 
As dextran has been prepared in PBS, a Slide-A-Lyser dialysis cassette (Thermo 
Scientific, USA) was used to transfer the dAb into PBS buffer. To achieve this, the 
dAb was placed in a PBS hydrated cassette by hypodermic needle, which was then 
placed in 2 L PBS and incubated at 4ºC overnight with stirring. PBS was then 
replaced and the cassette was incubated at 4 ºC with stirring for a further 2 hours. 
The dAb was then run on a 12% polyacrylamide gel at 165V for 45 minutes under 
reducing and non-reducing conditions to confirm its monomeric structure. 
 
For identification using a confocal microscope, the dAb was labelled using a Texas 
Red protein-X labelling kit (Molecular Probes, Life Technologies, USA) according to 
the manufacturer’s instructions. Briefly, 50 μL 1 M sodium bicarbonate solution was 
added to 0.5 mL of dAb solution. This was then placed in a 2 mL tube containing a 
metallic stirrer and DMSO-hydrated Texas Red dye. To label the dAb, this solution 
was then stirred at room temperature for 1 hour. The labelled protein was then 
placed in a column loaded with a purification resin and eluted into fractions. The most 
concentrated fraction was then measured by spectrometry to determine the final 
concentration and degree of labelling. 
 
2.3.4 Electrophoresis of antibodies  
 
To confirm that the dAb had a monomeric structure, dAb samples prior to and 
following protein L purification were boiled for 20 minutes under reducing and non-
reducing conditions. Thirty microlitres of each sample and 5 μL of protein ladder 
(SeeBlue II, Life Technologies) was then loaded into a 12% polyacrylamide gel (Life 
Technologies) and ran at 145 V for 45 minutes using a NuPAGE SDS-PAGE Gel 
system (Life Technologies). To confirm the molecular weights of each antibody used 
in size-exclusion experiments (rabbit IgG, F(ab’)2 and dAb), 5 μL of each antibody 
and 5 μL of protein ladder (Precision Plus, BioRad, USA)  were loaded into a 12% 
polyacrylamide gel and ran at 145 V for 45 minutes. 
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The gels were then fixed (50% methanol, 10% glacial acetic acid) for 1 hour at room 
temperature, stained (0.1% Coomassie Brilliant Blue (Sigma) for 20 minutes at room 
temperature, 50% methanol, 10% glacial acetic acid), then distained (40% methanol, 
10% glacial acetic acid) by 3 washes for 20 minutes, until the background of the gel 
was fully distained. Gels were then imaged using a GelDoc XR+ System (BioRad, 
USA). 
 
2.3.5 Proteins 
 
Recombinant and chimera proteins 
 
Recombinant and chimera proteins used in this study are detailed below in Table 2.3.  
 
Protein Concentration Source and Product 
Number 
Recombinant 0.05 mg/mL Abcam, UK; ab114201 
MICA-Fc 100 μg/mL R&D Systems, UK; 1300-MA-
050 
ICAM1-Fc 100 μg/mL R&D Systems, UK; 720-IC-
050 
Noggin-Fc 100 μg/mL R&D Systems, UK; 3344-NG-
050 
Table 2.3. Recombinant and chimera proteins used for quantification and NK cell activation. 
MICA, MHC class I polypeptide related sequence A; ICAM1, intercellular adhesion molecule. 
 
Low-density lipoprotein (LDL) 
 
LDL is a large protein complex (~500 kDa) that can bind to a specific receptor on the 
surface of vertebrate cells (391). An acetylated LDL conjugated to Alexa Fluor 488 
(Molecular Probes), supplied at 1 mg/mL, was used to assess its ability to enter the 
immune synapse. Acetylated LDL was used to reduce/prevent binding to LDL 
receptors expressed on cells. LDL was used as described in the relevant methods 
section. 
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2.4 Flow Cytometry 
 
Surface Receptor Expression 
 
NK cells were analysed for their surface expression of various receptors by flow 
cytometry. YTS/KIR and 221/Cw6 cells were assessed for their expression of 
KIR2DL1 or HLA-Cw6 respectively. Primary human NK cells were assessed for their 
expression of CD56, CD3, NKG2D and CD16 (see Table 2.2 for antibodies used). 
 
Briefly, 106 cells (or all cells from slide surface following stimulation) were collected 
and then resuspended in 1 mL flow buffer (0.1% FCS in PBS). The cells were 
incubated with primary conjugated antibodies at a dilution of 1:100 for 45 minutes at 
4ºC. Samples were then washed 3 times with FACS buffer and resuspended in 4% 
PFA for fixation at 4ºC for 20 minutes. Samples were then washed 3 times in flow 
buffer and transferred to FACS microtubes. Data was acquired on a FACSCanto II 
flow cytometer (Becton Dickinson, USA). 10 000 intact events, as determined in 
forward scatter/side scatter plots, were collected for each condition and data analysis 
was performed using FlowJo software version 9.7.6 (TreeStar). 
 
Cell Viability 
 
Primary human NK cells, YTS cells, and 221 cells were assessed for their viability 
after incubation with actin depolymerizing or stabilising drugs. Treated cells were 
washed and resuspended in flow buffer, before staining with DAPI (Molecular 
Probes) according to the manufacturer’s instructions, washed and resuspended in 
flow buffer prior to acquisition on the LSRFortessa, as described above for 
assessment of surface receptor expression.  
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2.5 Microscopy 
 
Confocal microscopy 
 
Confocal imaging was performed using commercially available laser scanning 
confocal microscopes (TCS SP5 RS and TCS SP8 CW; Leica, Germany) equipped 
with 63x and 100x oil immersion objectives (N.A. = 1.2 or 1.47 respectively. Nuclei of 
the cells were imaged using NucBlue (Hoechst 33342) (Molecular Probes) (λex = 405, 
λem = 415-450). Dextran was imaged depending on its specific dye: fluorescein (λex = 
495, λem = 505-560), Texas Red (λex = 595, λem = 605-660) and Alexa Fluor 647 (λex = 
647, λem = 657-700). Antibodies and LDL were imaged depending on their specific 
dye: Alexa Fluor 488 (λex = 488, λem = 498-560) or Texas Red (λex = 595, λem = 605-
660). All live cell-imaging experiments were performed at 37ºC. Fixed cells and 
immunostained PFN were imaged at room temperature. Time-lapse images were 
acquired every 60-100 seconds over 15-20 minutes.  
 
Total internal reflection fluorescence (TIRF) microscopy 
 
TIRF microscopy imaging was performed using a commercially available widefield 
fluorescence inverted microscope (SR GSD 3D; Leica, Germany) in TIRF illumination 
mode with an HC PL APO 160x oil immersion objective (N.A. = 1.43) using an Andor 
iXon3 EMCCD camera. Dextran was imaged using either a 488 nm or 532 nm laser, 
depending on its specific dye: fluorescein (λex = 488) and Texas Red (λex = 532). 
 
Images were analysed using ImageJ software (ImageJ; National Institutes of Health 
(NIH), USA). Brightness and contrast were altered in some images to make the 
intensity within the synapse visible in the figures shown, but analyses were 
performed on raw images and datasets. 
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2.6 Molecule access into the immune synapse 
 
2.6.1 Live cell confocal imaging of molecules within the immune 
synapse  
 
To assess the ability of molecules to penetrate the immune synapse, fluorescently 
labelled dextran of varying diameters or fluorescently labelled antibodies/low-density 
lipoproteins (LDL) were used at the concentrations detailed in table 2.4 below, unless 
otherwise indicated. Target cells were labelled with NucBlue (Molecular Probes) 
according to the manufacturer’s instructions. Briefly, 106 cells were collected and 
resuspended in 1 mL R10. Two drops of NucBlue were added to the medium and 
cells were incubated for 20 minutes at 37ºC. Cells were then washed 3 times and 
resuspended in phenol-red free R10 medium. 
 
NK cells and target cells were mixed at a total density of 105 cells/mL with dextran, 
antibodies or antibody fragments in 0.2 mL microcentrifuge tubes. Dextran final 
concentrations are detailed in Table 2.4 below, unless otherwise indicated in results. 
Conjugates were then plated in eight-well chambered borosilicate coverglasses 
(coated with 0.01% poly-L-lysine according to the manufacturer’s instructions, where 
indicated in results) and incubated at 37ºC for 5 minutes to allow the cells to settle 
and form synapses. Conjugates were then imaged by confocal microscopy, taking 
image stacks with a z-axial step size of 500 nm during a period of 15 – 30 minutes, to 
ensure that no synapse had been formed longer than this. Molecule penetration of 
the synapses was then analysed using ImageJ software. 
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Molecule Final Concentration (μM) 
Dextran – 3 kDa 50 
Dextran – 10 kDa 50 
Dextran – 40 kDa 50 
Dextran – 70 kDa 50 
Dextran – 500 kDa 5 
Dextran – 2, 000 kDa 2.5 
IgG monoclonal antibody 3.25 
F(ab’)2 fragment 4.5 
Domain antibody 3 
Low-density lipoprotein 1 
Table 2.4. The working concentrations of molecules used to assess size-dependent entry into 
the immune synapse.  
 
For experiments with Latrunculin A (Lat A, Sigma) and Jasplakinolide (Life 
Technologies), 1 μM or 0.5 μM, respectively, was added to the cells after 5 minutes 
incubation on PLL-coated slides. Conjugates were then imaged every minute 
following addition of the drug for a total of 5 minutes. 
 
2.6.2 Time-lapse imaging of molecules within the immune synapse 
 
To assess the entry of molecules into the immune synapse formed by effector and 
target cells over time, time-lapse confocal microscopy was used. Target 221 cells 
were labelled with NucBlue as described above. YTS and 221 cells were plated at a 
total density of 105 cells/mL on 0.01% poly-L-lysine- or 1 μg/mL fibronectin-coated 
slides (both according to the manufacturer’s instructions) and incubated at 37ºC for 5 
minutes prior to imaging to allow cells to settle. Dextran was added prior to or 
following plating on slides, as indicated in results. Conjugates or conjugate formation 
were imaged using a z-axial step size of 500 nm, taking stacks every 60 – 100 
seconds for 15 – 20 minutes.  
 
To assess the entry of molecules into the immune synapse formed with coated glass 
slides, cells were imaged using interference reflection microscopy (IRM) to visualize 
contact with the slide and by fluorescence microscopy to visualize dextran within the 
cell-slide interface. Primary human NK cells were plated with dextran on activating 
slides coated with 2 μg/mL MICA-Fc and 0.5 μg/mL ICAM1-Fc (both R&D Systems, 
UK) at a density of 105 cell/mL. 
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2.6.3 Time-lapse total internal reflection fluorescence microscopy of 
molecule clearance from the cell-slide interface 
 
To assess the clearance of molecules from the immune synapse, TIRF microscopy 
was used. Primary human NK cells were plated at a total density of 105 cells/mL on 
eight-well chambered borosilicate coverglasses coated with MICA-Fc and ICAM1-Fc, 
as previously described. Cells were imaged using a penetration depth of 110 nm in 
both the 488 nm and 532 nm laser channels. Time-lapse images were taken 
sequentially in either channel at intervals of 20 seconds from the initial moment of 
cell-slide contact for 5 minutes.  
 
2.6.4 Confocal imaging of antibody access into the cell-slide interface 
 
To assess the entry of antibodies into a synapse formed at the cell-slide interface, 
pNK cells were plated at a total cell density of 105 cells/mL on slides coated with 2 
μg/mL MICA-Fc, 0.5 μg/mL ICAM1-Fc and 5 μg/mL anti- antibody (Clone CE2.10). 
Cells were then incubated at 37ºC, 5% CO2 for 30 minutes. To confirm NK cell 
activation and PFN secretion, capture and staining, cells were removed and slides 
were incubated with fluorescent anti- antibodies [1]. To assess the access of 
fluorescent anti- antibodies into the synaptic cleft, primary cells were either fixed then 
incubated with fluorescent anti- antibodies [2] or incubated with anti- antibodies then 
fixed [3]. Specific methods are described below: 
 
1. Cell were removed from slides using 1x non-enzymatic cell dissociation buffer 
(Sigma-Aldrich, UK) for 20 minutes at 37ºC. Slides were washed 3 times with 
PBS and captured PFN was stained using a anti- antibody (Clone dG9) 
conjugated to Alexa Fluor 488 (α--488) for 1 hour at 37ºC.  
 
2. Cells were fixed with 4% paraformaldehyde (PFA) for 20 minutes at room 
temperature, then permeabilised using 0.2% Triton-X (Sigma) and stained for 
actin and PFN using Phalloidin conjugated to Alexa Fluor 647 (Molecular 
Probes) and anti-perfrorin-488 in a blocking buffer (3% BSA in PBS) for 1 
hour at room temperature.  
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3. Cells were fixed using 4% PFA then stained for PFN using anti-PFN-488 for 1 
hour at 37ºC.  
 
Cells/ were then imaged by interference reflection microscopy and confocal 
microscopy. 
 
2.6.5 Cell migration assay 
 
To analyse cell migration ability and speed, a cell migration assay was used. Firstly, 
3 x 106 primary human NK cells were stained with NucBlue according to the 
manufacturer’s instructions. Cells were then washed 3 times, resuspended in 3 
separate 1.5 mL microcentrifuge tubes in 1 mL of clone medium each. Then, either 1 
μL R10 medium, 1 μL DMSO or 1 μL Jaspalinolide (1 mM stock) was added to 106 
primary human NK cells resuspended in 1 mL clone medium and incubated for 5 
minutes at 37ºC 5% (vol/vol) CO2. Cells were then washed with clone medium, 
resuspended in 1 mL clone medium and 2 x 105 cells were plated in eight chambered 
borosilicate coverglasses and imaged by confocal microscopy. Single plane images 
were taken every 3 seconds for 10 minutes. Cell migration speed was measured 
using automated tracking software (Kalaimoscope; Transinsight). 
 
2.7 NK cell activation/degranulation and perforin capture 
 
2.7.1 Perforin capture assay 
 
To analyse PFN secreted by primary human NK cells, a protein capture assay was 
used. Eight-well chambered borosilicate coverglasses were coated with 0.01% PLL 
followed by MICA-Fc or anti-CD16 (Clone 3G8, BD Biosciences) (at amounts 
indicated in results section), 0.5 μg/mL ICAM1-Fc and 5 μg/mL anti-PFN (Clone 
CE2.10, Abcam) at 4ºC overnight. Slides were then washed 3 times with PBS and 
blocked for 20 minutes at 37ºC with R10 medium. Cells were plated on coated slides 
at a total density of 106 cells/mL and incubated for 1 hour (unless otherwise 
indicated) at 37ºC, 5% (vol/vol) CO2, then removed using 1x non-enzymatic cell 
dissociation solution (Sigma-Aldrich, UK) at 37ºC for 20 minutes. Slides were washed 
3 times with PBS and captured PFN was immunostained with anti-PFN-488 at 4ºC 
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overnight. Slides were washed 3 times with PBS and imaged by confocal 
microscopy. 
 
2.7.2 NK cell serial activation 
 
To analyse serial activation of primary human NK cells, the protein capture assay 
was performed in the following way. Eight-well chambered borosilicate coverglasses 
were coated with 0.01% PLL, then 2 μg/mL MICA-Fc or anti-CD16 (Clone 3G8) 
(where indicated in results section), 5 μg/mL ICAM1-Fc and 5 μg/mL anti-PFN (Clone 
CE2.10) at 4ºC overnight and blocked for 20 minutes at 37ºC with R10 medium. Cells 
were plated on coated slides at a total density of 106 cells/mL and incubated for 1 
hour at 37ºC, 5% (vol/vol) CO2, then removed using 1x non-enzymatic cell 
dissociation solution at 37ºC for 20 minutes and the slide was washed 3 times with 
PBS. Removed cells were then centrifuged at 956 g for 5 minutes, resuspended in 
clone medium, plated on a new slide surface (coated as indicated in results section) 
and incubated for 1 hour at 37ºC, 5% (vol/vol) CO2. This was repeated until cells had 
been activated as identified in the results sections. Captured PFN was 
immunostained with an anti-PFN-488 at 4ºC overnight. Slides were washed 3 times 
with PBS and imaged by confocal microscopy. 
 
2.7.3 Estimation of molecule number from fluorescence intensity 
 
To quantify the number of PFN molecules from the mean integrated intensity, 
Quantum Simply Cellular (QSC) beads (Bangs Laboratory Inc., USA) were used. 
QSC beads are provided in 4 populations of known surfaces densities of anti-murine 
IgG antibodies, termed the antibody-binding coefficients (ABC). The ABC values 
assigned to each bead are presumed to be monovalent antibody-to-surface receptor 
binding. Therefore, the ABC given is the number of antibodies that bind to the bead 
surface. The ABC of each population is detailed in Table 2.5 below.  
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Bead Population ABC 
1 3258 
2 35150 
3 145457 
4 371766 
Table 2.5. Bead populations and corresponding antibody-binding coefficients (ABC).  
 
Beads were prepared using a modified version of the manufacturer’s instructions. A 
drop (~50 μL) of each bead population was placed in 1.5 mL tubes and 50 μL PBS 
was added. Beads were then incubated at room temperature for 20 minutes with 1 
μL of murine anti-PFN antibody (clone CE2.10), and then washed 3 times in PBS by 
centrifugation at 17949 g for 5 minutes. Beads were then incubated at room 
temperature for 20 minutes with 5 μL of recombinant PFN (rPFN), and then washed 
3 times in PBS with centrifugation at 17949 g for 5 minutes. Finally, beads were 
incubated at room temperature for 20 minutes with an anti-PFN-488, then washed 3 
times in PBS with centrifugation at 17949 g for 5 minutes and resuspended in 200 μL 
PBS. Confocal microscopy was then used to image the labelled QSC beads, taking 
image stacks with a 0.34-μm z-axial step size. 
 
2.8 Data Analysis 
 
2.8.1 Molecule penetration of the immune synapse 
 
Confocal microscope images were analysed using ImageJ software with additional 
plugins where indicated. Brightness and contrast levels of images were altered and 
adjusted in Photoshop (Adobe, USA) to improve visualization and printing. However, 
raw data was used for analysis. 
 
Molecule entry into effector-target cell conjugates 
 
Fluorescence intensity of molecules within the synapses formed by effector and 
target cells in conjugate was measured and analysed as follows. At the imaging 
plane located at centre of the synapse in the z-axial direction, a 50-pixel-wide line 
was drawn across the conjugate, perpendicular to the synapse, from the extracellular 
solution across the cell bodies and synapse to the extracellular solution on the 
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opposite side of the conjugate. The centre of the line was placed at the synapse 
(Figure 2.1A). The mean fluorescence intensity was then measured as a profile plot 
(Figure 2.1B). One-micron-wide boxes were then drawn over the intensity profile at 
the synapse and extracellular solution (Figure 2.1C). The areas under the curve 
(corresponding to the integrated intensity at each point) were measured and the 
synapse intensity was divided by the extracellular solution intensity to give intensity 
at the synapse relative to the extracellular solution.  
 
 
 
Actin depolymerisation 
 
To analyse the effect that pharmacological agents had on actin, specifically 
depolymerisation or stabilisation compared to the DMSO vehicle control, ImageJ was 
used. A rectangular region of interest (ROI), ~50 μm2, was drawn across the cell 
membrane (Figure 2.2). The total raw intensity within the ROI was then measured for 
each condition. 
 
Figure 2.1. Analysis of fluorescence intensity within the immune synapse. Molecule entry into 
the immune synapse was measured as the intensity at the synapse relative to the extracellular 
solution. (A) A 50-pixel-wide line (yellow bar) was first drawn across the conjugates. (B) A profile plot 
was then measured taking the mean intensity across the width of the line drawn. (C) One micron 
boxes were drawn at the synapse (centre of the line) and the solution. The area under the line was 
measured to give the integrated intensity at each point. The area under the curve at the synapse 
was divided by the area under the curve at the solution to give the relative intensity.  
A B 
C 
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Molecule clearance from cell-slide interfaces 
 
To analyse fluorescence intensity at the cell-slide interface when using confocal 
microscopy, the ImageJ plugin ‘Time Series Analyzer, Version 4_H’ 
(http://rsb.info.nih.gov/ij/plugins/time-series.html) was used. An ROI was drawn over 
the region where the cell made contact with the slide (Figure 2.3A – C). The mean 
intensity at the cell-slide interface within the ROI was then measured at each time 
point prior to initial cell-slide interaction until the end of the time-lapse imaging. To 
measure the intensity of the extracellular solution, this was repeated using the same 
size ROI in a region where no cells came into contact with the slide (Figure 2.3D – 
F). The synaptic intensity was then divided by the extracellular solution intensity at 
the corresponding time points to give intensity at the synapse relative to the 
extracellular solution. 
 
Figure 2.2. Analysis of Phalloidin-stained actin fluorescence intensity. The change in actin 
compared to a DMSO vehicle control was measured at the cell periphery. An ROI of ~50 μm2 was 
drawn across the cell membrane (blue box in fluorescence panel). The total raw intensity within this 
region was then measured for each cell under each condition. (A) Panels show brightfield and 
corresponding fluorescence image of YTS cell stained for actin after 5 minutes DMSO treatment. (B) 
Panels show brightfield and corresponding fluorescence image of YTS cell stained for actin after 5 
minutes Lat A treatment. Scale bars; 10 μm.   
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To analyse dextran clearance from the cell-slide interface, a threshold was applied to 
TIRF images to first obtain the peripheral outline of the cell-slide interface (Figure 
2.4A). The area of the interface was then measured (Figure 2.4B). Raw images were 
then converted to 8-bit format. On these images, a threshold between 32 – 223 AU 
was applied (Figure 2.4C and D for images of 4 nm and 32 nm dextran respectively). 
Images were inverted and using an ROI, the area of pixels below 32 AU was 
measured in images of 4 nm and 32 nm dextran (Figure 2.4E and F for images of 4 
nm and 32 nm dextran respectively). The ratio of the pixels below 32 AU and the 
area of the cell interface were then used to calculate the percentage of the cell-slide 
interface occupied by pixels below 32 AU. 
 
Figure 2.3. Analysis of fluorescence intensity within the immune synapse at a cell-slide 
interface using confocal microscopy. Molecule entry into the immune synapse was measured as 
the intensity at the synapse relative to the extracellular solution using the ‘Time Series Analyzer’ 
plugin. The synapse and solution fluorescence intensities of dextran were measured at each time 
point within a region of interest (ROI). (A) A ROI used to measure fluorescence intensity at the 
synapse prior to cell-slide contact at time = 0 seconds. (B) A ROI measuring fluorescence intensity 
within the synapse at the point of cell-slide contact at time = 200 seconds. (C) A ROI measuring the 
fluorescence intensity of dextran within the synapse following synapse formation at time = 500 
seconds. (D – E) A ROI measuring fluorescence intensity of dextran within the solution where no cell 
contacts the slide surface at time = 0, 200 and 500 seconds respectively. Scale bars, 10μm. 
Time (seconds) 	  	  	  	  	  	  	  	   0                                   200                                  500 A B C 
D E F 
Time (seconds) 	  	  	  	  	  	  	  	   0                                   200                                  500 
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Antibody penetration of cell-slide interfaces 
 
To analyse the entry of anti-PFN-488 into the immune synapse formed by primary 
human NK cells with an activating surface, cells were scored on the staining of PFN 
at the cell-slide interface. The cell-slide interface was identified using the IRM image 
(darker regions). The presence of PFN was scored at positive (Figure 2.5A) and a 
lack of fluorescence signal was scored as negative (Figure 2.5B).  
 
Figure 2.4. Analysis of TIRF imaging of dextran clearance from the cell-slide interface. 
Dextran clearance from the cell-slide interface was identified as pixels below 32 AU in 8-bit TIRF 
images (A) The area of the cell-slide interface was determined using a threshold applied to TIRF 
images of 32 nm dextran. (B) The area of the cell slide interface was then measured. (C and D) 
TIRF images were converted to 8-bit format and a threshold of 32 – 223 AU was then applied to 
images of (C) 4 nm dextran or (D) 32 nm dextran . (E and F) Images were then inverted and the 
area of pixels below 32 AU was measured using an ROI around the cell-slide interface of images of 
(E) 4 nm dextran and (F) 32 nm dextran. Scale bars; 10 μm) 
A 
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2.8.2 Perforin secretion analysis 
 
Confocal microscope images were analysed using ImageJ software. Brightness and 
contrast levels of images were altered and adjusted in Photoshop to improve 
visualization and printing. However, raw data was used for analysis. 
 
Integrated intensity of immunostained  
 
Secreted PFN was measured on a ‘per cell’ basis where isolated clusters of PFN 
spots were assumed to have been secreted from one cell (Figure 2.6A). A default 
auto-threshold mask was selected to threshold images to remove any background 
fluorescence (Figure 2.6B). The threshold was first applied to images to isolate 
secreted PFN. A ROI was then drawn around each cluster of PFN spots and the 
integrated intensity was measured (Figure 2.6C).  
 
Figure 2.5. Analysis of antibody penetration at a cell-slide interface. Primary human NK cells 
were incubated on slides coated with MICA-Fc, ICAM1-Fc and anti-perforin. Cells were either fixed 
and incubated with fluorescent anti-perforin antibodies or incubated with fluorescent anti-perforin 
antibodies then fixed. Cells were then assessed for access of antibodies into the synapse by the (A) 
presence or (B) absence of fluorescence signal within the synapse at the cell-slide interface. Cell 
contact and synapse formation was determined by the presence of darker regions on the 
interference reflection microscopy (IRM) images (lower row). Scale bars; 10 μm. 
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Estimation of number of molecules from integrated intensity 
 
Imaging data from bead populations coated with an anti-PNF antibody, rPFN and 
anti-PFN-488 were used to estimate the number of molecules from integrated 
intensity (Figure 2.7A). Firstly, the upper most plane of an image stack that contained 
the top of the bead was isolated. A default auto-threshold was then applied to the 
image. The integrated intensity was then measured of each bead population and 
mean integrated intensity was plotted against the number of molecules per micron 
squared of the bead that was analysed (Figure 2.7B). The number of binding sites on 
the bead was given as the antibody-binding coefficient (ABC). As anti-PFN 
antibodies bound to the beads could bind 0, 1 or 2 rPFN proteins, the mean was 
assumed to be 1. These proteins would then be bound by an average of 1 
fluorescently labelled anti-PFN-488 antibody. Therefore, the ABC indicated the 
number of rPFN proteins bound to the bead surface and the integrated intensity 
would indicate a number of rPFN proteins per area. With this assumption, a line of 
best fit was plotted to give the relationship between number of molecules and 
integrated intensity (Figure 2.7C). This line gave the relationship between integrated 
intensity (y) and number of molecules (x), shown below. 
 𝑥 = 𝑦 − 1.0494.99  ×  10!! 
 
Figure 2.6. Analysis of perforin secretion by NK cells on activating slides. Perforin secretion 
was measured as the integrated intensity per cell. (A) Representative confocal image of captured 
perforin. (B) A default threshold was applied to the image to remove background. (C) A region of 
interest was drawn around perforin to measure the total integrated intensity. (Scale bar, 5 μm) 
A B C 
Chapter 2 – Materials and Methods 
 
 107 
 
 
To then quantify the number of molecules secreted by NK cells, the mean integrated 
intensities could be placed into the equation to provide an estimate.  
 
The estimated amounts of PFN were then used to calculate the concentration at 
which PFN would be at within the synapse. The diameter and depth of the IS 
(including all signalling and integrin receptor/ligand complexes) have been estimated 
to be ~16 μm (117, 123) ~32.5 nm (65) respectively. Based on these dimensions, the 
volume of the IS was estimated to be ~5 μm3, and therefore contains ~5 fL of fluid.  
The number of molecules of PFN could then be used to calculate the concentration of 
PFN in the volume of fluid at the synapse using the equations outlined below 
(equations 5.1 – 5.3). 
  
Figure 2.7. Estimation of number of molecules from fluorescence intensity. (A) Bead 
populations of increasing surface anti-murine IgG antibodies were sequentially bound with murine 
anti-human perforin antibodies, recombinant perforin and murine α-human perforin antibodies 
conjugated to Alexa Fluor 488. (B) Bead populations were imaged by confocal fluorescence 
microscopy. Panels show brightfield images (left column) and the corresponding fluorescence image 
(right column). Scale bars; 10 μm. (C) Integrated fluorescence intensity of each bead population was 
measured. Graph shows the mean intensity of each population and a linear line of best fit (R2 = 
0.9488).  
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Equation 5.1: 𝑄𝑢𝑎𝑛𝑡𝑖𝑡𝑦  𝑜𝑓  𝑝𝑟𝑜𝑡𝑒𝑖𝑛  (𝑚𝑜𝑙𝑒𝑠) =   𝑛𝑢𝑚𝑏𝑒𝑟  𝑜𝑓  𝑚𝑜𝑙𝑒𝑐𝑢𝑙𝑒𝑠𝐴𝑣𝑎𝑔𝑎𝑑𝑟𝑜!𝑠  𝑛𝑢𝑚𝑏𝑒𝑟  
 
Equation 5.2: 
 𝑚𝑎𝑠𝑠   𝑔 = 𝑞𝑢𝑎𝑛𝑡𝑖𝑡𝑦  𝑜𝑓  𝑝𝑟𝑜𝑡𝑒𝑖𝑛   𝑚𝑜𝑙𝑒𝑠 ×  𝑚𝑜𝑙𝑒𝑐𝑢𝑙𝑎𝑟𝑤𝑒𝑖𝑔ℎ𝑡  (𝐷𝑎𝑙𝑡𝑜𝑛𝑠) 
 
Equation 5.3: 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛  (𝑀𝑜𝑙𝑎𝑟) =   𝑄𝑞𝑢𝑎𝑛𝑡𝑖𝑡𝑦  𝑜𝑓  𝑝𝑟𝑜𝑡𝑒𝑖𝑛  (𝑚𝑜𝑙𝑒𝑠)𝑣𝑜𝑙𝑢𝑚𝑒  (𝑙𝑖𝑡𝑟𝑒𝑠)  
 
Using these equations, the molar concentrations of PFN at the synapse in each 
condition were calculated. 
 
2.8.3 Statistical analysis 
 
Significance of the data was determined by one-way ANOVA with Tukey multiple 
comparisons, Student’s t-test with Welch’s corrections or 95% confidence intervals 
(where indicated in figure legends). Error bars shown indicate mean ± standard 
deviation (SD). In the statistical analyses, differences were defined as non-significant 
(NS) where p ≥ 0.1 and statistically significant where p < 0.1 (indicated by a single 
asterisk *), p < 0.01 (**), p < 0.001 (***) and p < 0.0001 (****). All graphs were 
prepared and statically analysed using Prism (GraphPad, USA). 
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Chapter 3 – The Immune Synapse 
Clears and Excludes Molecules Above 
a Size Threshold 
 
3.1 Introduction 
 
3.1.1 The immune synapse gasket 
 
A relatively unexplored function of the IS is to form a gasket, or seal, around its 
secretory domains. This gasket may prevent the leakage of cytotoxic proteins from 
the synapse, protecting neighbouring cells from collateral damage during the lysis of 
diseased cells. In addition, this gasket could restrict the access of extracellular 
molecules into the synapse, preventing interference with proteins secreted across the 
synapse.  
 
A gasket may be formed by the dense accumulation of receptor-ligand complexes, as 
well as the close proximity and inter-digitation of the NK cell membranes (392). 
Previous measurements of the extracellular domains of receptor-ligand complexes 
and synaptic cleft distances have shown the membranes at the IS to be ~15-20 nm 
apart, with some areas of larger spacing, up to 50 nm, where integrin receptor-ligand 
complexes bind. The extracellular domain sizes of the receptor-ligand proteins at the 
synapse can influence both the clustering of similarly sized receptors and segregate 
larger membrane-bound particles (greater than the receptor-ligand complex spans) 
from the cell-cell interface (65, 189, 208). These complexes ensure close proximity of 
the cell membranes, within tens of nanometers. Such a tight interface may be 
essential in forming a gasket around the synapse. Previous studies have indirectly 
shown that proteins, such as monoclonal antibodies, are unable to access the IS 
(366, 367). Despite this anecdotal evidence, whether or not the IS forms a gasket 
has not been tested directly. 
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3.1.2 The physical properties of dextran 
 
Dextran is a soluble, hydrophilic, complex branched glucan (a glucose 
polysaccharide), which can be produced at varying molecular weights, with a range 
of sizes from 3 to 2, 000 kDa. Synthesised from sucrose by Leuconostoc 
mesenteroides and Streptococcus mutans (385), it is one of the main constituents of 
dental plaque (393) and was discovered by Louis Pasteur as a microbial product in 
wine (394). Dextran has many medical uses including an antithrombotic agent to 
reduce blood viscosity (395), an inhibitor of bacterial growth (396), and as a volume 
expander to treat anemia (397).  
 
Dextran can be conjugated to a range of fluorophores, enabling its visualisation using 
a fluorescence microscope. Fluorophores are conjugated to dextran using the 
reaction between a water-soluble amino dextran with the succinimidyl ester derivative 
of the dye followed by capping of any free amides with acetic anhydride. Depending 
on the dye being conjugated, this leads to different overall charges of the dextran; 
anionic, neutral (zwitterionic) and cationic. As dextran labelling uses free amide 
groups, the size of the molecule will determine the number of binding sites available 
and thus, larger dextrans have a greater number of fluorophores bound to their 
surface. Fluorophores (e.g. fluorescein) are around 1 nm in their longest dimension 
(398), and the dimensions of dextran provided in the literature are of dextrans 
labelled with this fluorophore.  
 
Dextran molecules have previously been measured to ascertain their hydrodynamic 
radii (386, 387) using dynamic light scattering (399). A hydrodynamic radius is the 
effective hydrated radius of a particle in solution. Due to the branched nature of 
dextran, the sizes given are nominal hydrodynamic radii. This can be measured by 
dynamic light scattering (DLS), which is commonly used to determine the distribution 
profile of small particles in suspension or polymers in solution. Expressing dextran 
sizes as a hydrodynamic radius (or diameter) allows the assumption of the size of the 
molecule, were it to exist as a sphere. Spatially, dextran exists as a dense coiled 
chain, whilst not an exact sphere, the larger molecules, which coil significantly more 
than smaller molecules, forming a spherical shape of which the hydrodynamic radius 
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is a sufficient measurement of size and commonly used in many studies where the 
particle size needs to be known (400). In addition, the biologically uncommon α-1,6-
glycosidic linkages between dextran chains are resistant to cleavage by most 
endogenous glucosidases, thus dextran molecules are not easily degraded. For this 
reason, dextrans have routinely been used for imaging cell loading of 
macromolecules, vesicular fusion and electroporation. Fluorescently labelled 
dextrans of varying sizes are commercially available. Based on these favourable 
properties, dextrans were used as a model of extracellular proteins in this study to 
investigate the IS gasket. 
 
3.1.3 Aims 
 
The IS is an organised cell-cell interface composed of a dense mesh of receptor-
ligand complexes and membrane inter-digitation that may form a gasket, or seal, to 
prevent the entry of extracellular molecules. However, the extent to which 
extracellular molecules can access the IS has yet to be investigated. The specific 
aims are as follows: 
 
i. To investigate the extent to which the IS functions as a gasket 
 
ii. To investigate the mechanism by which this occurs 
 
iii. To investigate how synapse formation affects molecules within the synaptic 
cleft during assembly 
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3.2 Results 
 
3.2.1 Dextran access to the NK cell activating immune synapse is size-
dependent 
 
The ability of small molecules to access the immune synapse was investigated using 
fluorescently labelled dextran. As discussed above, dextran, a coiled branched 
glucan, is available in a range of sizes conjugated to a wide variety of fluorophores. 
To assess whether differently sized dextrans have a differential capacity to access 
the IS, effector and target cells were co-incubated with fluorescently labelled dextrans 
of known sizes, then imaged by confocal microscopy. Dextran penetration of the 
synapse was measured relative to the extracellular solution, as described in the 
methods (Chapter 2, Section 2.8.1; Figure 2.1), to directly compare the access of 
differently sized dextrans into the synaptic cleft. 
 
The activating immune synapse excludes extracellular molecules in a size-
dependent manner 
 
To test the whether or not differently sized dextran can access the IS, YTS cells (a 
human NK cell line) and 221 cells, which are well-established sensitive targets for 
YTS cells (381, 401), were co-incubated with fluorescein labelled dextrans of 
diameters 3 – 54 nm. YTS-221 cell conjugates were then imaged by confocal 
microscopy. Imaging showed that as dextran size increased, its ability to access the 
IS decreased, with 54-nm-sized dextran completely excluded from the IS (Figure 
3.1A). The raw fluorescence intensity of dextran was measured across the solution, 
cell bodies and synapse (Figure 3.2). Dextran within the synapse was identified as a 
peak in the signal over the background fluorescence within the cell body. The peak in 
raw dextran fluorescence intensity within the synapse decreased as dextran size 
increased (Figure 3.1B and Figure 3.2). Importantly, the intensity of the 54 nm 
dextran within the synapse was consistent with the background measurement within 
the cell bodies (where there was no dextran), showing that the 54 nm dextran was 
completely excluded from the synapse. Quantitatively, access to the synapse was 
measured relative to the extracellular solution (Figure 3.1C). This was to correct for 
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any fluctuations in laser power and allow comparison between the various dextran 
sizes. Dextrans sized 3 and 4 nm were able to enter the synapse comparably 
(synapse intensity relative to the extracellular solution 0.09 ± 0.04 and 0.09 ± 0.05 
respectively). A decrease of almost 40% in fluorescence intensity was measured for 
dextran sized 10 nm (0.06 ± 0.03) compared to 3 or 4 nm dextrans, and an even 
greater reduction (~60%) was seen with dextran sized 13nm (0.04 ± 0.03). Dextran 
sized 32 nm was the largest molecule able to enter the IS formed by YTS cells (0.03 
± 0.02) and 54-nm-sized dextran was entirely excluded (0.01 ± 0.01). These data 
show that the IS excludes extracellular molecules in a size-dependent manner.  
 
Due to its physical properties, larger sized dextran has lower maximum solubility and 
a higher degree of labelling, resulting in greater brightness at lower concentrations. 
To compensate and increase relative brightness, smaller dextrans were added to cell 
conjugates at higher concentrations to improve their visualisation during microscopy. 
To test whether the differences seen were influenced by dextran concentration, YTS 
and 221 conjugates were co-incubated with both Texas Red-labelled 4 nm dextran 
and fluorescein-labelled 54 nm dextran at the same concentration (2.5 μM), and 
relative fluorescence intensities within the IS was measured for each dextran in the 
same synapse (Figure 3.1D). These data show that even at the same concentration, 
54 nm dextran is excluded from the IS whereas the 4 nm dextran remains able to 
access the synaptic cleft. Taken together, these data show that the IS indeed 
excludes extracellular molecules, but only those above a size threshold. Molecules 
below this threshold are able to access the synapse. 
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Figure 3.1. Dextran entry into the immune synapse formed by YTS cells is size-dependent. 
(A) Representative images of YTS and 221 conjugates co-incubated with fluorescein-labelled 
dextrans of various sizes, as indicated. Images show brightfield overlaid with target cell nuclear 
staining (upper rows) and the corresponding fluorescence images of dextran (lower rows). Scale 
bars; 10 μm. (B) Graph shows the mean raw intensities of differently sized dextrans, as indicated, 
across the synapse. (C) Dextran fluorescence intensity within the synapse was measured relative to 
the intensity of the extracellular solution for each dextran. Graph shows the mean ± SD. Data were 
analysed by one-way ANOVA with Tukey corrections (n = 49, 42, 47, 53, 39 and 39 for 2, 4, 10, 13, 
32 and 54 nm dextran respectively) (D) YTS and 221 cells were co-incubated with 4 and 54 nm 
dextrans labelled with Texas Red or fluorescein respectively. Fluorescence intensity within the same 
synapses was measured for each dextran relative to the extracellular solution of the corresponding 
dextran. Graph shows the relative intensity of each dextran size within the same synapse 
(connecting lines). Data were analysed using a Student’s t-test with Welch’s corrections (n = 30). All 
data are from 3 independent experiments. ****p<0.0001 
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The reason that the value for 3 and 4 nm dextrans is lower than 1 (which would 
suggest equal concentrations of fluorophore within the synapse and solution) is due 
to the point spread function (PSF) of the microscope capturing a larger volume of 
fluorescence in the solution, compared to the fluorescence in the narrow synaptic 
cleft. The theoretical spatial resolution, or PSF, of the objective and wavelength used 
to excite fluorescein molecules is 280 nm in the x- and y-axes and 1086 nm in the z-
axis, significantly larger than the 55 nm maximum intermembrane distance across 
the synapse (65). Therefore, intensity within the synapse appears dimmer than in the 
solution.  
 
Importantly, the cells imaged were known to be viable as cytoplasmic entry of 
dextran occurs following cell death. When a cell is undergoing apoptosis, the 
resultant breakdown of membrane integrity led to in an influx of dextran into the cell 
Figure 3.2. Raw intensity profiles of various sized dextrans across activating synapses 
formed by YTS cells. Dextran raw integrated intensity was measured using a 50-pixel-wide line 
across the solution, cell body (e.g. YTS cell), synapse, cell body (e.g. 221 cell) and solution. 
Graphs show either the raw intensity across the solution, cell bodies and synapse (left graph) or 
zoomed in the synapse (right graph) for each dextran size as indicated. Red lines show the mean 
intensity ± SD (n = 49, 42, 47, 53, 39 and 39 for 2, 4, 10, 13, 32 and 54 nm dextran respectively). 
3nm Dextran 4nm Dextran 
10nm Dextran 13nm Dextran 
32nm Dextran 54nm Dextran 
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body (data not shown). Therefore, a defined outline of the cells within the 
fluorescence images indicates that the cells are viable. 
 
The ability of dextrans sized 3 – 54 nm to access the IS was then assessed using 
primary human NK (pNK) cells and 221 target cells. Confocal imaging showed that 
dextran was also excluded from the pNK IS in a size-dependent manner (Figure 
3.3A). The raw fluorescence intensity of dextran was measured across the solution, 
cell bodies and synapse (Figure 3.4). The peak in raw dextran fluorescence intensity 
within the synapse decreased as dextran size increased (Figure 3.3B and Figure 
3.4), consistent with previous data from NK cell lines (Figure 3.1 and 3.2). This 
shows that the synapse formed by pNK cells also restricts the access of dextran into 
the cleft in a size dependent manner. In this instance, the intensity of both the 32 nm 
and 54 nm dextrans within the synapse were consistent with the background 
measurements within the cell bodies. This shows that dextrans 32 nm and larger are 
excluded from the pNK cell synapse. As before, dextran within the IS was measured 
relative to extracellular solution. This indicated that 3 and 4 nm-sized dextrans were 
able to penetrate the pNK IS to the same degree (0.09 ± 0.05 for both). This reflected 
the findings from our experiments using YTS cells.  
 
As seen in the YTS cell synapses, dextran access into the synaptic cleft decreased 
as dextran sized increased. However, an almost 50% decrease in relative 
fluorescence intensity was measured for the 10 nm dextran (0.05 ± 0.03) and ~70% 
for the 13 nm dextran (0.03 ± 0.02). Dextran sized 32 nm was excluded from the pNK 
synapse (0.01 ± 0.02), as was dextran sized 54 nm (0.01 ± 0.01) (Figure 3.3C). 
These data show that the pNK cell synapse excludes dextrans ≥32 nm. 
Unexpectedly, the size exclusion thresholds of synapses formed by YTS cells and 
pNK cells were not the same. Whilst the synapses formed by YTS cells were only 
able to exclude 54 nm dextran, the pNK cell synapse excluded those with a diameter 
of 32 nm and 54 nm. This suggests that the synapse formed by YTS cells is not as 
tight as pNK cells, possibly due to receptor-ligand complexes at the synapse. In 
support of this theory, the YTS cell primarily uses CD28 for activation (20), whereas 
pNK cells utilise a variety of receptors (118). These differences in synaptic structure 
could impact on the ability of the synapse to exclude extracellular molecules. 
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To test whether or not this size exclusion was due to the difference in molecule 
concentrations and/or dimensions, pNK-221 conjugates were also co-incubated with 
both Texas Red-labelled 4 nm dextran and fluorescein-labelled 54 nm dextrans at the 
same concentration (2.5 μM) (Figure 3.3D). Analysis of dextran access to the same 
synapses (relative to the extracellular solution) by 4 nm or 54 nm dextrans 
demonstrated that the 54 nm dextran was still unable to access the IS, whereas the 4 
nm dextran penetrated at a comparative level to higher concentrations in previous 
experiments. Therefore, both the YTS NK cell line and pNK cell IS are able to 
exclude extracellular dextran in a size-dependent manner. Whilst the exclusion 
threshold is lower for synapses formed by pNK compared to YTS cells, both 
synapses are able to restrict the entry of extracellular molecules below a defined size 
threshold. 
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Figure 3.3. Dextran entry into the immune synapse formed by primary human NK cells is 
size-dependent. (A) Representative images of primary human NK cells and 221 conjugates co-
incubated with fluorescein-labelled dextrans of various sizes. Images show brightfield overlaid with 
target cell nuclear staining (upper) and the corresponding fluorescence images of dextran (lower). 
Scale bars; 10 μm. (B) Graph shows the mean raw intensities of differently sized dextrans, as 
indicated, across the synapse. (C) Dextran fluorescence intensity within the synapse was measured 
relative to the intensity of the extracellular solution for each dextran. Graph shows the mean ± SD. 
Data were analysed by one-way ANOVA with Tukey corrections (n = 38, 32, 33, 31, 38 and 35 for 2, 
4, 10, 13, 32 and 54 nm dextran respectively) (D) YTS and 221 cells were co-incubated with 4 and 
54 nm dextrans labelled with Texas Red or fluorescein respectively. Fluorescence intensity within 
the same synapses was measured for each dextran relative to the extracellular solution of the 
corresponding dextran. Graph shows the relative intensity of each dextran size within the same 
synapse (connecting lines). Data were analysed using a Student’s t-test with Welch’s corrections (n 
= 29). All data are from 3 independent experiments. ****p<0.0001 
C 
A B 
D 
Dextran Diameter (nm) 
     3                  4                  10 
     13                 32               54 
Br
igh
tfie
ld 
Nu
cB
lue
 
De
xtr
an
 
Br
igh
tfie
ld 
Nu
cB
lue
 
De
xtr
an
 
Chapter 3 – The Immune Synapse Clears and Excludes Molecules 
Above a Size Threshold 
 
 119 
 
 
A caveat to the data analysis was that the labelling density and maximum solubility 
increased or decreased respectively as dextran size increased. Therefore, 
concentrations and microscope settings were adjusted accordingly to visualize the 
dextrans. For example, 32 nm dextran has up to 10-fold greater labelling denisty than 
4 nm dextran. In order to ensure that these factors did not introduce artefacts, 
fluorescein-labelled dextrans were mixed with unlabelled dextrans of the same 
molecular weight. This served to decrease the fluorescence intensity, but not the total 
amount of dextran within the solution. Dextrans sized 4 nm and 32 nm were mixed 
with YTS and 221 conjugates at labelled:unlabelled dextran ratios of 1:0, 1:1 and 
1:10 at a final dextran concentration of 2.5 μM. Conjugates were then imaged by 
confocal microscopy using the same settings optimised for the brightest dextran 
mixed at a 1:0 ratio. The results show that access to the synapse by the 4 nm (Figure 
3.5A and B) and 32 nm (Figure 3.5C and D) dextrans were not significantly different 
for all ratios of either dextran size. Further, relative intensities were comparable to 
Figure 3.4. Raw intensity profiles of various sized dextrans across activating synapses 
formed by primary human NK cells. Dextran raw integrated intensity was measured using a 50-
pixel-wide line across the solution, cell body (e.g. pNK cell), synapse, cell body (e.g. 221 cell) and 
solution. Graphs show either the raw intensity across the conjugate (left graph) or zoomed in across 
the synapse (right graph) for each dextran size as indicated. Red lines show the mean intensity ± 
SD (n = 38, 32, 33, 31, 38 and 35 for 2, 4, 10, 13, 32 and 54 nm dextran respectively). 
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previous experiments using unmixed dextrans at higher concentrations (Figure 3.1). 
Thus, the size-dependent access of dextran into the synapse remains similar, 
irrespective of the ratio of labelled to unlabelled dextrans. These data show that the 
access of dextran into the synapse is dependent on their physical dimensions, and 
the adjustment of microscope settings, based on the dextran brightness, did not 
affect their quantification. 
 
 
32 nm Dextran Labelled:Unlabelled 
4 nm Dextran Labelled:Unlabelled A 
Figure 3.5. Dextran entry into the immune synapse is not affected by the degree of dextran 
labelling. (A) YTS and 221 conjugates were co-incubated with fluorescein-labelled and unlabelled 4 
nm dextran at the ratios indicated and imaged by confocal microscopy using the same settings 
optimised to the labelled only (1:0) dextran. Panels show brightfield images overlaid with target 
nuclear staining (upper row) and the corresponding fluorescence image. Scale bars; 10 μm. (B) 
Dextran fluorescence intensity within the synapse was measured relative to the intensity of the 
extracellular solution for each dextran. Bars show the mean ± SD. Data were analysed by one-way 
ANOVA with Tukey corrections. (n = 25, 23 and 20 for 1:0, 1:1 and 1:10 labelled:unlabelled dextran 
mixtures). (C) YTS and 221 conjugates were co-incubated with fluorescein-labelled and unlabelled 
32 nm dextran at the ratios indicated and imaged by confocal microscopy using the same settings 
optimised to the labelled only (1:0) dextran. . Panels show brightfield images overlaid with target 
nuclear staining (upper row) and the corresponding fluorescence image. Scale bars; 10 μm. (D) 
Dextran fluorescence intensity within the synapse was measured relative to the intensity of the 
extracellular solution for each dextran. Bars show the mean ± SD. Data were analysed by one-way 
ANOVA with Tukey corrections. (n = 20, 21 and 22 for 1:0, 1:1 and 1:10 labelled:unlabelled dextran 
mixtures). All data from 3 independent experiments. NS = no significance. 
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Next, to test whether different sized dextrans could be imaged using the same 
settings and yield similar findings, 4 nm and 32 nm dextran were mixed at 
labelled:unlabelled ratios of 1:0 and 1:10 respectively. These were then co-incubated 
with YTS and 221 cells and imaged by confocal microscopy, with microscope 
settings optimised for the intensity of the 4 nm dextran (Figure 3.6A). The 4 nm 
dextran was able to access the synapse more effectively than the 32 nm dextran (0.8 
± 0.04 and 0.03 ± 0.03 respectively) (Figure 3.6B), at comparable levels shown in the 
previous data (Figure 3.1). This further demonstrates that microscope settings do not 
skew relative intensities within the synapse and penetration is governed by dextran 
size alone. 
 
 
 
To test whether or not dextran concentration had any effect on access to the IS, YTS 
and 221 conjugates were co-incubated with a fluorescein-labelled 4 nm dextran at a 
range of concentrations from 2 – 50 μM (Figure 3.7A). Whilst raw intensity values 
within the synapse were lower at reduced dextran concentrations, the relative 
intensities to the extracellular solution were not significantly different and did not 
reflect the change in concentration (Figure 3.7B). Therefore, whilst dextran access to 
Figure 3.6. Microscope settings do not introduce artefacts for analysis of entry of molecules 
into the immune synapse. (A) YTS and 221 conjugates were co-incubated with fluorescein-
labelled 4 nm dextran or a mix of fluorescein-labelled and unlabelled 32 nm dextran at a ratio of 1:10 
and imaged by confocal microscopy using the same settings optimised to 4 nm dextran. Panels 
show brightfield images overlaid with target nuclear staining (upper row) and the corresponding 
fluorescence image. Scale bars; 10 μm. (B) Dextran fluorescence intensity within the synapse was 
measured relative to the intensity of the extracellular solution for each dextran. Bars show the mean 
± SD. Data were analysed using a Student’s t-test with Welch’s corrections. (n = 32 for 4 nm dextran 
and 39 for 32 nm dextran).  Data are from3 independent experiments. P<0.0001.  
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the synapse is shown to be size dependent, the actual amount that enters the 
synapse is dependent on the extracellular concentration, resulting in equilibrium 
between the synapse and extracellular solution. Importantly, even at concentrations 
below that used for the 54 nm dextran, the relative intensity of the 4 nm dextran 
remained significantly higher. 
 
 
 
  
Figure 3.7. Dextran concentration does not affect the analysis of entry into the immune 
synapse. (A) Representative images of YTS and 221 conjugates co-incubated with fluorescein-
labelled 4 nm dextran at the concentrations indicated. Panes show brightfield overlaid with target 
nuclear staining (upper row) and the corresponding fluorescence image (lower row). Scale bars; 10 
μm. (B) Dextran fluorescence intensity within the synapse was measured relative to the intensity of 
the extracellular solution for each concentration. Bars show the mean ± SD. Data were analysed 
using a one-way ANOVA with Tukey corrections (n = 26, 25, 25, 23, 23 and 29 for 2, 4, 8, 16, 25 and 
50 μM concentrations respectively). Data are from 3 independent experiments. NS = no significance. 
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The net charge of a dextran molecule depends on the fluorophore and the method of 
preparation. Dextrans commercially available were prepared by the manufacturer 
using a reaction between water-soluble amino dextrans with the succinimidyl ester 
derivatives of the appropriate dye, due to their selectivity towards aliphatic amines. 
To prevent any cross-contamination with other molecules, unreacted amines are then 
capped with acetic anhydride, yielding a neutral or anionic dextran. Data from 
Figures 3.2C and 3.4C showed that when 4 nm and 54 nm dextrans were incubated 
with YTS or pNK cell conjugates simultaneously, the 4 nm dextran could access the 
IS, whilst the 54 nm dextran was excluded. However, the 4 nm Texas Red-labelled 
dextran has an overall neutral charge and the 54 nm fluorescein-labelled dextran is 
anionic. To rule out any effect of charge on the ability of dextran to enter the 
synapse, 4 nm dextrans labelled with either Texas Red or Alexa Fluor 647 were 
used. Dextran labelled with Alexa Fluor 647, like fluorescein, yields an anionic 
molecule. These dextrans were simultaneously co-incubated with YTS and 221 
target cells and imaged by confocal microscopy (Figure 3.8A). There was no 
significant difference between the access of IS of these differently labeled dextrans 
(relative intensity within the synapse compared to the extracellular solution of the 
corresponding dextran was 0.17 ± 0.05 for both Texas Red and Alexa Fluor 647 
labelled dextrans) (Figure 3.8B). This was repeated using pNK cells co-incubated 
with 221 target cells and both 4 nm dextrans (Figure 3.9A). Again, both dextrans 
were able to access the IS without any significant difference (0.15 ± 0.05 and 0.14 ± 
0.03 for Texas Red or Alexa Flour 647 labelled dextrans respectively) (Figure 3.9B). 
These assays demonstrate that charge does not affect the ability of dextran to 
access the IS, rather access is determined by physical size. This is consistent with 
previous data demonstrating size-dependent exclusion of dextran (Figure 3.1 and 
3.3). 
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Brightfield 
 NucBlue 
A B Texas Red 
Alexa Fluor 647 Merge 
Figure 3.8. Entry into the immune synapse formed by YTS cells is not affected by dextran 
charge. (A) Representative images of YTS and 221 conjugates were co-incubated with 4 nm 
dextran labelled with Texas Red or Alexa Fluor 647. Panels show brightfield overlaid with target cell 
nuclear staining (upper left panel), corresponding fluorescence images of Texas Red- and Alexa 
Fluor 647-labelled dextran (upper right and lower left respectively) and a marge of the fluorescence 
images (lower right). Scale bar; 10 μm. (B) Dextran fluorescence intensity was measured relative to 
the extracellular solution of the corresponding dextran. Graph shows the relative intensity of each 
dextran in the same synapse (connecting lines). Data were analysed using a Student’s t-test with 
Welch’s corrections. (n = 45). Data are from 3 independent experiments. NS = no significance. 
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In summary, the IS formed by YTS or pNK cells with 221 target cells excludes 
extracellular dextran in a size-dependent manner (Figure 3.1 and 3.3). Specifically, 
dextrans of diameters 3 – 4 nm are able to access the IS most effectively, with an 
increase in dextran size leading to a reduced ability of dextran molecules to access 
the IS. Dextrans sized 32 and/or 54 nm (using primary and cell line effector cells 
respectively) are unable to access the synapse, consistent with previous estimations 
of the IS cleft spacing (65, 189). Moreover, access to the synaptic cleft was shown to 
be exclusively dependent on dextran size. Dextran concentration and charge did not 
affect dextran intensities, and microscope settings had no impact on measurements 
(Figure 3.7 – 3.9). Therefore, the IS excludes extracellular molecules in a size-
dependent manner. Size is the only physical property that is a factor determining 
entry of extracellular proteins – and to what extent – into the synaptic cleft. 
 
  
Figure 3.9. Entry into the immune synapse formed by primary human NK is not affected by 
dextran charge. (A) Representative images of primary human NK cells and 221 conjugates were 
co-incubated with 4 nm dextran labelled with Texas Red or Alexa Fluor 647. Panels show brightfield 
overlaid with target cell nuclear staining (upper left panel), corresponding fluorescence images of 
Texas Red- and Alexa Fluor 647-labelled dextran (upper right and lower left respectively) and a 
marge of the fluorescence images (lower right). Scale bar; 10 μm. (B) Dextran fluorescence intensity 
was measured relative to the extracellular solution of the corresponding dextran. Graph shows the 
relative intensity of each dextran in the same synapse (connecting lines). Data were analysed using 
a Student’s t-test with Welch’s corrections. (n = 32). Data are from 3 independent experiments. NS = 
no significance. 
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The activating immune synapse excludes extracellular molecules in a size-
dependent manner with a variety of target cells 
 
The target cell line 221 had been used in the experiments discussed above, as they 
are sensitive targets for both YTS and pNK cells. In order to test whether or not the 
IS formed with other target cells also exclude dextran in a similar size-dependent 
manner, pNK cells were co-incubated with either a B cell lymphoblast cell line, Daudi, 
or a myeloid leukaemia cell line, K562, with a range of differently sized fluorescein-
labelled dextrans (4 – 54 nm) and imaged by confocal microscopy. 
 
The synapse formed by pNK cells co-incubated with Daudi cells (Figure 3.10A) was 
accessible by dextrans sized 4 or 13 nm (0.11 ± 0.05 and 0.06 ± 0.04 respectively). 
Dextrans sized 32 nm and 54 nm were significantly restricted or excluded (0.02 ± 
0.01 and 0.01 ± 0.01) (Figure 3.10B). Similarly, synapses formed with K562 target 
cells excluded dextrans in a size-dependent manner (Figure 3.11A). The relative 
intensities within the synapse for each dextran sized 4, 13, 32 and 54 nm (0.11 ± 
0.05, 0.06 ± 0.04, 0.02 ± 0.01 and 0.01 ± 0.01 respectively) (Figure 3.11B) were 
comparable to synapses formed with 221 (Figure 3.3C) and Daudi (Figure 3.10B) 
target cells. Therefore, irrespective of the target cell, the NK cell IS excludes 
extracellular molecules in a size-dependent manner.  
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A 
Figure 3.10. Dextran entry into the immune synapse formed by primary human NK cells and 
Daudi target cells is size-dependent. (A) Representative images of primary human NK cells and 
Daudi conjugates co-incubated with fluorescein-labelled dextrans of various sizes. Panels show 
brightfield images overlaid with target cell nuclear staining (upper row) and the corresponding 
fluorescence images of dextran (lower row). Scale bars; 10 μm. (B) Dextran fluorescence intensity 
within the synapse was measured relative to the intensity of the extracellular solution for each 
dextran. Graph shows the mean ± SD. Data were analysed by one-way ANOVA with Tukey 
corrections (n = 40, 39, 35 and 35 for 4, 13, 32 and 54 nm dextrans respectively) Data are from 3 
independent experiments. ****p<0.0001. 
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Figure 3.11. Dextran entry into the immune synapse formed by primary human NK cells and 
K562 target cells is size-dependent. (A) Representative images of primary human NK cells and 
K562 conjugates co-incubated with fluorescein-labelled dextrans of various sizes. Panels show 
brightfield images overlaid with target cell nuclear staining (upper row) and the corresponding 
fluorescence images of dextran (lower row). Scale bars; 10 μm. (B) Dextran fluorescence intensity 
within the synapse was measured relative to the intensity of the extracellular solution for each 
dextran. Graph shows the mean ± SD. Data were analysed by one-way ANOVA with Tukey 
corrections (n = 40, 38, 38 and 42 for 4, 13, 32 and 54 nm dextrans respectively) Data are from 3 
independent experiments. ****p<0.0001. 
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3.2.2 Dextran access to the T cell immune synapse is size-dependent 
 
The structured IS was first discovered between T cells and APCs (10). Whilst 
cytotoxic proteins are not secreted across this interface, various cytokines, essential 
to the regulation of immunity and mounting an immune response, are directionally 
secreted onto the target cell (194, 402-404). Many of the activating receptor-ligand 
complexes at the T cell IS are of a comparable size to those at the NK cell IS (209, 
405, 406).  
Therefore, in order to test whether or not the T cell IS also excludes extracellular 
dextran in a size-dependent manner, the leukaemic T cell line Jurkat was co-
incubated with superantigen Enterotoxin E (SEE)-loaded Raji cells. Conjugates were 
formed in the presence of fluorescein-labelled dextrans sized 4, 13, 32 and 54 nm 
and imaged by confocal microscopy. Analysis of fluorescence intensity of dextran 
within the synapse relative to the extracellular solution revealed that dextran was 
able to access the T cell synapse in a size-dependent manner (Figure 3.12A), 
comparable to synapses formed by NK cells. Specifically, dextrans sized 4 nm and 
13 nm dextrans were able to access the T cell IS (0.1 ± 0.05 and 0.09 ± 0.04 
respectively) whereas larger 32 nm and 54 nm dextrans were both significantly 
restricted or excluded from T cell synapses (0.04 ± 0.02 and 0.02 ± 0.02 respectively) 
(Figure 3.12B).  
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These data show that the T cell IS, which comprises receptor-ligand complexes of 
comparable size to those in the NK cell IS, restricts the access of dextran in a size-
dependent manner (Figure 3.1, 3.2, 3.10 and 3.11). This reflects the findings with NK 
cells. Therefore, the intermembrane span at the IS, determined by the extracellular 
domains of receptor-ligand complexes at the interface, may cause the size-
dependent exclusion of extracellular molecules. 
 
Figure 3.12. Dextran entry into the immune synapse formed by Jurkat cells and Raji target 
cells is size-dependent. (A) Representative images of Jurkat cells and superantigen Enterotoxin E-
loaded Raji conjugates co-incubated with fluorescein-labelled dextrans of various sizes. Panels 
show brightfield images overlaid with target cell nuclear staining (upper row) and the corresponding 
fluorescence images of dextran (lower row). Scale bars; 10 μm. (B) Dextran fluorescence intensity 
within the synapse was measured relative to the intensity of the extracellular solution for each 
dextran. Graph shows the mean ± SD. Data were analysed by one-way ANOVA with Tukey 
corrections (n = 34, 36, 33 and 37 for 4, 13, 32 and 54 nm dextrans respectively) Data are from 3 
independent experiments. *p<0.1 ,****p<0.0001. 
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3.2.3 The inhibitory synapse does not exclude extracellular molecules 
 
The inhibitory NK cell immune synapse is a short-lived, yet structured, interface that 
occurs when NK cells encounter a healthy cell or those expressing cognate ligands 
for their inhibitory receptors (9). To test whether or not inhibitory immune synapses 
exclude dextran in a similar manner to activating synapses, YTS cells transfected 
with the inhibitory receptor KIR2DL1 (YTS/KIR) were co-incubated with 221 cells 
expressing the cognate ligand for KIR2DL1, the class I MHC protein HLA-Cw6 
(221/Cw6) (Figure 3.13).  
 
 
 
Cells were co-incubated with fluorescein-labelled dextrans of various sizes and 
imaged by confocal microscopy. In contrast to the activating synapses, all dextran 
sizes tested were detected within the inhibitory synapse (Figure 3.14A). The raw 
fluorescence intensity of dextran was measured across the solution, cell bodies and 
synapse (Figure 3.15). Within inhibitory synapses, the peak in raw dextran 
fluorescence intensity within the synapse was similar for all dextran sizes tested 
(Figure 3.14B and 3.15). This shows that the inhibitory synapse does not restrict the 
access of dextran into the cleft. Strikingly, the peak of intensity within the synapse of 
the 54 nm dextran was similar to the smallest dextrans (3 and 4 nm), this 
demonstrates that none of the dextrans, diameters 3 – 54 nm, were excluded. 
Moreover, relative fluorescence intensities of the differently sized dextrans within the 
Figure 3.13. Flow cytometric analysis of YTS cells and 221 cells previously transfected with 
KIR2DL1 and HLA-Cw6 respectively. Surface expression of (A) KIR2DL1 on YTS cells or (B) HLA-
Cw6 on 221 cells was analysed by flow cytometry following transfection. Gates represent the 
percentage of intact singlet cells that stained positive for KIR2DL1 or HA-Cw6 (red line), when 
compared to the isotype control (grey shaded), respectively.  
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inhibitory IS (relative to the extracellular solution) were not significantly different 
(between 0.11 ± 0.06 – 0.14 ± 0.05). For example, the relative intensities of the 4 nm 
and 54 nm dextran within the inhibitory synapse were comparable (0.13 ± 0.06 and 
0.11 ± 0.04 respectively) (Figure 3.14C). These data show that the inhibitory synapse 
is unable to exclude extracellular molecules in a size-dependent manner.  
 
 
 
Dextran Diameter (nm) 
Figure 3.14. Dextran entry into the inhibitory immune synapse formed by YTS/KIR2DL1 and 
221/Cw6 target cells is not size-dependent. (A) Representative images of YTS cells expressing 
KIR2DL1 (YTS/KIR2DL1) and 221 cells expressing HLA-Cw6 (221/Cw6) conjugates co-incubated 
with fluorescein-labelled dextrans of various sizes. Images show brightfield overlaid with target cell 
nuclear staining (upper) and the corresponding fluorescence images of dextran (lower). Scale bars; 
10 μm. (B) Graph shows the mean raw intensities of differently sized dextrans, as indicated, across 
the synapse. (C) Dextran fluorescence intensity within the synapse was measured relative to the 
intensity of the extracellular solution for each dextran. Graph shows the mean ± SD. Data were 
analysed by one-way ANOVA with Tukey corrections (n = 42, 45, 41, 45, 35 and 35 for 2, 4, 10, 13, 
32 and 54 nm dextran respectively). Data are from 3 independent experiments. 
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In conclusion, these data show that dextrans of a range of sizes can access the 
inhibitory synapse, whereas they are excluded in a size-dependent manner from the 
activating IS. This suggests that the ability to exclude extracellular molecules relates 
to the properties of an activating synapse. 
 
  
Figure 3.15. Raw intensity profiles of various sized dextrans across inhibitory synapses 
formed by YTS/KIR cells. Dextran raw integrated intensity was measured using a 50-pixel-wide 
line across the solution, cell body (e.g. YTS/KIR cell), synapse, cell body (e.g. 221/Cw6 cell) and 
solution. Graphs show either the raw intensity across the conjugate (left graph) or zoomed in across 
the synapse (right graph) for each dextran size as indicated. Red lines show the mean intensity ± 
SD (n = 42, 45, 41, 45, 35 and 35 for 2, 4, 10, 13, 32 and 54 nm dextran respectively). 
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3.2.4 Dextran below the size exclusion threshold moves freely into and 
out of the immune synapse 
 
Activating NK and T cell synapses have been shown to restrict the access of 
dextrans present in the extracellular solution in a size-dependent manner (Figures 
3.1 – 3.12). However, dextran was present from the point of initial cell-cell contact 
and synapse assembly. Therefore, these experiments did not address whether 
dextran below the size exclusion threshold is able to enter a pre-formed synapse, or 
if dextran detected within the synaptic cleft is merely trapped during synapse 
assembly. 
 
To investigate this, YTS and 221 cells were mixed to form synapses and then plated 
on 0.01% PLL-coated chambered coverglasses to immobilise the conjugates. Cells 
were then imaged by time-lapse confocal microscopy. During imaging, 4nm (Figure 
3.16A) or 54 nm (Figure 3.16B) fluorescein-labelled dextrans were added to the 
solution (first image stack following dextran addition at time = 0). Fluorescence 
intensity of the 4 nm or 54 nm dextran was then measured at the synapse, relative to 
the extracellular solution, at each time point (Figure 3.16C). The data shows that 4 
nm dextran (Figure 3.16C, circles) could be detected within the synapse almost 
immediately after addition to the extracellular solution. The relative intensity 
increased over the first 2 – 4 minutes, before reaching a plateau. In contrast, the 54 
nm dextran (Figure 3.16C, squares) was unable to penetrate the IS throughout the 
course of imaging (up to ~15 minutes following dextran addition). These data are 
consistent with previous results showing that larger dextran (54 nm) is excluded from 
the IS and smaller dextran (4 nm) is able to enter the IS. Furthermore, the addition of 
dextran to the extracellular solution and its subsequent access or exclusion further 
demonstrates that the IS forms a physical barrier that can prevent the access of 
molecules above a size threshold, whereas those below this limit can freely pass into 
the synaptic cleft.  
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The 4 nm dextran can access the synapse when added either prior to or following 
synapse formation. However, whether dextran could move freely out of the synapse, 
had not yet been addressed. To test whether dextran was trapped or could move out 
of a formed synapse, YTS cells and 221 cells were plated on 0.01% PLL-coated 
chambered slides in the presence of a fluorescein-labelled 4 nm dextran at a final 
concentration of 50 μM. Immobilisation of conjugates on PLL allowed the same 
conjugate to be imaged by confocal microscopy whilst serially diluting the 
extracellular dextran concentration (Figure 3.17A). Dextran fluorescence intensity 
within the synapse relative to the extracellular solution intensity was then measured 
after each dilution (Figure 3.17B). Analysis showed that the relative dextran 
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Figure 3.16. Dextran is excluded from formed immune synapses in a size-dependent 
manner. (A) Representative time-lapse confocal images of YTS and 221 conjugates as a 
fluorescein-labelled 4 nm dextran was added to the solution (time = 0). Panels show brightfield 
images overlaid with target nuclear staining (upper row) and the corresponding fluorescence image 
(lower row). (B) Representative time-lapse confocal images of YTS and 221 conjugates as a 
fluorescein-labelled 54 nm dextran was added to the solution (time = 0). Panels show brightfield 
images overlaid with target nuclear staining (upper row) and the corresponding fluorescence image 
(lower row). Scale bars; 10 μm. (C) Dextran fluorescence intensity within the synapse was 
measured relative to the intensity of the extracellular solution at each time point following addition 
of dextran. Graph shows representative data of the 4 nm (circles) and 54 nm (squares) dextran 
from 5 independent experiments.  
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fluorescence intensity within the synapse remained similar, with no significant change 
following dextran dilution – establishing that dextran within the synapse equilibrates 
with the extracellular solution. This data shows that 4 nm-sized dextrans are not 
trapped within the synapse when present during its formation and are indeed able to 
freely move out of the synapse, in agreement with previous findings that show 
dextran equilibrates between the synapse and extracellular solution (Figure 3.7). 
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Figure 3.17. Dextran within the immune synapse equilibrates with the concentration in the 
extracellular solution. (A) Representative confocal images of a YTS and 221 conjugate as the 
extracellular solution was diluted. Panels show brightfield images overlaid with target cell nuclear 
staining (upper row) and the corresponding fluorescence image (lower row). Scale bars; 10 μm. (B) 
Dextran fluorescence intensity within the synapse was measured relative to the extracellular solution 
at each concentration. Graph shows the relative intensities of dextran at each concentration of the 
same conjugate (connecting lines) (n = 8). Data are from 8 independent experiments (each coloured 
line). The mean intensities at each concentration were analysed using one-way ANOVA with Tukey 
corrections. NS = no significance. 
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In a separate experiment, the impact of complete removal of dextran from the 
extracellular solution was investigated. YTS or pNK cells were co-incubated with 221 
cells and fluorescein-labelled 4 nm dextran on 0.01% PLL-coated slides and imaged 
by confocal microscopy. The medium containing dextran was then removed and 
replaced with dextran-free medium and conjugates were imaged for a second time. 
Dextran within the synapses prior to and following removal of dextran was assessed. 
This was then compared to the levels of extracellular dextran that was present prior 
to washing. Dextran was detected initially in the synapses formed by YTS cells (pre-
wash) but could not be detected following removal of the dextran (post-wash) (Figure 
3.18A). Relative intensities within the synapses fell from 0.12 ± 0.05 to 0.006 ± 0.003 
(Figure 3.18B). Dextran present in synapses formed by pNK cells could also be 
washed out of the synapse (Figure 3.19A). The relative dextran intensity fell 
significantly from 0.16 ± 0.04 to 0.006 ± 0.003 (Figure 3.19B). These data 
demonstrate that 4 nm dextran is not trapped within the IS and can be washed out. 
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Figure 3.18. Dextran can be washed out of the immune synapse formed by YTS cells. (A) 
Representative images of YTS and 221 target cells prior to (Pre-wash) and following (Post-wash) the 
removal of extracellular fluorescein-labelled 4 nm dextran. Panels show brightfield images overlaid 
with target nuclear staining  (upper row) and the corresponding fluorescence images (lower row). 
Scale bars; 10 μm. (B) Dextran fluorescence intensity within the synapse was measured relative to 
the extracellular solution intensity prior to (Pre-wash) and following (Pre-wash) the removal of 
dextran. Bars show the mean ± SD. (n = 38 for Pre-Wash and 40 for Post-Wash). Data was 
analysed using a Student’s t-test with Welch’s corrections. Data from 3 independent experiments. 
****p<0.0001 
Br
igh
tfie
ld 
Nu
cB
lue
 
De
xtr
an
 
Pre-Wash Post-Wash
0.00
0.05
0.10
0.15
0.20
0.25
0.30
In
te
ns
ity
 R
el
at
iv
e 
to
 S
ol
ut
io
n
****
Chapter 3 – The Immune Synapse Clears and Excludes Molecules 
Above a Size Threshold 
 
 138 
 
 
Taken together, the data in this study demonstrate that not only are larger 54 nm 
dextrans excluded from the synapse but that smaller 4 nm dextrans are able to move 
both in and out of the synapse, equilibrating with the extracellular solution. This 
suggests that the IS is not completely sealed but rather forms a barrier that can be 
penetrated by molecules below a size threshold. 
 
  
Pre-wash A Post-wash B 
Figure 3.19. Dextran can be washed out of the immune synapse formed by primary human 
NK cells . (A) Representative images of primary human NK cells and 221 target cells prior to (Pre-
wash) and following (Post-wash) the removal of extracellular fluorescein-labelled 4 nm dextran. 
Panels show brightfield images overlaid with target nuclear staining  (upper row) and the 
corresponding fluorescence images (lower row). Scale bars; 10 μm. (B) Dextran fluorescence 
intensity within the synapse was measured relative to the extracellular solution intensity prior to 
(Pre-wash) and following (Pre-wash) the removal of dextran. Bars show the mean ± SD. (n = 35 for 
Pre-Wash and 39 for Post-Wash).  Data was analysed using a Student’s t-test with Welch’s 
corrections. Data from 3 independent experiments. ****p<0.0001 
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3.2.5 Intact actin is required to exclude dextran from the immune 
synapse 
 
Previous experiments have shown that a formed synapse is able to exclude dextrans 
sized ≥32 nm, and those below are able to access the synapse in a size-dependent 
manner. During synapse formation, F-actin is rearranged at the synapse to form rings 
around a hypo-dense region through which cytotoxic mediators are secreted (117, 
187). The polymerisation of actin is thought to provide the pushing/pulling forces that 
polarise NK cells (including the MTOC and machinery for directed secretion), and 
may also form a rigid scaffold to support the synaptic structure (180, 181). These 
high tensile forces at the cell-cell interface may enable the exclusion of larger 
dextrans by maintaining the close proximities of the cell membranes and the 
organisation of the receptor-ligand complexes at the synapse. Latrunculin A (Lat A) is 
a drug produced by the sea sponge Latrunculia, and has been shown to 
depolymerise actin by binding monomeric G-actin in a 1:1 complex (407). 
Conversely, Jasplakinolide (Jasp), produced by the marine sponge Jaspis johnstoni, 
has been shown to stabilise actin, preventing the polymerisation or depolymerisation 
of actin monomers (408). These drugs were therefore used to test whether or not the 
actin structure at the synapse was required to exclude dextran.  
 
To first verify that Lat A depolymerises actin in both pNK cells and 221 cells, 106 cells 
were incubated with 1 μM Lat A or a vehicle control, DMSO, for 5 minutes. Cells were 
then fixed, permeabilised and stained for actin (using Phalloidin labelled with Alexa 
Fluor 647) before being imaged by confocal microscopy. Actin was depolymerised 
within 5 minutes in both pNK cells and 221 cells (Figure 3.20A and B). Actin raw 
intensity was reduced significantly compared to the DMSO control in pNK cells (6216 
± 2515 AU to 1435 ± 485 AU) and 221 cells (10858 ± 5841 to 3410 ± 1302 AU) 
(Figure 3.20C). Therefore, the addition of Lat A for 5 minutes is sufficient to 
depolymerise actin in pNK cells and 221 cells. 
 
Chapter 3 – The Immune Synapse Clears and Excludes Molecules 
Above a Size Threshold 
 
 140 
 
 
As Phalloidin competes with Jasp for actin binding (408), a cell migration assay was 
used to test the effect of actin stabilisation on NK cells, rather than by actin staining. 
To do this, pNK cells were plated on fibronectin-coated slides and imaged by time-
lapse confocal microscopy following incubation with either a negative control, R10 
medium (Figure 3.21A); a vehicle control, DMSO (Figure 3.21B); or 0.5 μM Jasp 
(Figure 3.21C) for 5 minutes. In R10 medium, pNK cell mean migration speed was 
0.34 ± 0.08 μm/min. Following incubation with Jasp, pNK cell migration was 
significantly decreased (0.22 ± 0.07 μm/min). Incubation with DMSO alone did not 
affect cell migration (0.39 ± 0.24 μm/min) (Figure 3.21D). This shows that incubation 
Figure 3.20. Latrunculin A depolymerises actin in primary human NK cells and 221 cells. (A) 
Primary human NK cells and (B) 221 cells were incubated with DMSO (left columns) or 1  μM 
Latrunculin A (right columns) for 5 minutes then stained for actin using Phalloidin labelled with Alexa-
647. Panels show brightfield images (upper rows) and the corresponding fluorescence image of 
actin (lower rows). Scale bars; 10 μm.  (C) Actin fluorescence was measured to determine the 
presence or depletion of actin at the cell periphery. Graph shows the mean raw fluorescence 
intniesty of actin. Bars represent mean ± SD (n = 119 and 117 for DMSO and Latrunculin A 
respectively for pNK cells and 111 and 113 for DMSO and Latrunculin A respectively for 221 cells). 
Data were analysed using a Student’s t-test with Welch’s corrections. ****p<0.0001. 
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with Jasp decreases NK cell migration, which is mediated through the stabilisation of 
actin filaments. 
 
 
 
Finally, it was investigated whether these concentrations of Lat A or Jasp had any 
significant effect on cell viability. Primary NK cells, YTS cells and 221 cells were 
incubated with Lat A or Jasp, at the same concentrations as previously used, then 
washed using R10 medium. Cells were also incubated with negative controls: DMSO 
or R10, and a positive control, 4% paraformaldehyde. As DAPI was used to stain for 
non-viable cells, fixation of cells using paraformaldehyde allowed the entry of DAPI 
staining, serving as a positive control (shown in blue, Figure 3.22). Once cells had 
been incubated with DAPI for 5 minutes, cell viability was assessed using flow 
cytometry. The results show that neither Lat A or Jasp had a negative effect on pNK 
cell, YTS cell or 221 cell viability (Figure 3.22). 
 
Figure 3.21. Jasplakinolide reduces NK cell migration by stabilising actin. Primary human NK 
(pNK) cells were incubated with (A) medium, (B) DMSO or (C) 0.5 μM Jasplakinolide for 5 minutes, 
then plated on fibronectin-coated slides. Cells were then imaged by time-lapse confocal microscopy 
for 10 minutes. Panels show tracked migration paths of pNK cells after incubation with the indicated 
additions, colour-coded by time as indicated on the scale chart. Scale bars; 10 μm. (D) Cell 
migration speed was measured. Graphs show the mean migration speeds following incubation with 
DMSO or Jasplakinolide, as indicated. Bars show mean ± SEM. (n = 34 for medium, 67 for DMSO 
and 30 for Jasplakinolide). Data are from 2 independent experiments. Data were analysed using a 
one-way ANOVA with Tukey corrections. p<0.1, ****p<0.0001. 
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Once the function of Lat A and Jasp had been verified, the requirement for intact 
actin for dextran exclusion from the synapse was then tested. To do this, either pNK 
cells or YTS cells were co-incubated with 221 target cells and dextran sized 32 nm 
on PLL-coated slides. Conjugates were then imaged by confocal microscopy. A 
DMSO vehicle control, 1 μM Lat A or 0.5 μM Jasp were then added to the solution 
and the same conjugate imaged every minute for 5 minutes. The relative intensity of 
dextran to the extracellular solution was measured at each time point to assess if 
dextran access to the synapse changed following changes to actin integrity or 
dynamics. 
 
The addition of DMSO to conjugates showed that this vehicle did not have any 
impact on the exclusion of the 32 nm dextran from synapses formed by either pNK 
cells or YTS cells. Analysis of the relative intensity of dextran showed that dextran 
within the synapse remained constant throughout the time course for synapses 
formed by either pNK cells (Pre-Treatment: 0.01 ± 0.01; 5 minutes post-treatment: 
0.009 ± 0.004) or YTS cells (Pre-Treatment: 0.027 ± 0.012; 5 minutes Post-
Treatment: 0.02 ± 0.01) (Figure 3.23 for pNK cells Figure 3.24 for YTS cells).  
 
Figure 3.22. Latrunculin A or Jasplakinolide are not detrimental to cell health of primary human 
NK cells, YTS cells or 221 cells. (A) Primary human NK cells, (B) YTS cells and (C) 221 cells were 
incubated with medium (peach), paraformaldehyde (blue), DMSO (orange), 1 μM Latrunculin A (light 
green), or 0.5 μM Jasplakinolide (dark green) for 5 minutes. Cell death was then assessed by flow 
cytometry using a DAPI nuclear stain. DAPI staining signifies cell death. Graphs show total number of 
dead cells positive for DAPI normalised to the mode for each condition, as indicated. Data are 
representative of 2 independent experiments. 
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Pre-
DMSO 0 mins 1 min 2 mins 3 mins 4 mins 5 mins 
Post-DMSO A 
Figure 3.23. Dextran is excluded from the primary human NK immune synapse when actin 
remains intact. (A) Primary human NK cells and 221 cells were co-incubated with 32 nm dextran and 
imaged by confocal microscopy (Pre-Treatment). A vehicle control, DMSO, was then added to the cells 
and the same conjugate was imaged every minute for 1 minute (time = 0 – 5). Panels show 
representative brightfield images overlaid with target cell nuclear staining (upper row) and the 
corresponding fluorescence image (lower row) at each time point, as indicated. Scale bars; 10 μm. (B) 
Dextran fluorescence intensity within the synapse was measured relative to the intensity of the 
extracellular solution at each time point Graph shows the relative intniesty for the same conjugate at 
each time point, shown by connecting lines. The mean relative intensities at each time point were 
analysed by one-way ANOVA with Tukey corrections (n = 7). Data are from 7 independent experiments 
for each dextran size. 
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Incubation of conjugates with 1 μM Lat A, shown previously to depolymerise actin, 
had a profound effect on the ability of the synapse to exclude dextran. Within minutes 
of Lat A addition, the 32 nm dextran was able to enter the synapse formed by pNK 
cells (Figure 3.25A). Prior to the addition of Lat A, the relative intensity of dextran 
within the pNK cell synapse was similar to previous experiments (0.01 ± 0.01). 
Immediately after the addition of Lat A, the exclusion of dextran was not affected 
(0.009 ± 0.005). However, after 5 minutes incubation with Lat A, the 32 nm dextran 
had penetrated the synapse (0.19 ± 0.05) (Figure 3.25B). These experiments were 
repeated with YTS cells co-incubated with 221 target cells and a fluorescein-labelled 
32nm dextran. The addition of Lat A also abrogated the exclusion of 32 nm dextran 
from the YTS cell synapse (Figure 3.26A). Dextran relative intensity increased from 
Pre-
DMSO 0 mins 1 min 2 mins 3 mins 4 mins 5 mins 
Post-DMSO A 
Figure 3.24. Dextran is excluded from the YTS cell immune synapse when actin remains intact. 
(A) YTS cells and 221 cells were co-incubated with 32 nm dextran and imaged by confocal microscopy 
(Pre-Treatment). A vehicle control, DMSO, was then added to the cells and the same conjugate was 
imaged every minute for 1 minute (time = 0 – 5). Panels show representative brightfield images 
overlaid with target cell nuclear staining (upper row) and the corresponding fluorescence image (lower 
row) at each time point, as indicated. Scale bars; 10 μm. (B) Dextran fluorescence intensity within the 
synapse was measured relative to the intensity of the extracellular solution at each time point Graph 
shows the relative intniesty for the same conjugate at each time point, shown by connecting lines. The 
mean relative intensities at each time point were analysed by one-way ANOVA with Tukey corrections 
(n = 10). Data are from 6 independent experiments for each dextran size. 
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0.02 ± 0.01 immediately after the addition of Lat A to 0.26 ± 0.11 after 5 minutes 
incubation (Figure 3.26B). This suggests that the integrity of actin at the IS enables 
the size-dependent exclusion of extracellular dextran. When actin integrity is 
compromised, here by addition of a depolymerizing agent, the reduction in 
membrane rigidity most likely enables entry of dextran into the synapse. 
 
 
 
Post-LatA A 
Figure 3.25. Depolymerisation of actin abolishes the exclusion of dextran from the primary 
human NK cell immune synapse. (A) Primary human NK cells and 221 cells were co-incubated with 
32 nm dextran and imaged by confocal microscopy (Pre-Treatment). Latrunculin A at a final 
concentration of 1 μM was then added to the cells and the same conjugate was imaged every minute 
for 1 minute (time = 0 – 5). Panels show representative brightfield images overlaid with target cell 
nuclear staining (upper row) and the corresponding fluorescence image (lower row) at each time point, 
as indicated. Scale bars; 10 μm. (B) Dextran fluorescence intensity within the synapse was measured 
relative to the intensity of the extracellular solution at each time point. Graph shows the relative 
intniesty for the same conjugate at each time point, shown by connecting lines. The mean relative 
intensities at each time point were analysed by one-way ANOVA with Tukey corrections (n = 6). Data 
are from 6 independent experiments for each dextran size. *p<0.1, ***p<0.001, ****p<0.0001. 
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Then, to test whether actin turnover was required to maintain size exclusion, Jasp 
was added to pNK cells or YTS cells in conjugates with 221 target cells in the 
presence of 32 nm dextran and imaged by confocal microscopy. Conjugates were 
imaged prior to the addition of 0.5 μM Jasp, then immediately after (time = 0) and 
again every minute for 5 minutes. The addition of Jasp to pNK-221 cell conjugates 
did not affect the exclusion of dextran (Figure 3.27A). Dextran relative intensity within 
the synapse remained constant prior to the addition of Jasp (0.01 ± 0.01) to 5 
minutes after addition of the drug (0.011 ± 0.004) (Figure 3.27B). Similar findings 
were seen with YTS-221 cell conjugates (Figure 3.28A), where the relative intensity 
of dextran at the synapse was not significantly altered (0.03 ± 0.01 prior to treatment; 
0.04 ± 0.02 after 5 minutes treatment) (Figure 3.28B). This suggests that following 
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Figure 3.26. Depolymerisation of actin abolishes exclusion of dextran from the YTS cell 
immune synapse. (A) YTS and 221 cells were co-incubated with 32 nm dextran and imaged by 
confocal microscopy (Pre-Treatment). Latrunculin A at a final concentration of 1 μM was then added to 
the cells and the same conjugate was imaged every minute for 1 minute (time = 0 – 5). Panels show 
representative brightfield images overlaid with target cell nuclear staining (upper row) and the 
corresponding fluorescence image (lower row) at each time point, as indicated. Scale bars; 10 μm. (B) 
Dextran fluorescence intensity within the synapse was measured relative to the intensity of the 
extracellular solution at each time point. Graph shows the relative intniesty for the same conjugate at 
each time point, shown by connecting lines. The mean relative intensities at each time point were 
analysed by one-way ANOVA with Tukey corrections (n = 10). Data are from 7 independent 
experiments for each dextran size. *p<0.1, ****p<0.0001. 
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synapse formation, further rearrangement of actin is not required and dextran above 
the size-exclusion threshold remains unable to penetrate the synaptic cleft.   
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Figure 3.27. Stabilisation of actin maintains the exclusion of dextran from the YTS cell immune 
synapse (A) YTS and 221 cells were co-incubated with 32 nm dextran and imaged by confocal 
microscopy (Pre-Treatment). Jasplakinolide at a final concentration of 0.5 μM was then added to the 
cells and the same conjugate was imaged every minute for 1 minute (time = 0 – 5). Panels show 
representative brightfield images overlaid with target cell nuclear staining (upper row) and the 
corresponding fluorescence image (lower row) at each time point, as indicated. Scale bars; 10 μm. (B) 
Dextran fluorescence intensity within the synapse was measured relative to the intensity of the 
extracellular solution at each time point. Graph shows the relative intniesty for the same conjugate at 
each time point, shown by connecting lines. The mean relative intensities at each time point were 
analysed by one-way ANOVA with Tukey corrections (n = 7). Data are from 7 independent experiments 
for each dextran size.  
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These data demonstrate that it is only the integrity of the F-actin structure at the IS 
that is important for maintaining exclusion of larger molecules. Within 5 minutes after 
the addition of Lat A, the loss of F-actin at the cell-cell interface allowed entry of 
dextrans that are otherwise excluded from the synapse. In contrast, when actin is 
stabilised at the synapse, this most likely maintains the structure and rigidity at the 
intercellular contact, thus there is no detectable change in exclusion of larger 
dextran. Therefore, whilst further rearrangement of F-actin at the synapse is not 
required, the integrity of the cytoskeleton is indeed critical to exclude larger dextran. 
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Figure 3.28. Stabilisation of actin maintains the exclusion of dextran from the primary human 
NK cell immune synapse (A) Primary human NK cells and 221 cells were co-incubated with 32 nm 
dextran and imaged by confocal microscopy (Pre-Treatment). Jasplakinolide at a final concentration of 
0.5 μM was then added to the cells and the same conjugate was imaged every minute for 1 minute 
(time = 0 – 5). Panels show representative brightfield images overlaid with target cell nuclear staining 
(upper row) and the corresponding fluorescence image (lower row) at each time point, as indicated. 
Scale bars; 10 μm. (B) Dextran fluorescence intensity within the synapse was measured relative to the 
intensity of the extracellular solution at each time point. Graph shows the relative intniesty for the same 
conjugate at each time point, shown by connecting lines. The mean relative intensities at each time 
point were analysed by one-way ANOVA with Tukey corrections (n = 7). Data are from 7 independent 
experiments for each dextran size. 
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3.2.6 Dextran is cleared from the immune synapse during assembly 
 
Whilst larger dextrans present from the initial moment of cell-cell contact (Figures 
3.1, 3.3, and 3.10 – 3.12), or added to formed synapses (Figure 3.16), are excluded 
from the IS, the processes involved in the initial exclusion of dextran have not been 
identified.  
 
To address this, YTS and 221 cells were co-incubated with fluorescein-labelled 4 nm 
or 54 nm dextran and plated on chambered coverglasses coated with 1 μg/mL 
fibronectin. This enabled migration of cells, facilitating imaging of the initial contact 
and synapse formation by time-lapse confocal microscopy. Dextran fluorescence 
intensity within the synapse was measured relative to the extracellular solution at 
each time point prior to and following the initial moment of cell-cell contact, and 
during synapse assembly (Figure 3.29A for the 4 nm dextran and 3.29B for the 54 
nm dextran). At the point of cell-cell contact, both the 4 nm and 54 nm dextrans were 
detected in the synapse prior to conjugation. There was then an initial decrease of 
signal for both dextran sizes. This was due to the reduction of the imaging volume 
below the PSF of the microscope relative to volume imaged within the extracellular 
solution. The relative fluorescence intensity of the 4 nm dextran decreased over the 
first 2 minutes following cell-cell contact, it then reached a plateau where it remained 
at a similar level for the duration of imaging (Figure 3.29C, solid line). Conversely, the 
relative intensity of the 54 nm dextran continued to decrease – until it was barely 
detectable (Figure 3.29C, dashed line). The decrease in relative fluorescence 
intensity of the 54 nm dextran occurred at a much greater rate than the 4 nm dextran. 
However, the point at which the 4 nm dextran reached a plateau and the 54 nm 
dextran was undetectable occurred at a similar time of around 3 – 4 minutes after 
cell-cell contact. These data suggest that the formation of the synapse causes a size-
dependent clearance of dextran during assembly, leading to the removal of 54 nm 
dextran from the cell-cell interface. 
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To further investigate the clearance of dextran from the IS, pNK cells were plated on 
activating surfaces coated with MICA-Fc and ICAM1-Fc, as previously described 
(117), in the presence of 4 nm or 32 nm dextrans. Initial contact and subsequent 
synapse formation with the activating surface was imaged by interference reflection 
microscopy (IRM) together with confocal microscopy (Figure 3.30A for 4 nm dextran 
and 3.30B for 32 nm dextran). Darker regions of the cell-slide contact in IRM images 
indicate areas of close slide-membrane proximity following cell spreading, and thus, 
this can be used to identify synapse formation. These images demonstrate that whilst 
regions of the synapse in close proximity to the slide (dark regions) are able to 
exclude the larger 32 nm dextran, the 4 nm dextran is able to access these regions. 
Furthermore, the smaller 4 nm dextran appears to collect within regions inside the 
Time (seconds) A 
C 
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Figure 3.29. Larger dextran is cleared from the YTS cell immune synapse during assembly. 
(A) Representative time-lapse confocal images of YTS and 221 initial contact (time = 0) and 
conjugate formation in the presence of a fluorescein-labelled 4 nm dextran. Panels show brightfield 
images overlaid with target nuclear staining (upper row) and the corresponding fluorescence image 
(lower row). Scale bars; 10 μm. (B) Representative time-lapse confocal images of YTS and 221 
initial contact (time = 0) and conjugate formation in the presence of a fluorescein-labelled 54 nm 
dextran. Panels show brightfield images overlaid with target nuclear staining (upper row) and the 
corresponding fluorescence image (lower row) at the indicated times. Scale bars; 10 μm. (C) 
Dextran fluorescence intensity within the synapse was measured relative to the intensity of the 
extracellular solution at each time point. Graph shows mean ± 95% confidence interval of the 4 nm 
(solid line) and 54 nm (dashed line) dextran from 8 independent experiments of each dextran size.  
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synapse where the membrane is inflected away from the slide (brighter regions of the 
IRM images). Importantly, whilst these regions can be identified with pNK cells in the 
presence of the 32 nm dextran, these areas remain devoid of dextran, as it is unable 
to penetrate into the synaptic cleft.  
 
Dextran fluorescence intensity was measured in the synapse at the cell-slide 
interface and the extracellular solution to give relative fluorescence intensities during 
the course of synapse formation. Profile plots of the cell-slide interface demonstrate 
the differences in intensity across the synapse of the differently sized dextran (Figure 
3.30C for the 4 nm dextran and 3.30D for the 32 nm dextran). The relative 
fluorescence intensity of the dextran at the cell-slide interface compared to the 
extracellular solution was measured at each time point following synapse formation. 
This showed a decrease in fluorescence intensity of the 4nm dextran over the first 2 
– 3 minutes, then a plateau for the remainder of the imaging (Figure 3.30E, red line). 
The plateaued value is lower than 1 due to the PSF volume of the microscope 
imaging a greater volume in the extracellular solution compared to the narrow 
synaptic cleft, discussed previously. However, after 2 – 3 minutes contact with the 
slide, during synapse formation, the 32 nm dextran was completely undetectable 
(Figure 3.30E, blue line). These data indicate that as the pNK cell synapse 
assembles, dextrans above the size exclusion threshold are cleared from the 
synapse, concurrent with the NK cell spreading response. 
 
Chapter 3 – The Immune Synapse Clears and Excludes Molecules 
Above a Size Threshold 
 
 152 
 
 
To investigate the mechanism of clearance, pNK cell synapse formation with MICA-
Fc/ICAM-Fc-coated slides was then imaged by TIRF microscopy in the presence of 
both Texas Red-labelled 4 nm dextran and fluorescein-labelled 32 nm dextran. 
Synapse formation was imaged every 20 seconds, from the initial moment of cell-
slide contact, for a total of 5 minutes. To further highlight the intensities of dextran 
within the synapse, a look-up table, HiLo, was applied to identify pixels above (red) 
and below (blue) intensity thresholds of 223 and 32 AU respectively (Figure 3.31A).  
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Figure 3.30. Larger dextran is cleared from the primary human NK cell immune synapse 
during assembly. (A and B) Primary human NK cell synapse formation with a MICA-Fc/ICAM1-Fc-
coated activating slide in the presence of fluorescein-labelled 4 nm (A) or 32 nm (B) dextran imaged 
by time-lapse interference reflection microscopy (IRM) and confocal microscopy. Panels show IRM 
(upper panel) and the corresponding fluorescence image (lower panel) at 500 seconds following 
contact with the slide. Scale bars; 10 μm. (C and D) Graphs show a profile plot of the mean 
fluorescence intensity (MFI) of 4 nm (C; red line) and 32 nm (D, blue line) measured across the cell-
slide interface along the dashed line indicated in fluorescence microscopy image panels A and B 
respectively. (C) Mean dextran fluorescence intensity over the time-lapse imaging was measured 
relative to the extracellular solution at each time point. Graph shows the mean (4 nm = red; 32 nm = 
blue) ± 95% confidence interval (grey) of 8 independent experiments (n = 8) of each dextran size. 
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The pNK cell synapse appears to form in a zipper-like manner, as dextran is cleared 
from the central region of the synapse towards the periphery. To quantify this, the 
percentage of cell-slide interface occupied by pixels below the threshold was 
measured (Figure 3.31B). There was no significant difference between the 
percentages of blue pixels (below the 32 AU threshold) in TIRF images of the 4 nm 
dextran compared to the 32 nm dextran after initial spreading (0.6 ± 0.8% for the 4 
nm dextran and 6.3 ± 5.5% for the 32nm dextran) and during the first 60 seconds of 
synapse formation (1.2 ± 1.3% for the 4 nm dextran and 20.6 ± 13.6% for the 32nm 
dextran). Following 120 seconds after initial cell-slide contact, the percentage of area 
occupied by blue pixels was significantly greater in images of 32 nm dextran (41.0 ± 
30.2%) than 4 nm dextran (0.8 ± 1.2%). There appeared to be a collection of dextran 
within the central region of the synapse (both 4 nm and 32 nm dextran) prior to 120 
Figure 3.31: The primary NK cell clears larger dextran from the immune synapse as it 
assembles in a ‘zipper-like’ fashion. (A) Primary human NK cells were plated on MICA-Fc/ICAM1-
Fc-coated slides with Texas Red-labelled 4 nm dextran and fluorescein-labelled 32 nm dextran and 
imaged by total internal reflection fluorescence (TIRF) microscopy. Time-lapse images were taken 
every 20 seconds from the point of cell-slide contact (time = 0). Panels show TIRF images of 4 nm 
(upper rows) and 32 nm (lower rows) dextran at the time points indicated. Image look-up tables 
(LUT) shown in HiLo, where greyscale pixels below 32 AU are highlighted as blue and those above 
223 AU are highlighted as red, as indicated on the colour scale. Scale bars; 10 μm. Images are 
representative of 6 cells from three experiments. (B) Graph shows the ratio of the area of pixels 
below 32 AU to the area of the cell-slide interface expressed as a percentage of pixels below 32 AU. 
Data were analysed by one-way ANOVA with Tukey corrections (n = 6). Data are from 5 
independent experiments. NS = no significance, ***p<0.001, ****p<0.0001. 
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seconds after initial contact. This was then pushed towards the periphery of the 
synapse. Following this clearance, the intensity of the 32 nm dextran continued to 
decrease, until the synapse was almost completely cleared of 32 nm dextran at 280 
seconds (76.9 ± 19% blue pixels). Conversely, the spreading and synapse formation 
of the same cell does not affect the 4 nm dextran to the extent of the 32 nm dextran, 
demonstrated by few or no blue pixels within the synapse interface (1.9 ± 3.8%). 
During the first 120 seconds of synapse formation, there was high variability in the 
percentage of area containing blue pixels. However, during 180 – 240 seconds 
following synapse formation, there is a decrease in the variability and no significant 
difference between the area of blue pixels in the 32 nm dextran images at 240 and 
280seconds. This suggests that within 240 seconds (or 4 minutes), the synapse has 
been cleared of dextran. This suggests that a zipper-like closing of the synapse, 
following effector cell spreading, facilitates the NK cell to clear larger dextrans from 
the interface, whilst smaller dextrans remain. 
 
Taken together, these data demonstrate that the IS is able to clear molecules larger 
than the receptor-ligand complexes formed at the synapse, whereas smaller dextrans 
remain within the synaptic cleft. Importantly, during both YTS and pNK cell synapse 
formation, at the point where relative intensities of either dextran plateaued, the 
presence of smaller dextran correlated with a complete absence of detectable larger 
dextran, suggesting that it is most likely cell spreading and synapse assembly that 
enables NK cells to clear these larger molecules from the IS. 
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3.3 Discussion 
 
3.3.1 Summary 
 
The main objective of this study was to determine whether or not the IS functions as 
a gasket. The results have demonstrated that the synapse does not seal the cleft, as 
the term gasket would suggest. Rather, extracellular molecules, here using dextran, 
can access the synaptic cleft in a size-dependent manner. Unexpectedly, the 
assembly and formation of a synapse actively cleared molecules above the size 
threshold. The main findings of this study are summarised below: 
 
 
• The activating IS formed by both NK and T cell lines and primary NK cells 
restricts the access of dextran (3 – 54 nm diameter) into the synaptic cleft in 
a size-dependent manner 
 
• Dextrans above a size threshold (32 – 54 nm diameter) are excluded from a 
formed IS 
 
• The inhibitory IS is unable to exclude extracellular molecules (3 – 54 nm 
diameter) 
 
• Dextrans of 4 nm are able to freely move into and out of the IS – resulting in 
an equilibrium of dextran concentration within the synapse and in the 
extracellular solution 
 
• Larger dextrans (32 or 54 nm diameter) are actively cleared from the IS 
during cell spreading and synapse assembly, whereas smaller dextran (4 
nm) are not cleared. 
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3.3.2 Implications of findings 
 
The results demonstrate that, whilst not forming a complete seal, the IS forms a 
physical barrier that restricts the entry of extracellular dextran in a size dependent 
manner. Smaller dextrans (4 – 13 nm and in some cases 32 nm) were able to access 
synapses formed by both NK and T cell lines and primary NK cells. In contrast, the 
54 nm-sized dextran, and 32 nm dextran for pNK cell synapses, was excluded from 
all synapses tested (Figure 3.1 – 3.4 and 3.10 – 3.12). These provide new insights 
into the nature of extracellular molecules that are able to access the IS. Moreover, 
larger dextrans were actively cleared from the synapse, suggesting a novel role of 
the effector cell spreading response and synapse assembly for the clearance of large 
molecules.  
 
These data are consistent with previous studies that characterised the dimensions of 
the IS. Specifically, crystal structures of receptor-ligand complexes, in addition to 
electron microscopy of the IS, have shown the intermembrane span to vary between 
15 and 50 nm (65, 208, 211). In addition, molecular ruling using quantum dots (QD) 
anchored to the NK cell membrane have demonstrated that larger QD are excluded 
from the cell-cell interface (189). These findings demonstrated the importance of 
membrane-anchored molecule size, in agreement with the kinetic segregation model, 
at the NK cell IS (213). The data shown here demonstrate directly for the first time 
that the sizes of receptor-ligand complexes govern the penetration of extracellular 
molecules into the cell-cell interface and IS (Figure 3.32). 
 
Not only do dextran have decreasing maximum solubility with increasing molecular 
weight, but the labelling densities of each dextran increase with their larger sizes. 
This leads to an increase in the number of dyes per dextran, with increasing 
molecule size. Consequently, dextrans of higher molecular weights are brighter than 
smaller molecules. Initial studies shown here (Figures 3.1A and B and 3.3A and B) 
used dextrans at a range of concentrations based on their maximum solubility and 
microscope settings were adjusted accordingly in each case to maximise the 
visualisation of each dextran. As a result, there was the potential that artefacts were 
introduced due to variance in concentrations and/or overall charges of dextran, and 
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the labelling densities, as well as the variations in microscope settings. These 
caveats were addressed by matching dextran concentrations (Figure 3.1D and 3.3D), 
limiting the fluorescence intensities of dextran (Figure 3.5 and 3.6) and co-incubating 
identically sized dextrans of different charges (Figure 3.8 and 3.9).  
 
The 32 nm dextran, measured by spectrometry, had as much as 10-fold greater 
labelling density than the 4 nm dextran. The use of the labelled:unlabelled mixes of 
the 4 nm and 32 nm dextrans showed that, irrespective of the size of dextran used, 
labelling densities did not affect their access to the synapse. Finally, having shown 
that labelled 32 nm dextran could be mixed with unlabelled dextran and yield the 
same results, the 4 nm and 32 nm dextran (at a labelled:unlabelled ratio of 1:10) 
were imaged with conjugates using the same microscope settings optimised to the 4 
nm dextran. The results confirm that dextran access to the synapse is size 
dependent and that artefacts are not introduced by the imaging techniques used. 
 
The results of these studies show that dextrans sized 3 – 13 nm are able to enter the 
activating IS, whereas those ≥32 nm were unable to penetrate into the synaptic cleft. 
In contrast, dextrans of all sizes were able to enter the inhibitory synapse. This 
suggests a mechanism unique to activating synapse formation provides the 
clearance of larger dextran from the synaptic cleft. Confocal and TIRF imaging have 
shown that this is a consequence of effector cell spreading and synapse assembly. 
This process occurs in a zipper-like manner and is able to drive out larger molecules 
from the synapse. 
 
The activating IS excludes dextran in a size-dependent manner 
 
To investigate the gasket function of the IS, effector and target cells were mixed with 
dextrans of increasing sizes and imaged by confocal microscopy. Establishing a 
synapse requires a tight synaptic cleft formed by nanometer spans of receptor-ligand 
complexes, and inclusion of molecules larger than this would require membrane 
bending at significant energetic penalties. The IS was able to accommodate dextrans 
3 – 13 nm in all instances, whereas those 32 – 54 nm are almost or completely 
excluded, depending on cell type and synapse – activating or inhibitory – that was 
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formed. This is in agreement with the KS model of the IS (213). The KS model has 
established that signalling at both T cell and NK cell synapses (124, 409) requires 
the clustering of similarly sized receptors to facilitate balanced signalling. Specifically, 
longer receptor-ligand pairs are physically segregated from shorter protein-protein 
interactions.(124) However, the physical exclusion of extracellular molecules by the 
IS has never been directly tested. These findings have shown that the NK cell IS 
restricts the entry or excludes extracellular molecules in a size-dependent manner. 
 
The data presented in Figures 3.1 – 3.4 establish that the IS, formed by both primary 
NK cells and a cell line, forms a physical barrier to extracellular dextran, restricting its 
entry in a size-dependent manner. Both raw and relative intensity data show that as 
dextran size increases, the ability of dextran molecules to penetrate and fill the 
synapse decreases. Dextrans sized 54 nm were excluded from all synapses tested, 
demonstrated by mean relative intensity values of 0.01, and raw intensity values that 
were constant across the cell bodies and synapse. These findings are in agreement 
with previous data that identified adhesive receptor-ligand complexes as the largest 
interactions within the synapse, spanning up to 50 – 55 nm (65). Intriguingly, the 32 
nm dextran was almost entirely excluded from the pNK cells whereas it was able to 
access the IS formed by YTS cells. This could be attributed to the nature of the 
synapse formed by YTS cells (CD28 being their only major activating receptor (20)). 
Primary NK cells possess a wide range of activating receptors that may provide a 
tighter interface with the target cell. Indeed, synapses formed by pNK cells with a 
range of targets cells, which likely use a range of activating receptors, were able to 
exclude 32 nm dextrans. This suggests that it is not the specific activating receptors 
bound at the synapse, but rather the formation of the activating synapse itself that 
dictates dextran exclusion in a size-dependent manner. Whilst the mean relative 
intensity within the synapse decreased with increasing dextran size, the large range 
of relative intensity measured for the smaller dextrans (≤13 nm) demonstrates a level 
of variability at each synapse.  
 
The variation in relative fluorescence intensity of small dextrans may occur for a 
number of reasons. Importantly, the IS is a dynamic interface with constant 
movement and recruitment of receptors and cytoskeletal proteins during signalling 
(13, 68, 173, 410). The difference in the size of receptors may influence the overall 
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structure of the synapse at different points in time, resulting in more or less dextran 
within the cleft at one point in time. Furthermore, the movement of receptors at the 
synapse will alter the dynamics of the cell membranes at the interface. This 
movement could cause fluctuations within the synapse, with downstream effects on 
the amount of dextran within the synaptic cleft. Whilst there is variability in the ability 
of smaller dextrans to access the synapse, the variation in excluded dextrans was 
significantly smaller. Similarly, the fluorescence intensities of dextran within inhibitory 
synapses, which were accessible to all sizes of dextran, have similar degrees of 
error. Therefore, the access of dextran and fluctuations of fluorescence intensity 
within the synapse may be causing variations in measurements. Thus, whilst 
dynamics at the synapse may influence measurements of smaller dextran at specific 
points in time, those excluded are unaffected by such fluctuations, indicated by 
minimal error bars.  
 
Secondly, data demonstrating the reduction of dextran fluorescence intensity within 
the forming synapse (Figure 3.29 – 3.31) show that dextran intensity is decreased at 
the developing interface. It is impossible to know at what stage of development each 
synapse is at when imaged. Thus, this variation in fluorescence intensity could be 
due to differences in the development stage of the synapses measured. This 
variability will then be reflected in the data, for example, in Figures 3.1C and 3.3C, 
and in the raw data (Figure 3.2 and 3.4).  
 
Finally, the dextran sizes given are nominal values, and therefore, each sample is 
likely to contain a range of sizes (molecular weight ± 15% the given nominal value; 
personal communication, Life Technologies). This variation could be reflected in the 
smaller and median sized dextrans (3 – 13 nm), where smaller dextrans within each 
sample could access the synapse better than the larger dextran present in the 
sample.  
 
The IS formed by Jurkat T cells with Raji target cells showed similar size exclusion of 
extracellular dextran (Figure 3.11). T cell receptor-ligand complex dimensions have 
are of similar sizes to those of NK cells (208, 209). Therefore, exclusion of dextran 
form the T cell synapse in a size dependent manner is not only in agreement with our 
findings from studies of NK cells but also reflects known size of the T cell synapse. 
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These data suggest that the extracellular spans of receptor-ligand complexes and the 
resultant accumulation of protein pairs that facilitate close proximity between the cell 
membranes, allow access of dextrans sized ≤13 nm to the IS. Those dextrans ≥32 
nm are almost, or completely, excluded, suggesting that their size exceeds that of the 
IS. As discussed above, dynamic membrane interactions likely cause some variability 
in the access of smaller dextrans to the IS. This variation is also seen in the data 
collected at the T cell synapse. Similarly, there was clear exclusion of dextrans with 
dimensions above the size threshold. 
 
The initial experimental methods to test the access of extracellular molecules into the 
synaptic cleft involved co-incubation of effector cells, target cells and dextran prior to 
imaging. In this setting, dextran was present during the initial contact and throughout 
synapse formation. Therefore, to test if dextran could penetrate formed synapses, 
conjugates were imaged by time-lapse confocal microscopy whilst dextrans of 4 nm 
or 54 nm were added to the extracellular solution. The synaptic penetration of only 
the 4nm dextran further demonstrated size exclusion at the synapse, with larger 
molecules physically excluded from the cell-cell interface.  
 
Whilst the IS does not form a complete seal around its secretory domains, the 
synapse acts as a size-restrictive barrier, most likely determined by both the dense 
accumulation and inter-membrane span of receptor-ligand pairs. The penetration of 
this barrier by smaller molecules was further demonstrated by the sequential dilution 
of 4 nm dextran during imaging of the same cell conjugate. The relative intensity of 
dextran within the synapse to the extracellular solution remained constant. This 
suggests that the dextran within the synapse equilibrates with the extracellular 
dextran, which could only occur if the molecules were able to move freely out of the 
synapse. Furthermore, the complete removal of dextran from the extracellular 
solution also resulted in loss of dextran from the synapse – demonstrating that 
dextran is not trapped within the synapse (Figure 3.16 and 3.17). Together these 
data show that dextrans below the size exclusion threshold are able to freely move 
into and out of the synapse. This establishes that the synapse is not a completely 
sealed structure, and can be accessed by molecules of specific physical dimensions. 
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Size, primarily of receptor-ligand pairs, has a direct impact on IS function – 
particularly on signalling (124). Here it has been demonstrated that the dimensions of 
the IS are not only crucial for signalling, but also determine the size of molecules that 
can access the synaptic cleft. The size-restrictions detailed in this study are in 
agreement with previous measurements of the synapse, specifically the receptor-
ligand complexes found at the interface (65, 84, 209-211, 356, 411). However, the 
consequence that the dimensions of these complexes have on extracellular 
molecules has not been investigated previously. Molecular ruling using QD anchored 
to NK cell membranes has shown that those of diameter greater than ~25 nm were 
unable to access the IS (189). These studies were similar to those that used 
elongated extracellular proteins protruding from the membrane to extend the size of 
the IS (124). The data presented here demonstrate that simply solving protein 
structures is insufficient to accurately predict the sizes of molecules that could enter 
the IS. Whilst the activating and inhibitory synapses possess membrane spans of 
similar dimensions, the data show here that the extent to which molecules can 
penetrate the synapse is also dependent on the nature of synapse formed.  
 
The inhibitory IS does not exclude extracellular dextran 
 
The lack of size exclusion from the inhibitory IS was unexpected. Whilst inhibitory 
synapses are short-lived interactions (412), membranes must come into close 
contact to allow the ligation of receptors and their cognate ligands. Previous crystal 
structure analyses of NK cell inhibitory receptor-ligand pairs have shown them to 
span ~15 nm (84), similar to activating receptor-ligand complexes. However, all 
dextrans tested (3 – 54 nm) were able to access the inhibitory synapse to similar 
degrees. In contrast with activating synapses, where the peak of intensity within the 
synapse reduces as dextran size increases, inhibitory synapses show similar peaks 
for all dextran sizes.  
 
Ligation of KIR2DL1 fails to induce a spreading response, shown by a lack of F-actin 
accumulation or the formation of rings at the synapse. This is in contrast with 
activation, which induces symmetrical F-actin rings that are formed by concurrent 
waves of actin moving away from the centroid of the synapse (123, 413). The 
absence of spreading and rearrangement of F-actin at the inter-cellular contact may 
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prevent the inhibitory synapse from excluding larger molecules. In agreement with 
this, drug-induced actin depolymerisation at the activating synapse allowed larger 
dextrans to access the synaptic cleft. This further demonstrated an important role for 
actin in establishing size-dependent exclusion at the cell-cell interface. Furthermore, 
without the effector spreading response, the larger dextran may not be cleared, as 
seen with the activating synapses (Figure 3.29 – 3.31). Therefore, the inhibitory 
synapse may not have the same ability to exclude dextran in solution, due to the 
absence of cell spreading and cytoskeletal structures following inhibitory signalling. In 
the absence of the organised structure as seen at the activating synapse, NK cells 
are able to make rapid and transient contacts with healthy cells, discerning their 
condition quickly. This means that diseased cells can be sought after and killed more 
efficiently. This more transient interaction occurs without the formation of a size-
dependent barrier to extracellular molecules. However, the exclusion of molecules 
from the inhibitory IS may not be essential, as no cytotoxic proteins or cytokines are 
secreted (9, 166). 
 
An intact actin structure at the immune synapse is required to exclude 
extracellular dextran in a size-dependent manner 
 
The involvement of F-actin and other proteins associated with its reorganisation 
(such as WASp) are known to be critical to synapse function. Previous studies have 
investigated the role of actin in the formation of the synapse and subsequent 
cytotoxicity (165, 414, 415), as well as the movement of receptors within the cell-cell 
interface (91). These data have shown that without F-actin turnover, the synapse 
cannot assemble and NK cell-mediated cytotoxicity is abrogated. Furthermore, 
signalling proteins required for actin reorganisation are cycled throughout the 
synapse lifetime, leading to repeated waves of actin polymerisation at the cell-cell 
interface (171). Due to the essential requirement for actin at the IS for its formation 
and for cytolysis, the role of actin in extracellular molecule exclusion was tested. 
 
The data demonstrate that further reorganisation of F-actin at the fully formed 
synapse is not required to exclude dextran, but actin is required for structural 
integrity, which is essential for exclusion to occur. Depolymerisation of F-actin 
abrogated the ability of the synapse to exclude dextran (Figure 3.25 and 3.26), 
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whereas its stabilisation had no aberrant effect (Figure 3.27 and 3.28). F-actin is 
important for maintaining the structure of the activating synapse, and its 
reorganisation is a crucial factor following the decision to initiate effector functions 
(108). Furthermore, actin is required to provide an anchor for integrins through such 
proteins as Talin (414, 416). It may be the combination of these interactions that 
provide rigidity at the membrane, which facilitates exclusion of larger molecules. This 
role may have important physiological consequences for the successful function of 
the synapse, providing a barrier to extracellular molecules that would otherwise be 
able to penetrate and interfere with the action of proteins secreted at the synapse. 
 
Clearance of dextran above the size exclusion threshold during IS assembly 
 
Dextran above the size exclusion threshold was excluded from, or unable to enter, 
the IS (Figures 3.2, 3.3 and 3.14). However, these initial experiments did not address 
the mechanism involved in exclusion of larger dextrans from the immune synapse. 
To investigate this, time-lapse confocal microscopy was used to image synapse 
formation in the presence of differently sized dextrans. This enabled the visualisation 
of dynamics at the synapse and the effect this had on dextran at the point of cell-cell 
contact and during synapse assembly. The data shows that following initial contact, 
both larger and smaller dextrans are present within the IS, but after 3 – 4 minutes, 
larger dextran are barely detectable within the cleft. This suggests that dextran is 
cleared from the synapse during assembly. Indeed, it has been well established that 
NK cells, when in contact with a target cell or activating surface, initiate a spreading 
response, mediated by the movement of F-actin waves, specifically following ligation 
of activating receptors (117, 123, 187). Whilst the decrease in fluorescence of the 54 
nm dextran at the synapse was much more rapid, the point at which the fluorescence 
intensity of the 4 nm dextran reached a plateau and the 54 nm dextran was 
undetectable both occurred around 3 minutes after initial cell-cell contact. This 
suggests that within the first 3 minutes of synapse assembly, processes such as 
spreading and ligand ligation may facilitate larger dextran clearance. 
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IRM images can be used to discriminate the distance between the NK cell membrane 
and the plane of the slide. Darker regions indicate a tighter interaction between the 
cell membrane and the slide and lighter areas demonstrate greater distances. Both 
lighter and darker regions can be seen in the NK cell interface when plated with 4 nm 
or 32 nm dextrans (Figure 3.30A and B). Moreover, the lighter regions of the IS 
(where the membrane curves away from the slide) correlate with brighter areas of 
fluorescence intensity of the 4 nm dextran. This suggests that the dextran is able to 
fill the spaces in between the cell membrane and slide, moving across the regions of 
tighter contact. In contrast, whilst these curvatures of the membrane can be seen at 
IS formed in the presence of the 32 nm dextran, there is no fluorescent signal within 
darker regions of the membrane, showing that the larger dextran has been cleared 
and cannot move across regions of tighter contact. This implies that following the 
clearance of dextran from the synapse, the structure of the IS acts as a barrier that 
prevents the movement of larger molecules into the synaptic cleft. 
 
Finally, the use of TIRF microscopy enabled high resolution imaging of both 4 nm 
and 32 nm dextrans at the cell-slide interface within an imaging depth of ~100 nm. 
These data show that the effector cell spreading response results in a zipper-like 
closure of the synaptic cleft (Figure 3.31A). It is this mechanism that appears to drive 
the clearance of molecules from the synapse. The images show that both the larger 
and smaller dextrans collect within the synapse during the initial stages of synapse 
formation. The subsequent spreading of the cell pushes dextran from the central 
region of the synapse towards the periphery. At this point, the 32 nm dextran is 
further excluded from the synapse until the synapse contains only 4 nm dextran. The 
timing of this clearance (within 180 – 240 seconds) is consistent across all time-lapse 
experiments. The quantification of the percentage area of the cell-slide interface with 
pixels below the 32 AU threshold shows that there appears to be a slight delay in 
dextran clearance, following effector cell spreading (Figure 3.31B). The approach to 
‘black’ pixels within the synapse indicates a close proximity between the cell 
membrane and the coverglass. This is initially seen in images of both the 4 nm and 
32 nm dextrans. It is not until the cell has spread that a significant proportion of the 
cell-slide interface is below the 32 AU threshold. This may be caused by a complete 
clearance of larger dextrans from the synapse initiated by a later stage of activating 
receptor binding. It may be this receptor ligation that initiates the mechanisms to 
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clear larger dextran from the synapse. These studies further demonstrate how 
effector cell spreading of an NK cell and its ligation of activating ligands provide the 
mechanism to clear dextran from the synapse. 
 
Consistent with the clearance of larger dextran from the synapse, Culley et al. 
showed that the NK cell spreading response reaches a maximum diameter at 3 – 4 
minutes following initial cell-cell contact (123) and Stinchcombe et al. demonstrated 
that CTL polarised their lytic granules to the synapse within 3 minutes (365). Within 
this time frame, the synapse may need to be cleared of extracellular molecules, 
perhaps in order to maximise concentrations of cytotoxic mediators within the 
synaptic cleft. The initial gradual decrease of fluorescence intensity of the dextran 
can be attributed to the PSF volume of the microscope imaging an increasingly 
smaller volume, to the order of nanometers compared to a PSF of up to 3 μm, at the 
cell-cell interface. However, once the IS had been assembled, the decrease in 
fluorescence intensity of the 4 nm dextran arrested and was maintained at a constant 
level for the remaining duration of imaging. Conversely, at the point of the 4 nm 
reaching a plateau, the 54 nm dextran had been completely excluded from the 
synapse. Therefore, the NK cell spreading response may provide a pushing force to 
clear larger dextran. More specifically, during the polarisation of the MTOC towards 
the synapse, proteins (such as WASp) facilitate F-actin rearrangement at the 
synapse. Moreover, Arp2/3 mediates the reorganisation of F-actin, through constant 
polymerisation and depolymerisation, in waves from the centroid of the synapse 
towards the periphery (169-171). It may be this dynamic reorganisation that drives 
the clearance of molecules from the synapse. 
 
These data collectively show that exclusion of larger dextrans from the IS may not 
only be a result of the formation of a dense mesh of protein-protein complexes, but 
that the NK cell spreading response and synapse assembly can physically clear 
molecules from the cell-cell interface. Once a synapse has been formed, this tight 
interface restricts further access of molecules greater in size than those of the 
receptor-ligand complexes that make up the synapse. The clearance of dextran from 
the interface demonstrates a novel role of the IS and its assembly that has not been 
shown previously. In conclusion, the immune synapse clears and excludes dextran 
above a size threshold. 
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Chapter 4 – Size-Dependent Exclusion 
of Functional Proteins from the 
Immune Synapse 
 
4.1 Introduction 
 
In Chapter 3, it demonstrated for the first time that the IS was able to exclude or 
restrict the entry of extracellular molecules below a size threshold. This was 
dependent on the assembly of the synapse and an intact F-actin scaffold. In addition, 
the formation of the synapse cleared larger dextran molecules from the synapse as it 
formed in a zipper-like manner. This size-dependent exclusion would likely also 
restrict the entry of functional extracellular molecules, for instance, monoclonal 
antibody therapies. Studies detailed in this chapter investigate the ability of 
antibodies of varying size to access the IS. 
 
4.1.1 Antibodies and fragments 
 
Monoclonal antibodies (mAb) are monospecific proteins, termed immunoglobulins 
(Ig). They are produced as clones from one parent plasma cell. Antibodies are ‘Y-
shaped’ glycoproteins that can form a variety of structures (multiple antibodies 
creating a polymer) that identify and/or neutralise foreign microbes such as viruses or 
bacteria (417). IgG antibodies are 150 kDa proteins, measuring 16 nm in their 
longest dimension, that consist of 2 light and 2 heavy chains comprising 2 or 4 
domains, respectively (418, 419) (Figure 4.1A). Each chain contains both constant 
and variable domains. The structures of constant domains are consistent for all 
antibodies, whereas the variable domains determine the specificity towards a specific 
epitope (420, 421).   
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MAb can be enzymatically processed in vitro to create smaller antigen-binding 
proteins, Fab’ and F(ab’)2 fragments. These can be generated from papain or pepsin 
digestion respectively (388). These enzymes cleave mAb at either the hinge region 
above the Fc fragment to generate a F(ab’)2 fragment or the entire hinge region 
generating two separate Fab’ fragments and an Fc fragment. F(ab’)2 fragments are 9 
nm in their longest dimension (386) (Figure 4.1B). 
 
Single variable domains were first discovered in camelids (even-toed ungulate 
mammal, e.g. camels) and have been shown to be able to bind a wide variety of 
epitopes (422). These single-domain antibodies have led to the development of 
nanobodies, exhibiting high stability and solubility (389). More recently, the 
production of human domain antibodies (dAb) has been developed (423, 424) Dab 
are antibody fragments that consist of the variable domain of an antibody heavy 
chain (VH) or light chain (VL)  (389). The smallest known antigen-binding dAb are 11 
– 15 kDa in molecular weight and ~4 nm in their longest dimension (425) (Figure 
4.1C). In comparison to mAb (150 kDa, 16 nm) and F(ab’)2 fragments (57 kDa, 9 nm), 
these single-domain fragments are significantly smaller. Human dAb are modified at 
the reside positions 44, 45 and 47 to those found in camel single-domain antibodies, 
leading to a more hydrophilic molecule. Such modifications can eliminate dAb 
aggregation and increase solubility (423). A major advantage of dAbs is that they can 
be expressed in phage display libraries, generating antibodies with affinities up to 
303 x 109 M-1 (426). Other modifications of dAb include the fusion of two dAbs 
together or fusion with an Fc portion of a monoclonal antibody. These properties 
make dAbs a diverse and useful technology that could have many advantages in 
future medical therapies (426). 
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4.1.2 Current immunotherapies and their limitations 
 
Paul Ehrlich first conceived the idea of a ‘magic bullet’, a compound capable of being 
selectively targeted against a disease-causing organism in the early 1900s. However, 
it was not until 1973, following the identification of paraproteins (an abnormal 
immunoglobulin produced in excess by multiple myeloma B cells) that the successful 
production of monoclonal antibodies was described (427) and in 1988, Greg Winter 
and his team pioneered the techniques by which humanized mAb could be 
successfully produced (428, 429). Since then, increasing numbers of monoclonal 
Figure 4.1. Schematic diagrams of the structures of a monoclonal antibody (mAb), a F(ab’)2 
fragment and a domain antibody (dAb). Antibodies can exist in whole or various fragmented 
forms and consist of light (green) and heavy (pink) chains that bind targets at the binding site located 
at the tip of the variable domains (yellow).  (A) Human mAb (e.g. IgG) are 150 kDa proteins 
comprising light and heavy chains consisting of 2 or 4 domains respectively. A mAb contains two 
Fab’ fragments (2 variable domains and 2 constant domains) and an Fc fragment (4 constant 
domains), linked at a hinge region (black lines). A monoclonal antibody is 16 nm in its longest 
dimension. (B) F(ab’)2 fragments are 100 kDa proteins comprising the 2 Fab’ fragments of a mAb 
connected by the hinge region. A F(ab’)2 fragment is 9 nm in its longest dimension. (C) Domain 
antibodies are 15 kDa proteins comprising the variable domain of the heavy chain. A dAb is 4 nm in 
its longest dimension. Diagrams not to scale. 
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antibodies have been used widely as immunotherapies to treat a variety of diseases 
(430). 
 
The treatment of autoimmune diseases (431-435) and cancer (326, 436, 437) using 
mAb has been extremely successful. A notable example is the development of a 
mAb against TNFα (438-440). To date, there are over 23 commercial mAb products 
approved for use on the US market (441). Recently, Fab’ fragments (442, 443), 
F(ab’)2 fragments (444, 445) and various forms of single domain antibodies (446-448) 
have been investigated as novel therapeutics and their development is currently 
underway. Targets include viral proteins (e.g. H5N1 surface protein), tumour cell-
expressed proteins (e.g. Folate-binding proteins of ovarian cancers) and NK cell 
activation (binding CD16). However, most of these trials or experiments have only 
been conducted in animal or in vitro studies.  
 
Despite the vast repertoire of specific antibody therapies available, they are targeted 
towards cell surface or soluble, non-directionally secreted proteins – primarily 
cytokines. This may be because current mAb therapies are unable to access 
structures through which proteins are directionally secreted, or presented, to other 
cells. It may also be the case that these targets have never been considered. Indeed, 
there is anecdotal evidence that the NK cell IS may restrict the entry of mAbs (366, 
367) and therefore, mAb therapies cannot be used in this setting. It is likely that this 
restriction is due to the large size of antibodies, which prevents them from accessing 
the synapse. Thus, it may be possible for smaller antibody fragments to access the 
IS, which would facilitate the potential use of target-specific therapies against 
proteins secreted across the IS, such as PFN. 
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4.1.3 Aims 
 
The data in Chapter 3 show that the IS does not form a gasket but rather a size-
restrictive barrier that can be penetrated by molecules of sufficiently small 
dimensions. The inability of therapeutic mAb to target proteins secreted across the IS 
could be due to the clearance and exclusion of mAb from the synapse by effector cell 
spreading. The extracellular domains of receptor-ligand complexes that govern the 
size of the synapse will likely also restrict access to mAb. However, antibodies 
engineered to be smaller than current therapeutic antibodies may be able to access 
the synaptic cleft. 
 
The main objective of this investigation was to use functional proteins, including 
antibodies of various sizes and low-density lipoproteins (LDL), to investigate if there 
is size-dependent access to the immune synapse. Specifically, the aims of this study 
are: 
 
i. To generate a domain antibody against an irrelevant target (not expressed by 
NK cells)  
 
ii. To determine whether antibodies and/or antibody fragments of various sizes 
are able to penetrate the IS 
 
iii. To investigate if the clearance and exclusion of extracellular molecules can 
restrict the access of serum proteins, such as LDL 
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4.2 Results 
 
4.2.1 Production of a domain antibody 
 
A dAb against GPVI was generated as previously described (390) and transferred to 
PBS buffer to maintain physiological salt concentrations during incubation with cells, 
and for consistency with dextrans tested in previous experiments. To confirm the 
monomeric structure of the dAb, the protein was run on an SDS-PAGE gel under 
reducing and non-reducing conditions (Figure 4.2). The bands at 15 kDa showed that 
the dAb is a monomeric protein, as expected. The dAb was then labelled with Texas 
Red fluorophore for visualisation using confocal fluorescence microscopy. To assess 
the ability of various sized antibodies to enter the synapse, fluorescently labelled 
murine mAb and a F(ab’)2 antibodies against murine IgG were also used. All antibody 
types were run on an SDS-PAGE gel under non-reducing conditions to confirm their 
relative molecular weights (Figure 4.3). The bands at 150 kDa, 100 kDa and 15 kDa 
indicate that the mAb, F(ab’)2 fragment and dAb are of the correct molecular weights 
and physical dimensions reported in the literature (386, 418, 425). 
 
 
 
Figure 4.2. SDS-PAGE of bacterially expressed anti-glycoprotein VI domain antibodies. 
Domain antibodies against glycoprotein VI were expressed in HB2151 E. coli. Samples were 
prepared either under reducing (left group) or non-reducing (right group) conditions as 
indicated. Bacterial cell exudates (left and central columns) or purified dAb (right column) 
were run on an SDS-PAGE gel.  
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4.2.2 The NK cell immune synapse restricts the access of antibodies in 
a size-dependent manner 
 
To test whether or not antibodies of various sizes were able to access the IS, YTS 
and 221 conjugates were co-incubated with fluorescently labelled antibodies (mAb), 
antibody fragments (F(ab’)2) or single domain antibodies (dAb) and imaged by 
confocal microscopy. Previous measurements of mAb, F(ab’)2 and dAb have shown 
them to be 16 nm (418), 9 nm (386) and 4 nm (425) in their longest dimensions. 
Confocal microscopy revealed that antibodies could access the YTS IS in a size 
dependent manner (Figure 4.4A), as described in chapter 3 using dextran. Access to 
the IS was quantified using the same method as was used previously to assess the 
entry of dextran. Fluorescence intensity of the antibody within the immune synapse 
was measured relative to the extracellular solution. Access to the IS of the largest 
antibody, mAb, was the least efficient (0.05 ± 0.02). Smaller F(ab’)2 fragments were 
able to access the synapse to a greater extent (0.08 ± 0.04) and the dAb, the 
smallest antibody tested, entered the IS most successfully (0.11 ± 0.04) (Figure 
4.4B). These data confirm that access of antibodies to the synapse is size-
dependent. 
Figure 4.3. SDS-PAGE of a goat anti-murine IgG monoclonal antibody (mAb), a goat anti-
murine IgG F(ab’)2 fragment and an anti-glycoprotein VI domain antibody (dAb). Antibodies, 
F(ab’)2 fragments and domain antibodies were run on an SDS-PAGE, as indicated, and then stained 
with Coomassie Blue. 
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Figure 4.4. Antibody entry into the YTS cell immune synapse is size-dependent. (A) 
Representative images of YTS and 221 conjugates co-incubated with fluorescently labelled 
monoclonal antibodies (mAb), F(ab’)2 fragments or domain antibodies (dAb). Panels show brightfield 
images overlaid with target cell nuclear staining (upper row) and the corresponding fluorescence 
images (lower row). Scale bars; 10 μm. (B) Antibody fluorescence intensity in the synapse was 
measured relative to the extracellular solution intensity. Bars show mean ± SD. (n = 41, 59 and 48 
for mAb, F(ab’)2 and dAb respectively). Data were analysed using a one-way ANOVA with Tukey 
corrections. Data from 3 independent experiments, **p<0.01, ****p<0.0001. 
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Whether these antibodies could penetrate a synapse formed by pNK cells was then 
tested. Co-incubation of pNK and 221 cells with fluorescently labelled mAb, F(ab’)2 
and dAb was imaged by confocal microscopy. Antibody access to the pNK synapse 
was size dependent (Figure 4.5A), consistent with synapses formed by YTS. Again, 
the mAb was least able to enter the synaptic cleft and was almost entirely excluded 
from the synapse (0.03 ± 0.01). The F(ab’)2 fragments accessed the synapse to 
some extent (0.06 ± 0.04), but crucially, the dAb were able to access the IS to the 
most efficiently (0.15 ± 0.01) (Figure 4.5B). The results demonstrate that the 
synapses of both YTS and pNK cells impose a size-dependent restriction on protein 
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Figure 4.5. Antibody entry into the primary human NK cell immune synapse is size-
dependent. . (A) Representative images of primary human NK cells and 221 conjugates co-
incubated with fluorescently labelled monoclonal antibodies (mAb), F(ab’)2 fragments or domain 
antibodies (dAb). Panels show brightfield images overlaid with target cell nuclear staining (upper 
row) and the corresponding fluorescence images (lower row). Scale bars; 10 μm. (B) Antibody 
fluorescence intensity in the synapse was measured relative to the extracellular solution intensity. 
Bars show mean ± SD. (n = 38, 35 and 39 for mAb, F(ab’)2 and dAb respectively) Data were 
analysed using a one-way ANOVA with Tukey corrections. Data from 3 independent experiments.  
***p<0.001, ****p<0.0001. 
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access to the synaptic cleft. These data were consistent with the size-dependent 
exclusion of dextran from the NK cell IS (Figure 3.1 and 3.3). This indicates that the 
use of mAb, such as IgG, to block proteins secreted across the IS is likely to fail due 
to the size restriction identified here. 
 
4.2.3 Monoclonal IgG antibodies against perforin are unable to access 
the immune synapse 
 
The restriction of a mAb demonstrates that the synapse can exclude antibodies from 
the synapse. This may explain why the IgG antibodies against proteins secreted 
across the synapse are unable to bind their targets. However, the anti-murine IgG 
antibodies used above are not specific to synapse-associated proteins. To test 
whether a mAb against PFN was able to bind its target when secreted across the 
synapse, a protein capture assay was used. Here, slides were coated with MICA-Fc 
and ICAM1-Fc in order to activate NK cells and induce degranulation. Following 
activation, cells were then incubated with fluorescently labelled anti-PFN antibodies, 
and their ability to bind PFN within the synapse was assessed by confocal 
microscopy. 
 
To show that the capture assay effectively induces degranulation of NK cells and 
captures PFN protein, pNK cells were incubated on coated slides for 30 minutes, and 
then incubated with a non-enzymatic cell dissociation solution to remove bound NK 
cells. Captured PFN was then immunostained with an anti-PFN antibody labelled 
with Alexa Fluor 488 (anti-PFN-488) and imaged by confocal fluorescence 
microscopy (Figure 4.6). The images show that the activating slides are sufficient to 
induce degranulation by NK cells and that secreted PFN can be captured and 
stained. 
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The capture of PFN at the cell-slide interface meant that the NK cell IS could next be 
tested for its ability to exclude IgG antibodies against PFN. To test this, pNK cells 
were plated on activating slides, as described above. To test whether cells were 
activated (identified by effector cell spreading and actin accumulation at the interface) 
and that PFN could be stained, NK cells were fixed, permeabilised and stained for 
actin (using Phalloidin conjugated to Alexa Fluor 647) and PFN. To then both test 
whether anti-PFN antibodies could penetrate the synapse, and whether cell fixation 
could affect exclusion, cells were incubated with anti-PFN-488 antibodies prior to or 
following fixation. 
 
Cells in contact with the slide were imaged by confocal fluorescence microscopy 
(Figure 4.7A). The results show that when NK cells were fixed and permeabilised, 
anti-PFN-488 antibodies were able to access PFN at the cell-slide interface 
(identified using the IRM images) and within the NK cell body. However, if cells were 
not permeabilised, the antibodies were significantly hindered in their ability to stain 
PFN at the IS, either following fixation or prior to fixation. In order to quantify this, 
cells were scored on the presence of fluorescent signal at the cell-slide interface.  
PFN staining was determined by the presence of fluorescence signal at the cell-slide 
interface. When cells were permeabilised, PFN was stained in 78% of cells. 
However, the percentages of cells positive for PFN staining at the cell-slide interface 
Figure 4.6. Perforin secreted by primary human NK cells can be captured on an activating 
surface. Primary human NK cells plated on slides coated with MICA-Fc, ICAM1-Fc and anti-perforin 
were incubated for 30 minutes. Cells were removed and captured perforin stained with an anti-
perforin antibody labelled with Alexa Fluor 488 antibody. Panels show zoomed out (left panel) and 
zoomed in regions (right panels) of captured and stained perforin. 
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following either fixation then staining or staining then fixation were 30% and 7% 
respectively (Figure 4.7B). This demonstrates that the formation of the IS restricts the 
access of mAb into the synapse.  
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Figure 4.7. The primary human NK cell immune synapse excludes anti-perforin antibodies.  
Primary human NK cells were plated on slides coated with MICA-Fc, ICAM1-Fc and anti-perforin 
antibodies and incubated for 30 minutes. Panels show fluorescence images and the corresponding 
interference reflection microscopy (dark areas indicate contact with the slide). (A) Cells were fixed, 
permeabilised and stained for actin and perforin by Phalloidin Alexa Fluor 674 and an anti-perforin 
antibody labelled with Alexa Fluor 488 respectively (Fix – Perm – Stain). Cells were fixed then 
stained for perforin using an anti-perforin antibody labelled with Alexa Fluor 488 antibody (Fix – 
Stain). Cells were stained for perforin using an anti-perforin antibody labelled with Alexa Fluor 488 
antibody then fixed (Stain – Fix). Scale bars; 10 μm. (B) Cells with positive staining for perforin were 
then counted. Graph shows the percentage of cells stained positive or negative for perforin in each 
condition as indicated. Data were analysed by one-way ANOVA with Tukey corrections. (n = 54, 49 
and 51 for permeabilised, fix – stain, and stain – fix, respectively). Data are from 2 independent 
experiments. ****p<0.0001. 
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The exclusion of anti- antibodies from the IS in up to 93% of synapses formed with 
an activating surface is in agreement with previous data demonstrating that mAb are 
excluded from the IS formed by pNK and 221 cells (Figure 4.5). Most likely their size 
prevents access into the synaptic cleft. Therefore, the structure of the synapse, 
specifically the binding of receptor-ligand complexes, forms a physical barrier that is 
able to prevent larger proteins from accessing the synapse, illustrating why directly 
secreted proteins cannot be targeted by conventional antibodies. 
 
4.2.4 Low-density lipoproteins are excluded from the primary NK cell 
immune synapse but not from the activating or inhibitory YTS cell 
immune synapse 
 
Low-density lipoproteins (LDL) are able to inhibit the cytolytic action of PFN by 
binding to its nascent hydrophobic domains; this prevents oligomerisation and pore-
formation (449, 450). Experimentally, this was first implicated by the inhibition of 
granule-mediated haemolysis by whole human serum, suggesting that one or more 
components prevented the action of the cytolytic proteins. Immunoblotting of 
incubations revealed that LDL were bound to PFN, confirming the cause of reduced 
granule-mediated lysis. Furthermore, incubation of granules with other serum 
proteins, such as albumin, has no impact on haemolysis. This demonstrated that the 
interaction between lipoproteins and PFN inhibits lytic action. For this reason, the 
presence of LDL within the IS would have a negative effect on NK cell lysis of 
targets.  
 
LDL have previously been shown to have a mean diameter 21.4 ± 1.3 nm  (451-453). 
To test whether LDL are excluded from the IS, YTS or pNK cells were co-incubated 
with 221 target cells and fluorescently labelled LDL. Conjugates were then imaged by 
confocal microscopy. In addition, the YTS/KIR and 221/Cw6 inhibitory synapse 
system was used to investigate whether LDL was excluded in this setting, as 
suggested by previous data (Figure 3.14). All conjugates were imaged by confocal 
microscopy and access to the synapse was measured relative to the extracellular 
solution (Figure 4.8A).  
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Confocal imaging revealed that the synapse formed by YTS cells and 221 target cells 
allowed the access of LDL from the synaptic cleft (relative intensity in the synapse 
compared to the solution 0.08 ± 0.04). Similarly, the incubation of YTS/KIR cells with 
221 target cells and LDL resulted in a non-significantly different access of LDL (0.9 ± 
0.04). However, the inhibitory synapses by YTS/KIR and 221/Cw6 cells were unable 
to exclude LDL (0.12 ± 0.03). This shows that the presence of inhibitory receptors 
does not affect the extent to which LDL enters the synapse– it is the formation of an 
inhibitory synapse that prevents molecule exclusion. The pNK cell activating synapse 
was also able to exclude LDL from the synapse (0.03 ± 0.01) (Figure 4.8B). These 
data demonstrate the inability of inhibitory synapses to exclude extracellular 
Figure 4.8.Low-density lipoproteins (LDL) are excluded from the activating immune synapse 
but not the inhibitory immune synapse. (A) NK cell lines forming activating (first and second 
columns) or inhibitory synapses (third column) and primary NK cells in conjugate with 221 target 
cells were co-incubated with fluorescently-labelled LDL and imaged by confocal microscopy.  Panels 
show brightfield images overlaid with target cell nuclear staining (upper row) and the corresponding 
fluorescence images (lower row). Scale bars; 10μm. (B) LDL fluorescence intensity within the 
synapse was measured relative to the extracellular solution intensity. Graph shows each data point 
and mean ± SD from 3 independent experiments. (n = 27, 25, 27 and 54 for YTS/221, YTS-
221/Cw6, KIR/KIR-221/Cw6 and pNK-221 respectively). Data were analysed using a one-way ANOV 
with Tukey comparisons. ****p<0.0001 
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molecules, and that the pNK cell synapse excludes larger extracellular molecules 
more efficiently than the activating YTS cell synapse, consistent with previous 
findings in Chapter 3.  
 
These results demonstrate that the pNK cell cytolytic synapse restricts access of LDL 
to the synaptic cleft, to a much greater extent than YTS synapses. This may provide 
a mechanism by which NK cell secretions are protected at the synapse, preventing 
inhibition of PFN, which may have a detrimental effect on target cell cytolysis. 
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4.3 Discussion 
 
4.3.1 Summary 
 
Previous data (Chapter 3) have shown that the size of a molecule dictates its ability 
to access the immune synapse. The main objective of this study was to determine 
whether functional proteins are excluded from the IS in a similar manner. Here we 
show that the IS restricts access of proteins based on their physical dimensions. The 
main results from this study are as follows: 
 
• The IS formed by both YTS and pNK cells excludes antibodies in a size 
dependent manner 
 
• MAb against PFN are unable to stain captured PFN secreted at the IS, due to 
exclusion of these molecules from the synapse by the size threshold 
 
• LDL are almost completely excluded from the synapse formed by pNK cells 
 
• Inhibitory synapses are unable to clear and exclude LDL 
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4.3.2 Implications of findings 
 
The experiments detailed in this chapter investigated whether the IS excluded 
functional proteins. The results demonstrate that extracellular proteins are subject to 
size-dependent exclusion from the synapse, consistent with the size-dependent 
exclusion of dextran molecules used in earlier studies. MAb were almost completely 
excluded from the pNK cell synapse, as were LDL, whereas the inhibitory synapse 
was unable to exclude LDL. However, smaller F(ab’)2 fragments and dAbs were able 
to access the synapse. Therefore, the activating IS is able to exclude all manner of 
extracellular molecules, which is dictated by their physical dimensions. 
 
Size-dependent exclusion of extracellular antibodies from the IS 
 
Synapses formed by both YTS and pNK cells restrict protein access to the synapse 
in a size-dependent manner. This is consistent with previous data demonstrating a 
size-dependent exclusion of dextran from the synapse (Chapter 3).  MAb were 
largely excluded from the synapses of both YTS cells and pNK cells, whereas 
smaller F(ab’)2 and dAb penetrated the synapse. The enhanced penetration of dAb 
compared to F(ab’)2 further demonstrates the importance of molecule size in 
determining whether it is able to penetrate the IS. The restriction of mAb is in 
agreement with previous studies that have suggested that mAb are unable to block 
proteins and cytokines secreted across the synapse (366, 367). For this reason, such 
mAb are prevented from blocking the action of cytotoxic mediators directly secreted 
across the IS.  
 
In addition to testing the ability of irrelevant antibodies to enter the synapse, a 
fluorescently labelled mAb against PFN was also tested. These antibodies were 
added to pNK cells engaged to MICA-Fc/ICAM1-Fc/anti-PFN-coated slides, prior to 
or following fixation to test the exclusion of antibody from the synapse, and whether 
fixation affected exclusion. PFN was stained in less than 10% of synapses. The 
greater incidence of PFN staining within the synapse of cells that were fixed prior to 
the addition of the anti-PFN-488 antibody may be due to breakdown of the IS 
following fixation. It has been demonstrated that fixation can cause shrinkage and 
expansion of cells (454). This will have a negative impact on the synapse, potentially 
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causing ruptures in the barrier between some of cells, allowing access of the mAb. 
The exclusion of anti-PFN antibodies from up to 97% of conjugates demonstrates 
that exclusion of these proteins from the synapse is almost total. Therefore, the pNK 
cell synapse consistently prevents the access of larger molecules into the IS. 
 
Taken together, these data demonstrate that the IS is able to exclude antibodies in a 
size-dependent manner. Domain antibodies have been shown to effectively access 
the IS, akin to dextrans of comparable sizes (Figure 3.2 and 3.3). Therefore, 
antibodies targeted against proteins secreted within the synapse should be 
engineered to the dimensions identified here. Specifically, a dAb, 4 nm in its longest 
dimension, is able to effectively access the IS, and could provide a therapeutic tool to 
target cytotoxic mediators within the IS. 
 
Cell-dependent exclusion of LDL from the IS formed by YTS or pNK cells 
 
LDL are micellar (a particle of colloidal dimensions that exists in equilibrium with the 
molecules or ions in solution from which it is formed) complexes constructed from 
proteins and lipids consisting of an amphipathic surface monolayer and a 
hydrophobic core (455-458). Formed in the circulation through a metabolic cascade 
of apolipoprotein B-100 (459), LDL particles are a heterogeneous group that vary in 
diameter (18 – 25 nm, mean 22 nm) and density (±1.019 – 1.063 g/mL) (452, 453).  
LDL inhibit the action of PFN, inhibiting oligomerisation and pore formation in the cell 
membrane (449). Co-incubation of lipoproteins with CTL-derived granules inhibited 
haemolysis by up to 70%. Further, HDL and LDL were shown to inhibit haemolysis by 
up to 60% and 100% respectively (450). Therefore, if LDL were present within the 
cytolytic synapse during degranulation, target cell lysis could be inhibited.  
 
Synapses formed by pNK cells almost completely excluded LDL from the interface. 
This suggests that clearance and exclusion of LDL from the synapse would protect 
PFN. The ability of LDL to inhibit PFN may have a protective role, preventing damage 
to bystander cells, should PFN be released into the serum. This may occur following 
cytosol leakage during necrosis of PFN-containing cells (460). Bacteria that secrete 
pore-forming proteins, known to be structurally similar to PFN (461), may also induce 
release from PFN-expressing cells (462). 
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The activating synapses formed by YTS and YTS/KIR cells excluded LDL to a similar 
degree, and the fluorescence intensities of LDL within these synapses, relative to the 
extracellular solution, were not significantly different. This suggests that the formation 
of an activating synapse by YTS cells, whether the inhibitory receptor KIR2DL1 is 
expressed or not, is able to exclude LDL to a similar degree. In contrast, the 
inhibitory synapse formed by YTS/KIR cells with 221/Cw6 cells was completely 
unable to restrict the access of LDL, with the relative intensities within the synapse 
comparable to those of all dextrans tested previously (Figure 3.14). This provides 
further evidence that the inhibitory synapse is unable to clear or exclude molecules 
from the cell-cell interface as efficiently as activating synapses. As discussed 
previously in Chapter 3, the transient nature of the inhibitory synapse means that 
exclusion of extracellular molecules does not occur. The expression of inhibitory 
receptors alone does not affect exclusion from the synapse, compared to the 
formation of an inhibitory synapse. This suggests that the process of activating 
synapse formation is essential for exclusion of extracellular molecules from the IS. 
 
The synapse formed by pNK and 221 cells almost completely excluded LDL from the 
cell-cell interface, compared to activating synapses formed by the NK cell line YTS. 
This could explain why YTS cells are less efficient killers than pNK cells (20, 463). 
Consistent with this, previous studies have demonstrated that the addition of high 
amounts of H/LDL to some CTL-target cell conjugates was unable to significantly 
affect cell-mediated lysis (449). However, CTL clones that were less efficient killers 
were more susceptible to the effect of LDL than their more effective counterparts. 
This suggests that there may be a link between the ability of a lymphocyte to kill and 
the extent to which it can exclude extracellular proteins. Therefore, the inclusion of 
LDL within the synaptic cleft may have a negative impact on YTS-mediated cytolysis. 
The exclusion of LDL from the pNK cell synapse may provide insight into why these 
cells are more efficient killers. It may also demonstrate the important role of the IS for 
protecting cytolytic proteins from such inhibitors present in the extracellular 
environment. 
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In conclusion, the clearance and exclusion of LDL from the pNK cell synapse may 
protect secretions at the IS. Both mAb and LDL are similarly excluded from the 
synapse, and both of these molecules could negatively affect NK cell-mediated lysis 
of target cells. The data presented here demonstrate that the IS excludes molecules 
above a size threshold, potentially to protect proteins secreted across the IS cleft – a 
novel role of the NK cell synapse.  
Chapter 5 – NK Cell Perforin Secretion Varies with Ligand Density and 
Serial Stimulation 
 
 186 
Chapter 5 – NK Cell Perforin Secretion 
Varies with Ligand Density and Serial 
Stimulation 
 
5.1 Introduction 
 
5.1.1 NK cell serial killing and redirected lysis 
 
NK cells require a skewed balance of signals in favour of activation to prevent the 
dephosphorylation of adapter protein ITAM motifs, which inhibit the intracellular 
signaling events that initiate cytolysis of a target cell (464). This can occur 
sequentially with a number of targets, termed serial killing. Serial killing is the 
sequential lysis of target cells by the same effector cell, previously demonstrated by a 
number of groups (465-467). Recently, Vanherberghen et al used microwells (silicon 
chips engineered to contain wells of area 650 μm2) to image NK cells and to 
characterise serial killers (467). These wells contained only a few cells (in the order 
of tens), which allowed individual NK cell interactions to be imaged over time. Single 
NK cells were reported to kill more than one target, and in some cases, a single NK 
cell could lyse up to 7 targets. Whilst there was a vast heterogeneity in the ability of 
NK cells to serially kill targets, the specific phenotype of these cells was not reported. 
This study suggests that subsets of NK cells possess the capacity for serial lysis of 
target cells, but how this is determined by the specific phenotype of individual NK 
cells remains to be determined.  
 
Serial killing has also been demonstrated using cytotoxic release assays with an 
excess of target cells. These studies illustrated that a percentage of target cell 
specific lysis could only have been achieved if NK cells were able to kill more than 
one target cell (466). NK cells are also able to serially kill tumour cells, particularly 
solid tumours, where there is a mass of transformed cells in a single location (465). 
In this setting, serial killing is required to enable the elimination of the tumour. Whilst 
not all NK cells are ‘serial killers’ (467), the mechanisms and prerequisites for this 
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phenotype are not yet known. However, the ability to induce serial lysis of target cells 
by individual NK cells would vastly improve immune responses, especially in the fight 
against cancerous tumours. 
 
Serial killing mediated by NK cells and CD8+ T cells has been exploited in both 
redirected lysis and the opsonisation of virally infected or transformed cells. 
Redirected lysis exploits both the Fc receptors expressed by some target cells and 
antibody ligation of activating receptors to induce effector cell activation (468). 
Antibodies can also be used to bind specific epitopes expressed by tumour cells 
(466) or presented by MHC proteins on virally infected cells (469). Once a target has 
been specifically opsonised by antibodies, the exposed Fc portions are ligated by the 
NK cell Fc receptor, CD16, triggering ADCC of the target cell (320). These 
techniques have been shown to not only promote the lysis of targets resistant to NK 
cell natural cytotoxicity (468), but to also direct and increase the efficacy of tumour 
cell lysis (151, 470-473). For efficient target cell clearance, these techniques require 
NK cells to be serially activated and degranulate sufficient amounts of PFN to lyse 
the target cell. Unfortunately, NK cells are only able to lyse a finite amount of targets. 
This may be due to receptor internalisation following ligation (474), or the finite stores 
of PFN immediately available within NK cells (466), possibly acting as a safety 
mechanism to limit NK cell killing should autolysis occur. However, NK cell serial 
killing is a focus for research into potential mechanisms of tumour control. 
Specifically, particular areas of interest include how this phenotype is maintained and 
ways to redirect NK cell-mediated cytolysis towards specific targets. Further work 
determining how and why serial killing occurs, and how it may be manipulated for 
therapeutic purposes, is an important focus for future research. 
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5.1.3 Aims 
 
Neural synapses can be activated in an analogue fashion, where the response is 
metered to the amount of stimulation received by the cell (475) NK cell activation is 
reported to function in a binary fashion, where a threshold of activation must be 
reached to initiate target cell lysis (476). An analogue response to the number of 
activating signals facilitating metered cytokine secretion by T cells has recently been 
reported (477). In addition, macrophages utilise the paracrine secretion of cytokines 
during innate and adaptive inter-system communication (478). Paracrine signalling 
delivers a dose-dependent response to cells, where those closer to the source are 
stimulated to a greater degree than those more distal. The report of analogue 
signalling within the immune - as well as neuronal - system, leads to the question of 
whether the PFN-mediated response of NK cells may also be dependent on the 
amount of activating signals received, and the nature of the ligand ligated. Whilst it is 
known that serial NK cell-mediated cytolysis can occur (467), the effect of repeated 
NK cell stimulation, on the actual amounts of PFN secreted has not been 
investigated. As secretion of PFN is paramount for NK cell-mediated cytolysis, the 
effect that receptor ligation has on PFN secretion is an important consideration when 
developing strategies to increase killing efficacy. Therefore, the specific aims of this 
study were as follows: 
 
i. To investigate the effect of ligand density on PFN secretion 
 
ii. To investigate the effect of different ligands on PFN secretion 
 
iii. To quantify the effect of serial activation through one or more ligands on PFN 
secretion 
 
iv. To estimate the amount of PFN, by number of molecules and concentration 
within the synapse, secreted by NK cells 
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5.2 Results 
 
NK cells elicit cytotoxicity to diseased target cells following the ligation of activating 
receptors by a range of stress signals. Cytolysis is initiated by a balance of signalling 
in favour of activation followed by polarisation and direct secretion of cytotoxic 
mediators onto the target cell (479). It is well established that secretion of PFN is 
paramount to successful lysis of target cells (258, 259).  
 
NK cells are activated and polarise upon contact with activating slides (117). To 
determine the relative amounts of PFN secreted by NK cells in response to ligand 
ligation, a protein capture assay was used (Chapter 2, Section 2.7.1). To do this, 
chambered microscope slides were coated with activating proteins along with the 
ICAM-Fc and anti-PFN antibodies. Cells were incubated on activating slides then 
removed with non-enzymatic cell dissociation solution. Captured PFN was then 
stained using fluorescently labelled anti-PFN antibodies. Stained PFN was imaged by 
confocal microscopy. Activation of NK cells on these slides induced the polarisation 
and secretion of PFN towards the coverglass, as shown previously (Chapter 4, 
Figure 4.7A). Following cell removal from the slide, PFN appeared as clusters within 
circular regions, covering a similar area to an activated NK cell. For this reason, each 
isolated cluster was assumed to be from one cell, and was used to determine the 
mean secretion of PFN per cell (Chapter 2, Section 2.8.2). 
  
Using a reconstituted S2 cell system, studies by Bryceson et al. have shown that NK 
cells are unable to degranulate in response to NKG2D or LFA1 signalling alone. 
Conversely, ligation of CD16 was sufficient to induce degranulation and lysis of target 
cells (8, 154). To verify these findings using the protein capture assay, NK cells were 
first incubated for one hour on control slides. All slides were first coated with PLL (to 
adhere proteins to the glass surface), then anti-PFN antibodies (to capture secreted 
PFN) in addition to other proteins/antibodies, as summarised in Table 5.1 (Figure 
5.1A).  
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Slide Surface Justification 
PLL + anti-PFN antibodies To test whether PLL and/or anti-PFN 
antibodies can induce degranulation 
Noggin-Fc To test whether Fc ligation can induce 
degranulation, as noggin does not ligate 
NK cell expressed receptors 
ICAM1-Fc To test whether ICAM1 alone can induce 
degranulation 
MICA-Fc To test whether MICA alone can induce 
degranulation 
Anti-CD16 antibodies To test whether anti-CD16 alone can 
induce degranulation 
MICA-Fc + ICAM1-Fc To test whether MICA and ICAM1 co-
ligation can induce degranulation 
Anti-CD16 antibodies + ICAM1-Fc To test whether anti-CD16 and ICAM1 
co-ligation can induce degranulation 
Table 5.1. Control surface coatings used for protein capture assay (Figure 5.1) 
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Figure 5.1. NK cell degranulation is induced through CD16 alone whereas NKG2D requires 
LFA1 co-ligation. (A) Primary human NK cells were plated on slides coated with anti-perforin only 
or in combination with Noggin-Fc, ICAM1-Fc, MICA-Fc, anti-CD16, MICA-Fc and ICAM1-Fc, or anti-
CD16 and ICAM1-Fc. After 1 hour incubation, cells were removed and captured perforin was stained 
with an anti-perforin antibody labelled with Alexa Fluor 488 and imaged by confocal microscopy. 
Panels show representative confocal images of perforin captured and stained on slides. Scale bars; 
10μm. (B) The integrated intensity of perforin spots in a defined area (one cell) were measured. Bars 
show the mean ± SD. Data were analysed using a one-way ANOVA with Tukey. (n = 102, 144, 101, 
106, 141, 102, and 107 respectively). Data from 3 independent experiments. NS = no significance, 
****p<0.0001. 
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The data show that anti-PFN murine IgG antibodies, noggin-Fc, ICAM1-Fc or MICA-
Fc did not induce NK cell PFN secretion (0.14 ± 0.02, 0.13 ± 0.07, 0.14 ± 0.05 and 
0.22 ± 0.03 AU respectively). In agreement with Bryceson et al., NK cells required 
CD16 signalling (5.2 ± 2.7 AU) or co-ligation of NKG2D or CD16 with LFA1 (15.5 ± 
5.3 and 16.2 ± 5 AU respectively) to induce PFN secretion (Figure 5.1B). PFN 
secretion induced by anti-CD16 alone was significantly less than when anti-CD16 or 
MICA-Fc was added in the presence of ICAM1. Secretion on either activating ligand 
with ICAM1-Fc was similar. These initial findings show that NK cells can secrete PFN 
following stimulation through CD16 alone, but that the co-ligation of CD16 and LFA-1 
increased the amount of PFN secreted by NK cells. NKG2D signalling also required 
LFA-1 to initiate PFN secretion. Finally, the ligation of the Fc control, noggin-Fc 
showed that the Fc portion of the chimera proteins was insufficient to induce PFN 
secretion.  
 
5.2.1 NK cells perforin secretion begins within three minutes of 
activation 
 
CTL polarise and/or trigger apoptosis in transformed target cells within minutes (177, 
365). Therefore, the time scale of PFN secretion following activation was assessed. 
NK cells were plated on activating slides coated with either MICA-Fc or anti-CD16 
with ICAM1-Fc and incubated for various times between 3 – 120 minutes (3-minute 
intervals for 15 minutes and 15-minute intervals for 120 minutes). Following which, 
NK cells were removed and captured PFN stained and imaged by confocal 
microscopy. 
 
The detection of fluorescence signal showed that NK cells activated on MICA-Fc 
coated slides began to secrete PFN within 3 minutes. The size and intensity of these 
spots increased with increasing lengths of incubation on activating slides (Figure 
5.2A). PFN secretion after 3 minutes activation (mean integrated intensity/cell of 3.2 
± 1.2 AU) continued to increase for around 30 – 45 minutes, until there was no 
further significant change in PFN (18.3 ± 7.4 AU at 45 minutes and 23.3 ± 8.43 AU at 
120 minutes) (Figure 5.2B). Similarly, activation on anti-CD16 induced NK cell 
degranulation within 3 minutes (1.9 ± 1.0 AU). Secretion of PFN increased with 
longer incubation times (Figure 5.3A), similarly to cells activated through NKG2D. NK 
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cells continued to secrete PFN for ~60 minutes on anti-CD16/ICAM1-Fc-coated 
slides, following which no further increase of integrated intensity was detected (16.4 
± 5.6 AU at 60 minutes and 20.1 ± 6.4 AU at 120 minutes) (Figure 5.3B). 
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Figure 5.2. NK cells activated through NKG2D/LFA1 secrete perforin within three minutes of 
activation. (A) Primary human NK cells were plated on slides coated with MICA-Fc, ICAM1-Fc and 
anti-perforin for the times indicated. Cells were removed and captured perforin was stained with an 
anti-perforin Alexa Fluor 488 antibody. Slides were then imaged by confocal microscopy. Panels 
show representative images of secreted perforin captured and stained at each time point. Scale 
bars; 5 μm. (B) The integrated intensity of perforin spots in a defined area (one cell) were measured. 
Bars show the mean ± SD. Data were analysed using a one-way ANOV with Tukey corrections. (n = 
88, 103, 122, 119, 122, 105, and 100, respectively). Data from 3 independent experiments. NS = no 
significance, **p<0.01, ****p<0.0001 
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These data show that NK cells, upon co-ligation of NKG2D or CD16 with LFA1, 
secrete PFN within 3 minutes. On both ligands, NK cells continue to secrete PFN for 
45 – 60 minutes. Whilst ligation by MICA-Fc induced a greater amount of PFN in a 
shorter time frame, the maximum amounts of PFN measured on both ligands were 
not significantly different.  
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Figure 5.3. NK cells activated through CD16/LFA1 secrete perforin within three minutes of 
activation. (A) Primary human NK cells were plated on slides coated with MICA-Fc, ICAM1-Fc and 
anti-CD16 for the times indicated. Cells were removed and captured perforin was stained with an 
anti-perforin Alexa Fluor 488 antibody. Slides were then imaged by confocal microscopy. Panels 
show representative images of secreted perforin captured and stained at each time point. Scale 
bars; 10 μm. (B) The integrated intensity of perforin spots in a defined area (one cell) were 
measured. Bars show the mean ± SD. Data were analysed using a one-way ANOV with Tukey 
corrections. (n = 113, 102, 102, 101, 95, and 111, respectively). Data from 3 independent 
experiments. **p<0.01, ****p<0.0001 
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5.2.3 The amount of perforin secreted by NK cells varies with ligand 
density 
 
Ligand distribution and density on the target cell has been shown to control 
cytotoxicity. Regunathan et al. demonstrated that murine NK cell-mediated lysis of 
target cells in vitro was directly proportional to the expression level of cognate 
activating ligands on the target cell surface (480). Further to this, Martinez et al. 
demonstrated that when ULBP1 (a cognate ligand for NKG2D) was fused to the 
extracellular domain of CD45, the reduced number of receptor-ligand micro-clusters 
caused a decrease in NK cell-mediated cytotoxicity (481). This suggests that the 
clustering of ULBP1 on the target cell membrane is crucial for efficient lysis. 
Consistent with these data, downregulation or shedding of stress-induced ligands 
decreases tumour cell susceptibility to NK cell-mediated lysis (482, 483). These data 
together suggest that the extent of activating receptor ligation can control NK cell 
cytotoxicity.  
 
To test the effect of ligand density on NK cell PFN secretion, NK cells were plated 
and incubated for one hour on slides coated with ICAM1-Fc, anti-perforin and 
increasing amounts (25, 50, 100, 200 or 400 ng) of either MICA-Fc or anti-CD16. 
One-hour incubation was chosen as previous data indicated that maximum PFN 
secretion occurred by this time point on both MICA-Fc- and anti-CD16-coated slides 
(Figure 5.4A). Images show that PFN secreted by NK cells increased with greater 
densities of activating ligand. NK cell activation on 25 ng MICA-Fc resulted in the 
lowest PFN secretion (3.1 ± 2.0 AU) and activation on 400 ng MICA-Fc induced the 
greatest PFN secretion (15.7 ± 5.6 AU), a 5-fold increase. NK cells plated on ICAM1-
Fc alone did not degranulate (0.10 ± 0.01 AU) (Figure 5.4B), as shown previously 
(Figure 5.1). Whilst PFN secretion was not directly proportionate to ligand density 
(i.e. a 2-fold increase of ligand did not result in a 2-fold increase of PFN), increased 
PFN secretion is consistent with previous work demonstrating that NK cell-mediated 
lysis was proportional to the expression of target cell ligands (480).  
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Similarly, increasing amounts of anti-CD16 resulted in increased PFN secretion 
(Figure 5.5A). NK cell degranulation increased over 3-fold when activated on 400 ng 
of anti-CD16 (16.4 ± 5.1 AU) compared to 25 ng (5.2.1 ± 3.37 AU) (Figure 5.5B). 
Activation on ICAM1-Fc alone did not induce PFN secretion (0.10 ± 0.01 AU), as 
shown in the control experiments (Figure 5.1). Activation on increasing densities of 
anti-CD16 did not induce directly proportional increases of PFN. The amounts of PFN 
secreted on the lowest density of either ligand (25 ng) were statistically different (p = 
0.0004, two-tailed Student’s t-test with Welch’s corrections), whereas no difference 
was measured between the amounts secreted on the greatest density (400 ng) (p = 
0.3592, two-tailed Student’s t-test with Welch’s corrections).  
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Figure 5.4. The amount of perforin secreted by NK cells varies with the density of activating 
ligand MICA-Fc. (A) Primary human NK cells were plated on slides coated with MICA-Fc (at 
amounts indicated), ICAM1-Fc and anti-perforin for 1 hour. Cells were removed and captured 
perforin was stained with an anti-perforin Alexa Fluor 488 antibody. Slides were then imaged by 
confocal microscopy. Panels show representative images of secreted perforin captured and stained 
at each ligand density. Scale bars; 10 μm. (B) The integrated intensity of perforin spots in a defined 
area (one cell) were measured. Bars show the mean ± SD of integrated intensities of perforin 
secreted from each cell. Data were analysed using a one-way ANOV with Tukey corrections. (n = 
102, 74, 103, 107, 92, and 103, respectively).  Data from 3 independent experiments. ****p<0.0001 
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Increased densities of activating ligand are shown here to modulate the amount of 
PFN secreted by NK cells. Whilst a variation in the density of either ligand was able 
to induce a metered response, this was not directly proportionate to the amount of 
protein plated. This suggests that NK cells are sensitive to ligand density at the IS 
and that this signalling is not digital (an all-or-nothing response) but analogue 
(metered), where an increase of ligand ligation can trigger an increased response, 
consistent with previous studies. 
 
  
0 25 50 75 100 125 150 175 200 225 250 275 300 325 350 375 400
0
10
20
30
40
anti-CD16 (ng)
In
te
gr
at
ed
 In
te
ns
ity
/
C
el
l (
A
U
)
**** **** **** **** ****
Figure 5.5. The amount of perforin secreted by NK cells varies with the density of activating 
ligand anti-CD16 antibody. (A) Primary human NK cells were plated on slides coated with anti-
CD16 (at amounts indicated), ICAM1-Fc and anti-perforin for 1 hour. Cells were removed and 
captured perforin was stained with an anti-perforin Alexa Fluor 488 antibody. Slides were then 
imaged by confocal microscopy. Panels show representative images of secreted perforin captured 
and stained at each ligand density. Scale bars; 10 μm. (B) The integrated intensity of perforin spots 
in a defined area (one cell) were measured. Bars shows the mean ± SD. Data were analysed using a 
one-way ANOV with Tukey corrections com. (n = 102, 44, 60, 100, 98, and 109, respectively). Data 
from 3 independent experiments. ****p<0.0001 
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5.2.3 The amount of perforin secreted by NK cells decreases with 
subsequent serial stimulations 
 
The number of targets that can be serially killed by individual NK cells varies 
significantly, where 25% of NK cells can lyse up to 2 targets compared with only 6% 
or less capable of serially lysing 3 or more (467). However, it is not currently known 
what the effect of serial killing is on the amounts of PFN secreted by NK cells. To 
investigate the effects of serial killing on the amounts of PFN secreted by NK cells, a 
serial activation assay was used (Chapter 2, Section 2.7.2).  
 
Serial activation through NKG2D resulted in a decrease of PFN secretion with every 
subsequent stimulation (Figure 5.6A). Following the initial amount of PFN secreted 
after the first activation (15.3 ± 6.8 AU), PFN release decreased to 10.7 ± 4.7 AU, 5.4 
± 3.3 AU and finally, 2.8 ± 2.2 AU. By the fourth stimulation, the amount of PFN 
secreted had decreased by 81.5% (Figure 5.6B). This suggests that NK cells either 
secrete a specific proportion of their total PFN stores, decreasing with each 
degranulation, or they lose ability to release as much PFN following serial 
stimulation. Similarly, serial stimulations on anti-CD16 decreased the amount PFN 
secreted by NK cells (Figure 5.7A). The initial stimulation induced PFN secretion 
(16.9 ± 6.5 AU) similar to previous experiments. Subsequent stimulations decreased 
PFN secretion to 9.81 ± 3.0 AU, 4.9 ± 1.8 AU and finally, 2.3 ± 1.3 (Figure 5.7B). 
After four stimulations on anti-CD16, the PFN secreted by NK cells was only 13% of 
that induced by the first stimulation. 
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Figure 5.6. NK cells secrete reducing amounts of perforin following serial stimulation 
through NKG2D/LFA1. (A) Primary human NK cells were plated on slides coated with MICA-Fc, 
ICAM1-Fc and anti-perforin for 1 hour. Cells were removed, washed and plated again. Activation 
was repeated until NK cells had been activated 4 times. Captured perforin was stained with an anti-
perforin Alexa Fluor 488 antibody. Slides were then imaged by confocal microscopy. Panels show 
representative images of secreted perforin captured and stained at each ligand density. Scale bars; 
10 μm. (B) The integrated intensity of perforin spots in a defined area (one cell) were measured. 
Bars show the mean ± SD. Data were analysed using a one-way ANOV with Tukey corrections. (n =  
130, 104, 61, and 33, respectively). Data from 3 independent experiments. NS = not 
significant.****p<0.0001. 
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Serial activation of NK cells results in a reduced capacity to secrete PFN. The 
decrease in PFN secreted correlated with previous experiments showing a decrease 
of ligand density induced less PFN secretion (Figure 3.4 and 3.5). This suggests that 
the reduction in the ability of NK cells to secrete PFN may be due to a loss of surface 
receptors, diminishing their ability to bind ligands, resulting in a reduction in PFN 
secretion.  
 
  
1 2 3 4
0
10
20
30
40
50
Serial Stimulation
Int
eg
ra
te
d I
nt
en
sit
y/
Ce
ll (
AU
)
**** **** ****
**
Figure 5.7. NK cells secrete reducing amounts of perforin following serial hits of activation 
through CD16/LFA1. (A) Primary human NK cells were plated on slides coated with anti-CD16, 
ICAM1-Fc and anti-perforin for 1 hour. Cells were removed, washed and plated again. Activation 
was repeated until NK cells had been activated 4 times. Captured perforin was stained with an anti-
perforin Alexa Fluor 488 antibody. Slides were then imaged by confocal microscopy. Panels show 
representative images of secreted perforin captured and stained at each ligand density. Scale bars; 
10 μm. (B) The integrated intensity of perforin spots in a defined area (one cell) were measured. 
Bars show the mean ± SD. Data were analysed using a one-way ANOV with Tukey corrections. (n =  
96, 100, 55, and 51, respectively). Data from 3 independent experiments. **p<0.01, ****p<0.0001 
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5.2.4 Effective restimulation of NK cells is receptor-dependent 
 
The binding of cognate ligands has been shown to cause the internalisation of NK 
cell activating surface receptors (484), in addition, serial killing is associated with a 
loss of NK cell PFN and GzmB stores (466). To test whether NK cell activation 
induced the secretion of a pre-determined percentage of total PFN stores or whether 
NK cells became desensitised to a specific ligand, cells were serially activated on 
alternating ligands (Figure 5.8A), as summarised in Table 5.2. 
 
Stimulation Surface Coating 
1 MICA-Fc + ICAM1-Fc 
2 MICA-Fc + ICAM1-Fc 
3 Anti-CD16 + ICAM1-Fc 
4 Anti-CD16 + ICAM1-Fc 
Table 5.2. Pattern of activating surface coating used to test restimulation of NK cells (Figure 5.8) 
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Consistent with previous experiments, a second stimulation through NKG2D reduced 
PFN secretion (15.7 ± 7.4 AU to 11.4 ± 6.1 AU). The third stimulation, on anti-CD16, 
triggered an increase in PFN secretion (15.0 ± 7.3). The fourth stimulation continued 
to decrease the amount of PFN secreted (7.8 ± 5.5 AU)  (Figure 5.8B). However, the 
amount of PFN secreted at this point was greater than after 4 stimulations on either 
MICA-Fc (Figure 5.6) or anti-CD16 (Figure 5.7). These data suggest that, whilst 
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Figure 5.8. Serial stimulation through NKG2D/LFA1 does not affect subsequent stimulation 
through CD16/LFA1. (A) Primary human NK cells were plated on slides coated with MICA-Fc or 
anti-CD16 (as indicated), ICAM1-Fc and anti-perforin for 1 hour. Cells were removed, washed and 
plated again. Activation was repeated until NK cells had been activated 4 times. Captured perforin 
was stained with an anti-perforin Alexa Fluor 488 antibody. Slides were then imaged by confocal 
microscopy. Panels show representative images of secreted perforin captured and stained at each 
ligand density. Scale bars; 10 μm. (B) The integrated intensity of perforin spots in a defined area 
(one cell) were measured using a threshold mask. Bars show the mean ± SD. Data were analysed 
using a one-way ANOV with Tukey corrections. (n = 132, 118, 97, and 34, respectively).  Data from 
3 independent experiments. NS = no significance, ****p<0.0001 
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serial stimulation by MICA-Fc results in a decrease of PFN secreted, PFN secretion 
through CD16 is not affected. Next, NK cells were activated twice on anti-CD16, 
followed by twice on MICA-Fc, as summarised in Table 5.3.  
 
Stimulation Surface Coating 
1 MICA-Fc + ICAM1-Fc 
2 MICA-Fc + ICAM1-Fc 
3 Anti-CD16 + ICAM1-Fc 
4 Anti-CD16 + ICAM1-Fc 
Table 5.3. Pattern of activating surface coating used to test restimulation of NK cells (Figure 5.9) 
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The amounts of secreted by NK cells continued to decrease, irrespective of the 
ligand variation (Figure 5.9A). The first two stimulations on anti-CD16 induced 
decreasing amounts of PFN secretion (15.5 ± 6.0 AU to 12.8 ± 6.1 AU). The third 
stimulation, on MICA-Fc, did not increase PFN secretion, but rather resulted in a non-
significant decrease (10.4 ± 8.3 AU). The fourth stimulation resulted in a substantial, 
significant decrease in the amount of PFN secreted (3.1 ± 2.1 AU) (Figure 5.9B). 
These data imply that ligation of MICA-Fc following anti-CD16 ligation cannot trigger 
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Figure 5.9. Serial stimulation through CD16 affects subsequent stimulation through NKG2D. 
(A) Primary human NK cells were plated on slides coated with anti-CD16 or MICA-Fc (as indicated), 
ICAM1-Fc and αPerforin for 1 hour. Cells were removed, washed and plated again. Activation was 
repeated until NK cells had been activated 4 times. Captured perforin was stained with an anti-
perforin Alexa Fluor 488 antibody. Slides were then imaged by confocal microscopy. Panels show 
representative images of secreted perforin captured and stained at each ligand density. Scale bars; 
10 μm. (B) The integrated intensity of perforin spots in a defined area (one cell) were measured 
using a threshold mask. Bars show the mean ± SD. Data were analysed using a one-way ANOV 
with Tukey corrections. (n = 136, 141, 55, and 27, respectively). Data from 3 independent 
experiments. NS = no significance, ****p<0.0001. 
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increased PFN secretion by NK cells, suggesting that CD16 ligation has an effect on 
NKG2D-mediated PFN secretion. 
 
To further test whether this response was a direct effect of stimulation on anti-CD16 
following MICA-Fc stimulation, NK cells were serially stimulated on MICA-Fc twice, 
and then the same population of NK cells was split and plated 50/50 on either MICA-
Fc/ICAM1-Fc-coated slide or anti-CD16/ICAM1-Fc-coated slides (Figure 5.10A), as 
summarised in Table 5.4.  
 
Stimulation Surface Coating NK cells plated  (%) 
1 MICA-Fc + ICAM1-Fc 100 
2 MICA-Fc + ICAM1-Fc 100 
3a MICA-Fc + ICAM1-Fc 50 
3b Anti-CD16 + ICAM1-Fc 50 
Table 5.4. Pattern of activating surface coating used and percentage of total NK cells plated to 
test restimulation of NK cells (Figure 5.10) 
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The first 2 stimulations on MICA-Fc decreased the amount of PFN secreted (15.6 ± 
4.2 AU to 10.4 ± 5.0 AU). When NK cells were then plated on either MICA-Fc/ICAM1-
Fc or anti-CD16/ICAM1-Fc, PFN secretion decreased (6.3 ± 3.4 AU) or increased 
(13.1 ± 6.9 AU), respectively (Figure 5.10B). These findings further demonstrate that 
following serial stimulation through NKG2D, CD16 ligation can trigger an increase in 
PFN secretion by NK cells, whereas continued NKG2D stimulation reduces 
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Figure 5.10. Serial stimulation through NKG2D/LFA1 affects continued stimulation through 
the same receptors but not CD16/LFA1 stimulation. (A) Primary human NK cells were plated on 
slides coated with MICA-Fc, ICAM1-Fc and anti-perforin for 1 hour. Cells were removed, washed 
and plated again. NK cells were then removed, and 50% plated out on slides coated with MICA-Fc 
or anti-CD16, ICAM1-Fc and anti-perforin. Captured perforin was stained with an anti-perforin Alexa 
Fluor 488 antibody. Slides were then imaged by confocal microscopy. Panels show representative 
images of secreted perforin captured and stained at each ligand density. Scale bars; 10 μm. (B) ) 
The integrated intensity of perforin spots in a defined area (one cell) were measured. Bars show the 
mean ± SD. Data were analysed using a one-way ANOV with Tukey corrections. (n = 116, 101, 47, 
and 92, respectively). Data from 3 independent experiments. **p<0.01, ****p<0.0001 
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degranulation. These findings are consistent with previous experiments (Figure 5.2 
and 5.8 and 5.8) 
 
This experiment was then repeated, activating NK cells on anti-CD16 twice, then 
plating NK cells 50:50 on either anti-CD16/ICAM1-Fc or MICA-Fc/ICAM1-Fc (Figure 
5.11A), as summarised in Table 5.5.  
 
Stimulation Surface Coating NK cells plated  (%) 
1 Anti-CD16 + ICAM1-Fc 100 
2 Anti-CD16 + ICAM1-Fc 100 
3a Anti-CD16 + ICAM1-Fc 50 
3b MICA-Fc + ICAM1-Fc 50 
Table 5.5. Pattern of activating surface coating used and percentage of total NK cells plated to 
test restimulation of NK cells (Figure 5.11) 
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The decrease in PFN secreted when serially activated by anti-CD16 was similar to 
previous experiments (15.4 ± 5.2 AU, 9.8 ± 4.6 and 4.0 ± 1.8 AU). A third stimulation 
on either MICA-Fc or anti-CD16 resulted in a decrease in PFN secretion that were 
not significantly different (4.0 ± 1.9 AU on MICA-Fc/ICAM1-Fc and 3.9 ± 2.2 AU on 
anti-CD16/ICAM1-Fc) (Figure 5.11B). These results show that subsequent serial NK 
cell activation though CD16 decreases the amount of PFN secreted by NK cells and 
that ligation of NKG2D cannot increase PFN secretion. 
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Figure 5.11. Serial stimulation through CD16/LFA1 affects further stimulation through both 
NKG2D/LFA1 and CD16/LFA1. (A) Primary human NK cells were plated on slides coated with anti-
CD16, ICAM1-Fc and anti-perforin for 1 hour. Cells were removed, washed and plated again. NK 
cells were then removed, and 50% plated out on slides coated with anti-CD16 or MICA-Fc, ICAM1-
Fc and anti-perforin. Captured perforin was stained with an anti-perforin Alexa Fluor 488 antibody. 
Slides were then imaged by confocal microscopy. Panels show representative images of secreted 
perforin captured and stained at each ligand density. Scale bars; 10 μm. (B) ) The integrated 
intensity of perforin spots in a defined area (one cell) were measured. Bars show the mean ± SD. 
Data were analysed using a one-way ANOV with Tukey corrections. (n = 128, 93, 45, and 39, 
respectively). Data from 3 independent experiments. NS = no significance,  ****p<0.0001. 
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Taken together, these findings suggest that stimulation through NKG2D or CD16 
gradually desensitises NK cells to further stimulation through the same receptor. 
However, stimulation through NKG2D does not affect PFN secretion through 
subsequent CD16 ligation, whereas CD16 stimulation causes the desensitisation of 
NK cells to both anti-CD16 and MICA-Fc.  
 
5.2.5 Serial stimulation affects the surface expression of NK cell 
receptors 
 
In order to test whether the ligation of NKG2D or CD16 was inducing downregulation 
of receptors, NK cell surface expression of NKG2D and CD16 was measured by flow 
cytometry. NK cells were first incubated for one hour on control slides (PLL, Noggin-
Fc, ICAM1-Fc, MICA-Fc, or anti-CD16). Cells were then assessed for surface 
expression of NKG2D and CD16, calculating the proportion of cells expressing the 
receptors and measuring the geometric mean fluorescence intensity (gMFI) of 
expression. To calculate the percentage of cells that were positive for receptor 
expression, histograms were gated on all events with stain levels above that of an 
isotype control. GMFI provides a measure of the amount of each receptor that was 
expressed on the surface of NK cells under different conditions. To compare the 
gMFI, data were normalised to expression levels following incubation on PLL, where 
no activating stimulation would have occurred. 
 
The incubation of pNK cells on control slides demonstrated that the proportion of 
cells expressing NKG2D or CD16 did not alter (70 – 87% for NKG2D and 97% – 86% 
for CD16) (Figure 5.12A). The gMFI of NKG2D expression levels remained similar (0 
– 3% decrease) (Figure 5.12B), except in the case of ICAM-Fc (19% decrease 
compared to incubation on PLL). Similarly, the level of CD16 expression was 
unchanged on negative controls (0 – 2% decrease), however stimulation with MICA-
Fc or anti-CD16 resulted in a decrease in the expression of CD16 (27% and 32% 
respectively) (Figure 5.12C). This suggests that NKG2D expression is not affected by 
any of the ligands alone, whereas CD16 expression can be altered by either MICA-
Fc or anti-CD16 ligation. The negative controls, particularly, Noggin-Fc, indicate that 
this is an effect of the MICA protein, not the Fc portion, as incubation on Noggin-Fc 
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did not induce a change in either NKG2D or CD16 expression. However, exposure to 
ICAM1-Fc decreased NKG2D expression, suggesting that ligation of LFA1 can have 
a direct impact on the levels of NKG2D on the surface of NK cells. 
 
 
 
The expression of NKG2D was then measured on pNK cells after serial stimulation 
by MICA-Fc/ICAM1-Fc or anti-CD16/ICAM1-Fc. In contrast to stimulation on MICA-
Fc alone, simultaneous exposure to MICA-Fc and ICAM1-Fc led to a reduction in the 
proportion of NK cells expressing NKG2D, with decreased expression between 1 and 
4 stimulations (51% to 26%) (Figure 5.13A). In parallel, there was an even more 
marked reduction in the expression levels (40% to 67%, first and fourth stimulation 
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Figure 5.12. NKG2D expression is not affected by single receptor ligation whereas CD16 is 
affected by ligation of either MICA-Fc or anti-CD16. Primary human NK cells were plated on 
slides coated with poly-L-lysine (PLL), ICAM1-Fc, MICA-Fc, anti-CD16 antibodies or Noggin-Fc and 
incubated for 1 hour at 37ºC, then removed using an EDTA solution. (A) Cells were analysed by flow 
cytometry. Cells were first gated for CD3- CD56+ populations, and then expression of NKG2D (upper 
row) and CD16 (lower row) was measured. Data representative of 2 independent experiments from 
2 donors. (B) The geometric mean fluorescence intensity (gMFI) of NKG2D expression levels were 
normalised to expression following plating on PLL-coated slides. Bars show mean ± SEM. (C) The 
gMFI of CD16 expression levels were normalised to expression following plating on PLL-coated 
slides. Bars show mean ± SEM. Data from 2 independent experiments from 2 donors. 
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respectively). There was no effect on expression by MICA-Fc alone, and only a minor 
decrease in response to ICAM1-Fc (Figure. 5.13B). Stimulation through CD16/LFA1 
also caused a decrease in the proportion of NK cells expressing NKG2D (compared 
to plating on PLL) (58% positive for NKG2D after the first stimulation, and 39% after 
the fourth) (Figure 5.13C). The expression level of NKG2D was unchanged after the 
first stimulation (1% decrease compared to PLL control). However, expression had 
decreased by more than 25% after the fourth stimulation through CD16 and LFA1 
(Figure 5.13D). This suggests that it is only exposure to MICA-Fc and ICAM1-Fc in 
tandem – not anti-CD16/ICAM1-Fc – that greatly impacts the expression level of 
NKG2D.  
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Next, the expression of CD16 was examined after serial stimulation on slides coated 
with MICA-Fc/ICAM1-Fc or anti-CD16/ICAM1-Fc. Serial ligation of NKG2D had little 
impact on the expression of CD16 (96% of cells were positive for CD16 after the first 
stimulation and 83% after the fourth). (Figure 5.14A). The expression levels of CD16 
were reduced comparatively to MICA-Fc alone when ICAM1-Fc was present (20% 
decrease compared to plating on PLL). Serial stimulation continued to decrease the 
level of CD16 expression; with a 67% decrease detectable by the fourth stimulation 
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Figure 5.13. NK cell surface expression of NKG2D is down regulated following serial 
stimulation through either NKG2D/LFA1 or CD16/LFA1. Primary human NK cells were plated on 
slides coated with ICAM1-Fc and MICA-Fc or anti-CD16 and incubated for 1 hour at 37ºC, then 
removed using an EDTA solution. (A) Cells serially stimulated by ICAM1-Fc/MICA-Fc were analysed 
by flow cytometry. Cells were first gated for CD3- CD56+ populations, then expression of NKG2D 
was measured after each stimulation, as indicated. Data representative of 2 independent 
experiments from 2 donors. (B) The geometric mean fluorescence intensity (gMFI) of NKG2D 
expression levels after each stimulation on MICA-Fc (M1–4) were normalised to expression following 
plating on PLL-coated control slides. Bars show mean ± SEM. Data from 2 independent experiments 
form 2 donors. (C) Cells serially stimulated by ICAM1-Fc/anti-CD16 were analysed by flow 
cytometry. Cells were first gated for CD3- CD56+ populations, then expression of NKG2D was 
measured after each stimulation, as indicated. Data representative of 2 independent experiments 
from 2 donors. (B) The geometric mean fluorescence intensity (gMFI) of NKG2D expression levels 
after each stimulation on anti-CD16 (C1–4) were normalised to expression following plating on PLL-
coated control slides. Bars show mean ± SEM. Data from 2 independent experiments from 2 donors. 
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(Figure 5.14B). Serial stimulations on anti-CD16/ICAM1-Fc-coated slides decreased 
the proportion of cells expressing CD16 to a greater extent than NKG2D ligation 
(89% positive after the first stimulation to 58% after the fourth stimulation) (Figure 
5.14C). The co-ligation of CD16 and LFA1 had a profound effect on the expression 
levels of CD16, particularly when compared to anti-CD16 alone. After the first 
stimulation, the level of expression decreased by 70%. Following 3 or 4 stimulations, 
expression remained relatively constant (92% and 93% decrease, respectively, 
compared to PLL) (Figure 5.14D).  This suggests that CD16 expression is affected to 
a greater extent by anti-CD16 ligation, compared to MICA-Fc. The co-ligation of anti-
CD16 and ICAM1-Fc had a greater impact on both the proportion of cells expressing 
CD16 and the level of expression.  
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These data show that NKG2D/LFA1 co-ligation decreased the expression levels of 
both NKG2D and CD16, but only dramatically affected the proportion of cells 
expressing NKG2D. Whilst simultaneous exposure to anti-CD16 and ICAM1-Fc 
decreased both the proportion of cells expressing NKG2D and CD16 and the levels 
of expression, CD16 expression levels were decreased to a greater extent. This 
shows that CD16 ligation has a greater impact on NKG2D expression than the effect 
of NKG2D ligation on the CD16 expression. These findings are consistent with the 
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Figure 5.14. NK cell surface expression of CD16 is down regulated following serial 
stimulation through either NKG2D/LFA1 and CD16/LFA1. Primary human NK cells were plated 
on slides coated with ICAM1-Fc and MICA-Fc or anti-CD16 and incubated for 1 hour at 37ºC, then 
removed using an EDTA solution. (A) Cells serially stimulated by ICAM1-Fc/MICA-Fc were analysed 
by flow cytometry. Cells were first gated for CD3- CD56+ populations, then expression of CD16 was 
measured after each stimulation, as indicated. Data representative of 2 independent experiments 
from 2 donors. (B) The geometric mean fluorescence intensity (gMFI) of CD16 expression levels 
after each stimulation on MICA-Fc (M1–4) were normalised to expression following plating on PLL-
coated control slides. Bars show mean ± SEM. Data from 2 independent experiments form 2 donors. 
(C) Cells serially stimulated by ICAM1-Fc/anti-CD16 were analysed by flow cytometry. Cells were 
first gated for CD3- CD56+ populations, then expression of CD16 was measured after each 
stimulation, as indicated. Data representative of 2 independent experiments from 2 donors. (B) The 
geometric mean fluorescence intensity (gMFI) of CD16 expression levels after each stimulation on 
anti-CD16 (C1–4) were normalised to expression following plating on PLL-coated control slides. 
Bars show mean ± SEM. Data from 2 independent experiments from 2 donors. 
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PFN secretion data, which demonstrated that CD16 ligation abrogated the ability of 
NKG2D to induce increased PFN secretion. However, flow cytometric analysis of 
pNK cells has shown that NKG2D expression is not severely affected by CD16 
ligation. This suggests that a decrease in the ability of NK cells to secrete PFN may 
be attributable to intracellular signaling events, rather than receptor expression alone. 
 
5.2.6 Estimation of perforin secretion by NK cells 
 
To investigate the number of PFN proteins secreted by NK cells, bead populations 
with known densities of anti-murine IgG antibodies (antibody binding coefficient; 
ABC) were washed and incubated sequentially with an excess of murine anti-PFN 
antibodies, recombinant PFN and anti-PFN-488 antibodies. Beads were then imaged 
by confocal microscopy to determine the relationship between integrated intensity to 
number of molecules. 
 
This was used to estimate the amounts of PFN secreted by NK cells. The data 
indicate that after 3 minutes of stimulation, NK cells had secreted 4500 ± 3000 
molecules of PFN on MICA-Fc/ICAM1-Fc-coated slides and 2000 ± 1900 molecules 
on anti-CD16-coated slides. Upon stimulation by MICA-Fc/ICAM1-Fc or anti-
CD16/ICAM1-Fc for 120 minutes, NK cells secreted a mean of 38500 ± 17100 or 
36700 ± 12900 molecules of PFN respectively. Whilst these values are obtained from 
NK cells in contact with a slide in the absence of any inhibitory signals, they provide 
some indication as to the amount of PFN secreted by NK cells within the IS. As 
described in the methods, these numbers of molecules can be used to estimate the 
concentration of PFN within the synapse. Based on a volume of ~5 μm3 containing 
~5 fL of fluid, the following estimations of PFN concentration can be made. After a 3-
minute stimulation, PFN concentration within the synapses was 0.6 ± 1.0 μM or 0.7 ± 
0.6 μM on MICA-Fc- or anti-CD16-coated slides respectively. After 120 minutes, PFN 
concentration had increased to 13.0 ± 5.7 μM or 12.2 ± 4.3 μM on MICA-Fc- or anti-
CD16-coated slides respectively. 
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However, these higher concentrations at 120 minutes would most likely not be 
reached within the synapse in a physiological setting, i.e. within a cell-cell conjugate 
rather than in response to contact with a slide, due to internalisation/endocytosis of 
PFN by the target cell. Vanherberghen et al. report that the majority of NK cell-
mediated killing occurred within 10 minutes of conjugation (467). Therefore, it may be 
more physiologically relevant to determine the amounts and concentrations around 
this time point. The number of molecules of PFN secreted by 12 minutes on MICA-Fc 
or anti-CD16 was 10700 ± 7200 and 10000 ± 7000 molecules respectively. These 
amounts would give concentrations within the synapse of 3.6 ± 2.4 and 3.3 ± 2.2 μM 
respectively.  
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5.3 Discussion 
 
5.3.1 Summary 
 
The main objective of this study was to investigate the amount of PFN secreted by 
NK cells. Using ligand/integrin-coated slides, PFN secretion was investigated over 
time, in response to different activating ligands, different ligand densities and serial 
stimulation through the same or alternating ligands. Finally, the amount and 
concentration of PFN secreted into the synaptic cleft was estimated. The data 
indicate that NK cells are sensitive to the amount of ligand that they come into 
contact with and are affected by previous stimulations. Importantly, the activating 
receptor that is ligated can have profound effects on subsequent stimulations. The 
main results from this study are as follows: 
 
• NK cells secrete PFN within 3 minutes of MICA-Fc or anti-CD16 exposure 
 
• NK cell PFN secretion varies proportionately with ligand density 
 
• Serial stimulation reduces the amount of PFN secreted by NK cells 
 
• Ligation of CD16 following NKG2D-mediated PFN secretion can recover 
levels of PFN secretion after serial stimulation of NKG2D, whereas NKG2D 
ligation is unable to induce increased PFN secretion following CD16 ligation 
 
• NK cells can secrete up to 10700 ± 7200 molecules of PFN into the synapse 
within 12 minutes of activation, the average time to kill, which correlates to a 
3.6 ± 2.4 μM concentration within the synaptic cleft. 
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5.3.2 Implications of findings 
 
The main purpose of this study was to quantify PFN secretion by NK cells, estimating 
the amount released following activation through either NKG2D or CD16. A protein 
capture assay was developed to image PFN secreted by NK cells. This comprised 
incubating pNK cells on slides coated with anti-PFN antibodies to capture secreted 
PFN. This was done in the presence of Fc-conjugated ICAM1 or MICA, or anti-CD16 
bound to the surface of the well, to mimic exposure to adhesion molecules and 
activating ligands. PFN was then stained by fluorescently labelled anti-PFN 
antibodies and imaged by confocal microscopy. This assay could be used to assess 
the secretion of PFN in response to different ligands over time, with varying densities 
and following serial stimulation. 
 
The results demonstrate that whilst MICA-Fc alone is insufficient to induce NK cell 
degranulation, anti-CD16 can trigger the secretion of PFN. These findings are 
consistent with previous studies by Bryceson et al., demonstrating that ligation of 
NKG2D alone cannot trigger cell-mediated lysis of target cells, whereas CD16 
ligation is sufficient (154). NK cells secreted PFN within 3 minutes following 
stimulation by either activating ligand, and secretion continued for up to 60 minutes. 
This suggests that the NK cell response to activation is rapid but can be sustained for 
a long period of time with continued signalling through either NKG2D or CD16. 
Furthermore, signalling through either NKG2D or CD16 was shown to be an 
analogue response, as opposed to an all-or-nothing binary response. The density of 
ligand that the cell came into contact with modulated the amount of PFN that was 
secreted. This was consistent with previous studies of murine NK cells showing that 
NK cell-mediated lysis is proportionate to expression levels of activating ligands on 
target cells (480). 
 
The ability of NK cells to serially lyse targets has been shown previously (467), 
however, the effect that this has on PFN secretion had yet to be determined. Levels 
of PFN secretion decreased following serial activations with the same ligand. 
Unexpectedly, binding to anti-CD16 could recover PFN secretion when NK cells had 
been repeatedly stimulated with MICA-Fc, whereas NKG2D ligation after CD16 serial 
stimulation was unable to trigger an increase. Flow cytometric analysis of the 
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expression of NKG2D and CD16 after serial stimulations with slides coated with 
either MICA-Fc or anti-CD16 antibodies in the presence of ICAM1-Fc showed that 
co-ligation of either receptor along with LFA1 affects the expression of both NKG2D 
and CD16. CD16 ligation had a greater impact on NKG2D expression than NKG2D 
ligation had on CD16, but these changes do not account for the inability of NK cells 
to be sufficiently activated by MICA-Fc following anti-CD16 stimulation. This suggests 
that it is intracellular signalling following receptor ligation that may differ. Specifically, 
ligation of CD16 desensitised NK cells to further stimulation through either the same 
ligand or with MICA-Fc, whereas NKG2D ligation did not have this effect. Therefore, 
following a cytotoxic response to NKG2D ligands, NK cells remain highly sensitive to 
stimulation that induces ADCC, possibly through signalling pathways utilised by 
CD16 independently of NKG2D. 
 
Finally, using beads of known antibody concentrations to sequentially capture anti-
perforin antibodies, PFN protein and fluorescently labelled anti-PFN antibodies, the 
relationship between fluorescence intensity to number of molecules was determined. 
This was used to estimate the amount of PFN secreted by NK cells. Using the 
fluorescent intensities of labelled PFN at various time points, the results showed that 
at around 12 minutes after stimulation, the average time to kill a target cell (467), NK 
cells had secreted between 3.3 ± 2.2 μM and 3.6 ± 2.4 μM of PFN into the synaptic 
cleft.  
 
The results of these studies show that NK cell PFN secretion is dependent not only 
on the ligation of receptors but, more importantly, the density and type of ligand. This 
indicates that NK cells are sensitive to the amount of ligand they encounter, as well 
as the type of cytotoxicity triggered through a specific ligand. Most importantly, these 
findings demonstrate that in order to modulate the NK cell response, through 
redirected lysis or ADCC, the consequences of NK cell receptor ligation should be 
considered in order to mediate the appropriate response. 
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NK cells require co-ligation of receptors for efficient degranulation 
 
Secretion of PFN is a tightly regulated process. The binding to activating ligands is 
required in sufficient number in order to overcome inhibition. A balance in favour of 
phosphorylation over dephosphorylation of activating receptor-associated ITAMs, 
caused by inhibitory receptor ligation, is necessary to induce polarisation of LG to the 
synapse and the release of cytotoxic proteins (485). The assay used in this study 
was designed to enable the capture of PFN proteins in order to quantify the amounts 
secreted by NK cells in response to different conditions. The results have 
demonstrated the varying effects that ligands and ligand densities can have on PFN 
secretion. 
 
Firstly, the Fc portions of the MICA and ICAM1 chimera proteins were shown to be 
unable to induce degranulation. To test this, NK cells were incubated on Noggin-Fc 
proteins, a negative control, as Noggin is not a ligand for NK cells. The lack of 
degranulation or a change in receptor expression profile indicates that the Fc 
proteins are insufficient, or unable, to bind CD16. Therefore, it can be assumed that 
these Fc portions do not have an effect on NK cell responses and that degranulation 
and changes in receptor profiles were due to ligation of the NK cell activating 
receptors CD16 and NKG2D, and/ or the adhesion molecule LFA1.  
 
In contrast to data shown here, Bryceson et al. (154) demonstrated that co-ligation of 
CD16 and LFA1 reduced the degranulation of freshly isolated NK cells. Here, 
increased secretion of PFN was detected in response to CD16 and LFA-1 co-ligation 
(Figure 5.5). This difference may be due to the use of freshly isolated NK cells by 
Bryceson and colleagues, whereas the pNK cells used in the protein capture assays 
described here were IL-2-expanded and 6-day rested. This previous study also 
demonstrated that the co-ligation of NKG2D and 2B4 was sufficient to induce the 
degranulation of NK cells, independently of LFA-1 signalling. Therefore, the 
degranulation of NK cells – IL-2 activated or not – appears to require the co-ligation 
of at least 2 activating receptors against cell-expressed ligands, or CD16 ligation 
alone. The effect of LFA1 signalling increasing the amount of PFN secretion could be 
attributed to the activation and expansion of NK cells using IL-2. Previously, 
stimulation using this cytokine has been shown to upregulate a vast number of 
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transcriptional cytotoxic factors (486). The addition of IL-2 mimics the influence of this 
cytokine during an infection, where it effectively primes NK cells for attack against a 
pathogenic cell (virally-infected or transformed) (8). Despite the differences between 
this study and those performed using fresh NK cells, both suggest that NK cell 
cytotoxicity through ‘cell surface-expressed ligands’ requires signalling from more 
than one receptor. In addition, IL-2 activated cells appear more sensitive to activation 
and degranulation than freshly isolated cells. In conclusion, the initial results of this 
study show that activated NK cells require the co-ligation of LFA-1 and NKG2D to 
induce degranulation, whereas CD16 binding alone is sufficient.  
 
Secretion of PFN occurs within 3 minutes of activation and continues for up to 
60 minutes 
 
Previous studies have shown that NK cell polarisation of the MTOC can take up to 30 
minutes following cell-cell contact (173). However, NK cells have also been shown to 
rapidly degranulate without full MTOC polarisation, allowing for an extremely fast 
response to a pathogenic or transformed target cell within a matter of minutes (192). 
This may be a response that is accentuated during cytotoxicity to enhance the 
clearance of diseased cells, particularly transformed cells, where cytolysis versus 
proliferation is extremely important in the successful elimination of disease. The PFN 
secretion response of NK cells may therefore play a significant role in the early 
detection and elimination of viral infection or cellular transformation. 
 
Activation and degranulation using the protein capture assay showed that NK cells 
were able to secrete PFN within 3 minutes, demonstrated by small spots of 
fluorescence signal on the capture assay slides. The size and intensity of the spots 
increased during the first 60 minutes, suggesting that NK cells secreted PFN up until 
this time point. Secretion of PFN for up to 60 minutes raises the question as to why 
NK cells can, or would, secrete PFN for such a long period of time. Immune cells 
have been shown to be extremely sensitive to surface tension (487, 488). A tension-
sensitive system within NK cells may govern their continued secretion of PFN. During 
IS formation, the spreading and subsequent contraction of the membranes would 
result in a high tensile force between the cells (10, 489-491). Following secretion of 
cytotoxic mediators, apoptosis and breakdown of the target cell would release this 
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tension. NK cell sensing of this change may result in signals that initiate the 
detachment from the dying cell (492, 493). The high tensile forces resulting from NK 
cell binding to a coverglass may explain why NK cells continue to secrete PFN for up 
to 60 minutes. There is no release in tension, thus termination signaling does not 
occur, and the NK cell would not be instructed to detach. However, the reason for the 
cessation of secretion after 60 minutes is not known. Restimulation of NK cells, and 
the repeated secretion of PFN (albeit in decreasing amounts), demonstrated that 
arresting secretion is not due to a complete depletion of PFN stores. Therefore, there 
may exist a finite level of signalling, as opposed to continuous restimulation, that 
receptor ligation can induce, limiting the total amount of PFN that can be released by 
NK cells. 
 
PFN secretion is dependent on ligand density 
 
Exposure to higher densities of activating ligands induced increased PFN secretion 
by NK cells, compared to those exposed to low density of ligands. This finding 
suggests that the number of ligands bound by NK cells directly affects the amount of 
PFN secreted, possibly a result of enhanced intracellular signalling. This type of 
secretion is termed analogue, where the response is metered by the amount of 
signal, as opposed to a digital on/off system, which is all-or-nothing.  
 
Such a metered response by a cytotoxic cell was not expected. The decision to kill a 
target cell, determined by a balance of signals in favour of activation, must be 
carefully tuned so that the correct response is initiated. The release of PFN in 
response to a small number of ligands could have dangerous consequences, should 
healthy cells express such self-ligands. However, an analogue NK cell response has 
been demonstrated with ex vivo murine NK cells. Cytotoxicity release assays have 
shown that the level of expression of activating ligands on a target cell is directly 
proportional to the amount of cytotoxicity mediated by NK cells (480). Furthermore, 
NK cells secrete greater amounts of IFNγ in response to higher concentrations of 
bacterial antigen (494, 495). Recent work also suggests that this response occurs 
with increasing concentrations of plate-bound MICA (personal communication; 
Kathryn Lagrue, unpublished data). Thus, the density-dependent secretion of NK 
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cells shown here, suggests that a metered response may play an important role in 
PFN secretion. 
 
This analogue response could have advantages for both low and high ligand 
densities and/or surface expression of receptors. Whilst stress-induced ligands, such 
as MICA/B, are upregulated on virally infected or transformed cells (496-498), it has 
been shown that some types of normal, healthy cells express low levels of activating 
ligand mRNA transcripts or proteins (499). Reduced responses to lower ligand 
densities may be a mechanism used to prevent the erroneous secretion of PFN onto 
otherwise healthy cells, or perhaps release only a small amount of PFN that is sub-
lytic, which the target cell can survive. The balance of signals on these healthy 
targets will also be in favour of inhibition, yet the dynamic regulation of PFN secretion 
may provide some further protection against collateral damage. Furthermore, the 
presence of inhibitory ligands can also meter the NK cell cytotoxic response (480), 
indicating that the effect inhibitory signals have on PFN secretion is of important 
consideration for future investigation.  
 
Ligand density-dependent secretion of PFN may also have a negative impact on 
control of tumour growth. Tumour cells are known to upregulate activating ligands in 
the event of initial transformation (496). However, selective pressure from the 
immune system directs their ‘evolution’ to subsequently downregulate such surface 
proteins to evade detection (483, 500-502). The downregulation of activating ligands 
on tumour cell surfaces would have a negative impact on PFN secretion, resulting in 
the secretion of sub-lytic amounts of PFN, which fail to lyse the target cell. Evasion 
by this means would result in the expansion of a colony of reduced-ligand bearing 
cells, allowing immune escape and excessive proliferation of tumour tissue.  
 
Evidence from studies assessing cytolysis of tumour cells that have downregulated 
stress-induced ligands have demonstrated a reduced susceptibility to NK cell-
mediated lysis (480, 482). However, there have been no direct investigations 
addressing the effect of ligand density on the amount of PFN secreted by NK cells, or 
other CTL. Therefore, one outcome of density-dependent ligand binding by NK cells 
may be the modulation of PFN secretion. Whilst this study did not dissect the 
mechanisms of increased PFN release in response to greater ligand density, the 
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evidence that PFN secretion varies with the density of activating ligand illustrates that 
pharmacological modulation of NK cell activity should consider this phenomenon.  
 
NK cells secrete less PFN following serial stimulations 
 
Serial activation of NK cells, through either NKG2D or CD16, resulted in decreased 
ability to secrete PFN. This data may suggest that the ligation of an activating 
receptor initiates the release of a percentage of total PFN. However, an alternative 
interpretation of this finding is a loss of sensitivity to that ligand, possibly through 
internalisation and downregulation of its receptor (484).  
 
A number of techniques have been used to demonstrate that NK cells are able to 
serially kill targets. These include single-cell imaging and chromium release assays 
using an excess of target cells (465-467). It has been reported that certain subsets of 
NK cells possess the ability to sequentially lyse more than one target. A study by 
Choi et al., showed that NK cells are able to kill up to 14 target cells over a period of 
6 hours, but that initial kills are slower – especially with ‘poor’ targets. Data shown in 
this chapter suggest that NK cells secrete less PFN with serial stimulations. The 
experiments performed by Choi et al. were run over a course of 6 hours, with time 
between kills up to 20 minutes, potentially allowing for the recovery of NK cells. The 
diminished ability to kill, shown by various groups, and the decrease in PFN secretion 
shown here, may be a response mechanism to re-stimulation. This response may be 
employed to prevent lysis of healthy host cells unnecessarily. This mechanism could 
be facilitated by the downregulation, or internalisation, of activating receptors, 
following ligation (484). Indeed, both soluble and cell-bound ligands have been 
shown to induce downregulation of activating receptor expression (483, 503). 
NKG2D on the NK cell surface is internalised and degraded in response to soluble or 
cell-surface MIC proteins (504), and ligation of CD16 has shown to cause 
degradation or shedding of the bound receptor (505).  
 
The data presented here, along with previously published data, suggest that serial 
ligation of receptors negatively impact NK cell-mediated lysis. Desensitisation to a 
specific ligand, potentially mediated by receptor internalisation, will render NK cells 
unresponsive to other target cells expressing this ligand. Whilst this could represent a 
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protective mechanism to avoid aberrant lysis of healthy cells, the reduced secretion 
of PFN and resulting decrease in lytic capacity, may have the undesirable 
consequence of unchecked growth and development of tumour cells, or persistent 
viral infections in vivo. 
 
NK cell desensitisation to further stimulation is ligand-dependent 
 
Serial activation of NK cells using the same ligand reduced the amount of PFN 
secreted upon repeated stimulation. However, PFN secretion increased following 
stimulation via CD16, following serial ligation of NKG2D. However, this restimulation 
could not be achieved when CD16 was ligated first. This demonstrated that 
decreased NK cell-mediated lysis was not due to a depletion of PFN stores, 
contradictory to the mechanism suggested by other studies (466). Findings described 
here suggest that repeated activation through the same receptor leads to 
desensitisation to that particular ligand, rather than a depletion of PFN stores, 
particularly during initial serial killing. Furthermore, the response of NK cells to 
specific ligands differs, depending on the type of response – ligation of ‘natural’ cell-
expressed ligands or induction of ADCC. Therefore, the specific receptor ligated by 
NK cells to mediate cytolysis may play a significant, and previously unappreciated, 
role. This is an NK cell-mediated response that should be considered if/when 
developing therapies to target activating receptors to enhance NK cell function.  
 
Ligation of activating receptors on NK cells leads to a signalling cascade, ultimately 
causing degranulation (506). NKG2D and CD16, whilst both activating receptors, 
signal through different pathways, albeit converging to the same MAPK signalling 
events. The main differences between NKG2D and CD16 signalling are within initial 
stages. NKG2D associates with DAP10, whereas CD16 associates with CD3ζ and 
FcRγ (122). Importantly, NKG2D signalling is independent of Syk-family protein 
tyrosine kinases (146, 507) and is associated with signalling through Grb2/Vav1, 
whereas CD16 signals through Syk, ZAP70, and Vav2/3 (152, 508). Both of these 
signalling pathways eventually converge to Rac (509). The different signalling 
pathways employed by these receptors may therefore result in the overall 
desensitisation of NK cells by CD16 signalling, whilst downstream signalling following 
NKG2D ligation may not have the same impact on receptor expression. Potentially, 
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the lack of Syk-associated signalling may explain why NK cells can be activated 
through both NKG2D and then CD16 serially, whereas CD16 ligation prior to NKG2D 
may desensitise NK cells to both receptors. Therefore, CD16 ligation may affect 
NKG2D expression, possibly through inducing receptor internalisation, or by 
signalling through pathways independent of NKG2D signalling. 
 
The re-stimulation of NK cells following receptor ligation is not exclusively 
dependent on receptor expression 
 
The flow cytometric analysis of NK cell populations showed that upon serial 
stimulation, NKG2D and CD16 expression decreased. The identification and 
characterisation of NK cell ‘serial killers’ by Vanherbergen et al. show that a small 
number were responsible for a significant amount of killing (467). Whilst no 
phenotypic analysis was performed in that study, the serial killing phenotype may be 
attributed to the expression of cell surface receptors, or previous contact with other 
cells. In their study, Vanherbergen et al. showed that a very small number of cells 
(2%) were able to serially kill up to 7 target cells, whereas the majority of NK cells 
could lyse at least 1 target cell. This is in parallel with the findings presented here, 
demonstrating a decrease in the population of cells expressing either receptor 
following serial stimulation, suggesting that ligation has an effect on the ability of NK 
cells to lyse a subsequent target. Regardless of the ligands ligated, the results of the 
study investigating PFN secretion showed that by the fourth hit, PFN levels were 
massively reduced. This was not due to cell viability during the assays, as forward 
scatter/side scatter plots showed the majority of cells were viable (data not shown). 
In this study, both NKG2D and CD16 ligation severely affected both the proportion of 
cells expressing NKG2D and the level of expression on the cell surface. This is in 
agreement with the serial killer characterisation by Vanherberghen et al. Reduced 
function may be due to the expression profiles of the individual NK cell, as a result of 
previous cell-cell interactions. Those cells expressing a higher density of receptors 
may be able to respond more efficiently to ligation of receptors, whilst also being able 
to more efficiently serially lyse target cells. It would be extremely interesting, using 
the microwell system employed by Vanherberghen et al., to investigate whether the 
addition of antibodies to trigger ADCC part way through the time course improved 
serial target cell lysis. This would begin to establish the relationship between serial 
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killing and the ligands ligated, and more importantly, whether this has a direct 
physiological effect on the ability of NK cells to serially lyse targets. 
 
The flow cytometric analysis of NK cell receptor expression does not explain the 
severe abrogation of PFN secretion through NKG2D stimulation following anti-CD16 
exposure. As discussed above, this effect could be due to differences in the 
intracellular signalling pathways employed by NKG2D and CD16. In support of this 
theory, Syk-/- ZAP70-/- murine NK calls are able to lyse targets through NKG2D, but 
not ADCC (507). Conversely, PLCγ has been shown to be critical for natural 
cytotoxicity (510-512), but dispensable in ADCC (513). Whilst the cytolytic capacity of 
NK cells has been addressed through pharmacological inhibition or gene KO, the 
involvement of signalling pathways in serial activation is yet to be addressed. Data 
presented here suggest that, following activation of NK cells through natural ligands 
or ADCC, there may be cross talk between signalling pathways. Unfortunately, the 
dissection of these pathways was beyond the scope of this thesis. Further 
investigation will uncover the roles that both natural cytotoxicity and ADCC can play 
in mediating and maintaining NK cell serial lysis. 
 
The ability of NK cells to secrete increased amounts of PFN in response to anti-CD16 
after NKG2D ligation highlights the advantages of antibody-based therapies aimed at 
improving an NK cell lytic response to infection or transformation. This could be 
through either redirected lysis or the opsonisation of specific cells. The data here 
demonstrate that NK cell degranulation is markedly increased with CD16 ligation 
following serial activation through NKG2D. Therefore, as most transformed or virally 
infected cells would express ligands for the natural cytotoxicity receptors, these 
targets could be opsonised with IgG antibodies against proteins expressed 
specifically on their surface. Ligation of the NK cell Fc-receptor CD16 may increase 
degranulation, improving the clearance of transformed or virally infected cells.  
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Estimation of perforin secretion 
 
Estimation of the amounts of PFN using the mean integrated intensities from the 
protein capture assays showed that NK cells secreted up to 38500 ± 17100 
molecules of PFN. The number of molecules was then used to estimate the 
concentration of PFN within the synapse. The results indicate that the concentration 
of PFN within the synapse would be 13.0 ± 5.7 μM. More physiologically relevant, the 
amount of PFN secreted after 12 minutes of stimulation, the modal time for NK cells 
to kill (467), was 10700 ± 7200 and 10000 ± 7000 molecules on MICA-Fc- or anti-
CD16-coated slides respectively, which give theoretical concentrations within the 
synapse of 3.6 ± 2.4 and 3.3 ± 2.2 μM. 
 
Whilst the quantification of PFN secreted at the IS has not been investigated before, 
the effect of PFN in solution at various concentrations has been addressed by other 
groups. Keefe et al. and Voskoboinik et al. directly investigated the effects of soluble 
PFN on U937 cells (a lung lymphoblast cell line) and erythrocytes, respectively (248, 
261). These studies show conflicting results, with 50% lysis triggered by either 5 μM 
(Keefe) or 0.175 μM  (Voskoboinik) of PFN – a 29-fold difference. Whilst the sources 
of PFN differed for each study (Keefe et al. isolated PFN from rat NK cells whereas 
Voskoboinik et al. expressed recombinant PFN in insect cells), it was unexpected 
that the reported concentrations of PFN required for 50% lysis differed so greatly. 
The difference between isolated and recombinant PFN may have different effects on 
the lysis of target cells, and indeed, different target cells may require different 
concentrations of PFN to initiate cytolysis – possibly depending on their surface 
receptor expression. In addition, PFN has been shown to be extremely sensitive to 
the concentration of calcium ions and pH within medium (248, 255, 291, 514-516) 
and therefore, slight differences in experimental conditions may be the cause of the 
conflicting results.  
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In summary, these data have begun to address the physiological amounts of PFN 
secreted by NK cells. Whilst these data are only estimations, the reported 
concentrations at critical time points during NK cell effector function are in agreement 
with previous studies. However, these amounts will vary depending on the receptors 
ligated, both number and, most likely, the combination. Therefore, further 
development of this assay would enable a more accurate quantification of PFN 
secretion by NK cells. 
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Chapter 6 – Discussion and 
Conclusions 
 
6.1 Overview 
 
The ability of NK cells to recognise and lyse virally infected and transformed cells is 
integral to the body’s defense against disease. These effector functions are tightly 
controlled through a structured cell-cell interaction, the IS. Ligation of a dense 
accumulation of activating and inhibitory receptors, coupled with integrins, trigger a 
balance of signals towards either activation or inhibition of NK cell-mediated 
cytolysis. A balance in favour of activation induces NK cell polarisation and secretion 
of cytotoxic mediators, including PFN and Gzms. A relatively unexplored function of 
the IS is to form a gasket, or seal, around its secretory domains. The structure of the 
IS, including dense protein-protein complexes, close membrane proximation and 
inter-digitation, may contribute to forming this barrier, which may function to prevent 
both the leakage of secreted proteins and the access of extracellular molecules. 
 
Using fluorescently labelled molecules of nanometer-scale diameters, this study 
revealed that the IS does not function as a gasket per se, but rather excludes 
molecules above a size threshold. This barrier excludes larger functional proteins, 
including mAb and LDL, preventing access into the synaptic cleft. Molecules that are 
below the size exclusion threshold, such as dAb, are able to access the synapse. 
These could be engineered to target proteins directionally secreted across the 
synapse. Unexpectedly, time-lapse imaging revealed that molecules above the size 
exclusion threshold were actively cleared from the cell-cell or cell-slide interface 
during synapse assembly. This suggests a role of IS assembly, including the 
spreading response coupled with receptor ligation, to move larger extracellular 
proteins from the synaptic cleft. These data demonstrate that antibody-based 
therapies targeting directly secreted proteins within the synapse must be engineered 
below the size threshold identified here to avoid clearance and exclusion from the 
synapse. 
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PFN secretion by NK cells is critical for mediating cytolysis. However, the amount 
released by NK cells had not yet been investigated or quantified. A protein-capture 
assay, activating NK cells on varied ligand densities, revealed that NK cell signalling 
appears to be an analogue-based system. In addition, the number of times receptors 
had previously been stimulated directly affected NK cell PFN secretion. Estimation of 
the amount of PFN secreted at the synapse revealed that after 12 minutes 
stimulation, the typical time taken for an NK cell to lyse its target, around 10000 
molecules of PFN had been released. This was estimated to be a 3.5 μM 
concentration of PFN within the synaptic cleft. Previous studies have demonstrated 
serial target lysis mediated by NK cells. Whilst the efficiency of cytolysis decreases 
with increased frequencies of serial lysis, the effect this has on PFN secretion is 
unknown. It is shown here that serial stimulation rendered NK cells refractory to 
further engagement with the same ligand. However, following NKG2D ligation, 
stimulation through CD16 was able to trigger PFN secretion similar to their initial 
activation. NKG2D ligation following stimulation through CD16 was, however, unable 
to trigger the same response. 
 
In summary, this investigation has revealed that the NK cell IS acts as a physical 
barrier to extracellular molecules above a size threshold, and that PFN secretion at 
the IS is a result of analogue signalling, dependent on ligand densities and influenced 
by previous exposure to activating ligands.  
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6.2 The immune synapse clears and excludes extracellular 
molecules in a size-dependent manner 
 
Formation of an IS and subsequent activating or inhibitory signalling is critical in 
regulating host defense against pathogens and transformed cells, whilst preventing 
the lysis of healthy cells. The ability to exclude molecules above a size threshold, 
coupled with the clearance of larger molecules during synapse assembly, 
demonstrates that the process of IS formation, and the resulting dimensions of the 
synaptic cleft, have a direct effect on molecules in the extracellular environment.  
 
F-actin reorganisation at the synapse facilitates the effector cell spreading response. 
The accumulation of receptors, with an underlying F-actin scaffold, at the IS has 
been demonstrated by a number of groups (13, 18, 66, 410, 517). The data show 
that the structure of the F-actin scaffold at the synapse is critical in excluding dextran. 
In contrast, further reorganisation after synapse formation is not required. The 
movement of the NK cell, over a target cell or activating surface, cleared larger 
molecules from the interface. This is most likely due to the formation of receptor-
ligand constructs that are smaller than excluded molecules. High-resolution TIRF 
imaging demonstrated that this occurs as the synapse forms in a zipper-like manner, 
excluding larger dextran following the cell spreading response, from the central 
region of the synapse towards the periphery. 
 
The dense accumulation of complexes, including both activating, inhibitory and 
integrin receptor-ligand pairs, is required to facilitate an appropriate response from 
the NK cell. Prior to this work, the hypothesis that the IS functions as a gasket (366, 
367, 518, 519) had not been directly tested. Studies detailed here indicate that the 
formation and inter-membrane span of the IS should be considered when designing 
therapeutics to access the IS. Any potential therapy should be engineered below the 
size thresholds identified here to avoid clearance and to facilitate access to 
directionally secreted proteins. 
 
Initial analysis and quantification of dextran within the synapse addressed the ability 
of differently sized molecules to enter the IS. The most significant caveat to the 
investigation was the varying solubility and degrees of labelling of the dextrans – 
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larger dextrans had lower solubility with increased labelling densities – which could 
influence quantification. Varying microscope settings were used to optimise the 
visualisation of differently sized dextran at the IS. These differences in settings had 
the potential to introduce artefacts when quantifying dextran concentration. To rule 
out any artifactual bias, conjugates were imaged with increasing concentrations of 
dextran or mixtures of labelled and unlabelled dextrans to dilute their fluorescence 
intensities. This meant that the same settings on the microscope could be used to 
image dextrans of significantly different sizes (Figure 3.5 and 3.6). Neither varying 
dextran concentration nor reducing fluorescence intensity by addition of unlabelled 
dextrans affected the quantification of molecule access into the IS. Therefore, whilst 
the IS is able to restrict the access of dextrans into the synaptic cleft, this occurs in a 
size-dependent manner, irrespective of dextran concentration or labelling density. 
 
Dextrans sized 3 – 13 nm were able to access the synapse, with the increase in size 
determining the extent dextran was able to enter the synapse. Dextrans sized 32 and 
54 nm were completely excluded from the pNK cell synapses. Dextran fluorescence 
intensity was measured across the solution, cell bodies and synapse. The mean raw 
intensity profiles demonstrate that dextrans that access the synapse have a peak in 
intensity over background across the synaptic cleft. This decreased with increasing 
dextran size (Figure 3.1B and 3.3B). Similar findings were obtained for conjugates 
formed by the NK cell line YTS or pNK cells with 221 targets, suggesting that the IS 
excludes dextrans in a size-dependent manner (Figure 6.1). To further demonstrate 
that the synapse functions as a size-dependent barrier, rather than a gasket, dextran 
was shown to be able to either equilibrate within the synapse or be washed out 
completely (Figure 3.7 and 3.17 – 3.19). If a true gasket were formed, dextran would 
neither be able to equilibrate nor be washed out from the synapse. 
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The similar size of the TCR and NK cell activating receptors (208, 211) may explain a 
comparable size threshold for T cell and NK cell synapses. The exclusion of serum 
proteins such as LDL would be beneficial for CD8+ cytotoxic T cells that, like NK 
cells, directly secrete cytotoxic proteins to lyse diseased cells (520, 521). The 
interaction of a CD4+ T cell and APC, is the site of directed secretion of cytokines 
(19). Whilst the NK cell may function to prevent the leakage of cytotoxic proteins, the 
cytokine IFNγ (shown to be ~6 nm in their longest dimensions (522)) was shown to 
leak from the CD8+ T cell synapse formed with an antigenic target cell (523). This 
may provide a paracrine, dose-dependent response to surrounding cells following the 
activation of a single T cell. In addition, a study by Perona-Wright and Mohrs in 
murine infection with the Th2-inducing gastrointestinal helminth Heligmosomoides 
polygyrus demonstrated a polarised response throughout the entire draining lymph 
node (LN) (524). Whilst IFNγ production within the LN is localised primarily to the T 
cell-APC synapse, this study found that during H. polygyrus infection, the majority of 
T cells within the LN were activated. This was confirmed by microscopy studies, 
Figure 6.1.  NK cell size-dependent exclusion of dextran molecules of various sizes from the 
activating immune synapse. The activating NK cell immune synapse forms following the ligation of 
integrin (yellow/green) and activating (red/purple) receptor-ligand complexes. This results in the 
spreading of the NK cell membrane that clears molecules above a size threshold from the synaptic 
cleft. The exclusion of dextran is determined by the maintenance of F-actin (dashed lines) at the 
synapse and the span of the various receptor-ligand complexes that accumulate at the cell-cell 
interface. Dextrans sized 54 nm (red) and 32nm (yellow) are largely excluded, whereas those 13 nm 
(orange), 10 nm (turquoise), 4 nm (brown) and 3 nm (blue) are able to access the synapse, where 
penetration increases with decreasing dextran size. Diagram not to scale. 
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demonstrating the directional secretion of IFNγ, but multidirectional secretion of IL-4. 
Whilst not considered in this study, the leakage of such cytokines from the T cell 
synapse, as shown by Sanderson et al., may explain how the activation of a single T 
cell can have a paracrine, as opposed to local, effect. However, close membrane 
proximities, due to the dimensions of the extracellular domains of the receptor-ligand 
complexes, will exclude larger proteins from the T cell synapse. As a result, the T cell 
IS will exclude larger serum proteins. This may be to provide both a greater 
concentration of cytokines or cytotoxic mediators within the synapse to elicit as 
potent a response as possible. 
 
Dextran was actively cleared from the cell-cell or cell-slide interface (Figure 3.29 – 
3.31). The data suggest that the NK cell spreading response (123, 213), an integrin-
mediated force that pushes the NK cell outwards from its contact point, physically 
clears molecules that are above the size exclusion threshold. The TIRF microscopy 
of synapse formation in the presence of both 4 nm and 32 nm dextran demonstrated 
this clearly. The accumulation of dextran within the cell-slide interface at early time 
points, only to be pushed out of the central region of the synapse, suggests that the 
synapse forms in a zipper-like manner. This spreading may be dependent on integrin 
ligation and preceded by the ligation of activating receptors, which enable the 
clearance of the larger dextran after an initial lag period (Figure 6.4). This suggests 
that it is later signalling events that initiate the clearance of larger dextran from the 
interface. Consistent with the kinetic segregation model (213), the clearance of larger 
molecules may depend on bending of the membrane, minimizing the energy required 
at the synapse. This idea is consistent with previous studies demonstrating that 
receptors (124) or large particles bound to the NK cell membrane (189) are 
segregated according to size. Whilst these proteins require reorganisation at the cell-
cell interface, extracellular molecules can be physically cleared from the synapse to 
prevent expenditure of energy at the synapse. Therefore, the cell spreading 
response, coupled with receptor ligation on a dense F-actin scaffold, may provide a 
force to remove large molecules from the synaptic cleft (Figure 6.2).  
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Functional and therapeutic implications of size-dependent exclusion at the 
synapse 
 
The co-incubation of fluorescently labelled antibodies or LDL with effector-target 
conjugates showed that these too are subject to size discrimination regarding their 
access to the synapse. Importantly, mAb were almost completely excluded from the 
pNK synapse, whereas smaller antibodies, F(ab’)2 fragments and dAb, could be 
found in the synaptic cleft (Figure 6.3). These data show that size is important for 
therapeutic antibody access to the IS, in agreement with previous anecdotal 
evidence demonstrating their inability to block secreted proteins, such as PFN or IL-
18 (366, 367). For this reason, antibody-based therapeutics designed to access the 
synapse must be engineered within these size constraints in order to target 
directionally secreted proteins. For instance, the blockade of PFN during cell-
mediated destruction of pancreatic tissue in type I DM may reduce or prevent the 
loss of β cells within the islets of Langerhans. Additionally, previous work by Perona-
Figure 6.2. The NK cell activating immune synapse clears and excludes larger molecules 
during cell spreading and assembly. NK cell immune synapse formation clears larger 32 nm 
dextran from the synapse in a zipper-like fashion. (A) Prior to NK cell contact with the slide, NKG2D 
(purple) and LFA1 (green) are not engaged with MICA (pink) or ICAM1 (yellow) and both 4 nm 
dextran (brown) and 32 nm dextran (orange) are homogenous throughout the solution. (B) After 
initial contact, both 4 nm and 32 nm dextran intensities are decreased as some dextran is pushed 
from the cell-slide interface as initial ICAM1-LFA1 receptor-ligand complexes form. (C) Following 
initial contact, the NK cell spreads on the slide, creating more ICAM1-LFA1 complexes, collecting 
the larger dextrans into areas of wider span between the slide and the cell membrane. Soon after 
spreading, NKG2D receptors begin ligating their ligand, MICA, resulting in increased removal of 32 
nm dextran from the synapse. (D) As further NKG2D receptors engage their ligands, this results in a 
wave outwards from the central region of the synapse, clearing the larger 32 nm dextran from the 
synapse, in a zipper-like manner, until only the 4 nm dextran remains within the cleft and the 32 nm 
dextran are excluded form the interface. 
A B 
C D 
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Wright and Mohrs (524), described above, demonstrated a polarised LN phenotype 
orchestrated by IFNγ, despite its directional secretion into the synapse. In this 
setting, dAb targeted against IFNγ may be able to block the intercellular secretion of 
IFNγ, whereas mAb would only serve to inhibit the cytokines that leak from the 
synapse. This may enable to inhibition of the response in all cells within a tissue, 
including those where cytokines are directionally secreted into the synaptic cleft. 
 
 
 
The exclusion of LDL from the synapse suggests a physiologically relevant role of 
molecular clearance and exclusion from the synaptic cleft. Previously, LDL has been 
shown to inhibit the pore-formation of PFN (449, 450). The lipid components of LDL 
bind to PFN, preventing both membrane insertion and oligomerisation. This has a 
negative impact on the cytolytic capacity of PFN. Therefore, inclusion of LDL within 
the IS could inhibit the ability of PFN to puncture the target cell membrane. 
Therefore, it is possible that clearance and exclusion of LDL from the IS protects 
PFN secreted across the synapse. LDL was able to access the YTS cell IS to a 
Figure 6.3. NK cell size-dependent exclusion of proteins of various sizes from the activating 
immune synapse. The activating NK cell immune synapse forms following the ligation of integrin 
(yellow/green) and activating (red/purple) receptor-ligand complexes. This results in the spreading of 
the NK cell membrane that clears molecules above a size threshold from the synaptic cleft. The 
exclusion of dextran is determined by the maintenance of F-actin (dashed lines) at the synapse and 
the span of the various receptor-ligand complexes that accumulate at the cell-cell interface. Low-
density lipoproteins [~24 nm diameter] (green) and immunoglobulin G antibodies [~16 nm diameter] 
(pink, yellow and green) are excluded from the synapse, whereas F(ab’)2 fragments [~9 nm 
diameter] (pink and green), and to a larger extent domain antibodies [~4 nm diameter] (pink and 
yellow), are able to access the synaptic cleft. Diagram not to scale. 
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greater extent than the synapse formed with target cells and pNK. It is likely that the 
access of LDL to the YTS synapse could reduce the lytic capacity of these cells, 
although this is yet to be directly tested. Unlike pNK cells, YTS express fewer 
activating receptors, which may alter the functional dimensions of the synaptic cleft. 
Indeed, this was demonstrated by the fact that 32 nm dextran was entirely excluded 
from the IS of pNK cells (Figure 3.3), but could still be found, to some degree, in the 
target cell interface with YTS cells (Figure 3.1).  
 
The size threshold of the synapse is consistent with previous measurements of 
intercellular spaces and receptor-ligand crystal structures at the IS (65, 189, 208, 
211, 357). The membrane spacing between an effector and target cell have been 
shown to be 10 – 30 nm, with some areas of larger span to accommodate larger 
integrin receptor-ligand complexes, up to 40 – 55 nm. Another possible explanation 
for the difference in size thresholds of YTS and pNK cells is variation in the density, 
rather than size, of activating receptors utilised by these cells. YTS cells use the co-
stimulatory receptor CD28 as the only activating receptor, hence they are only able to 
efficiently lyse the target cell line 221 through CD80/86 ligation (20). In contrast, pNK 
cells possess a range of activating receptors (118), which may be paramount in the 
establishment of a tight and size restrictive interface/structure. The dense 
accumulation of these receptors, may create a more selective barrier around the IS. 
Despite these structural differences in IS formation, dextrans sized 3 or 4 nm and 
dAb (sized 4 nm in their longest dimension) accessed both the YTS and pNK IS to 
the greatest extent, demonstrating that molecules of this size are able to freely 
penetrate the synaptic cleft.  
 
Monoclonal antibodies are unable to access the synapse, and therefore would be 
unable to block secreted proteins. Therapeutically, this suggests that dAb, and to 
some extent F(ab’)2 fragments, could be administered to bind cytotoxic proteins 
and/or cytokines secreted at the synapse. It has been demonstrated here that the 
access of antibodies into the synapse is dependent on physical dimensions. This 
provides direct evidence as to why previous experiments have failed to block 
directionally secreted proteins. Importantly, dAb administered as a therapeutic could 
be used to inhibit aberrant cytolysis or directed cytokine secretion across synapses 
(Figure 6.4). Furthermore, the evidence that not only NK cells but also T cells are 
able to exclude molecules above this threshold demonstrates that therapeutics could 
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be developed to target not only proteins secreted at the NK cell synapse, but also 
those at the T cell synapse, including cytotoxic proteins and cytokines. 
 
 
 
The inhibitory immune synapse does not exclude extracellular molecules 
 
The inhibitory NK cell IS does not result in the secretion of proteins – signalling or 
cytolytic (9). Therefore, the synaptic penetration of dextran suggests that the 
retention of secreted proteins or the exclusion of extracellular molecules does not 
occur at the inhibitory synapse. Despite the similar size of the extracellular domains 
of inhibitory and activating receptors (83, 84, 124, 210), inhibitory synapses were 
unable to exclude molecules of any size. Therefore, the clearance and exclusion of 
extracellular molecules is specific to the activating synapse. 
 
Figure 6.4. Domain antibodies can access the immune synapse and could be used to target 
proteins secreted across the synaptic cleft. (A) Immunoglobulin G antibodies are excluded from 
the synapse due to their dimensions. As a result, they cannot access directly secreted proteins and 
have no effect on NK cell effector functions. (B) Domain antibodies fall below the size exclusion 
threshold and the immune synapse and can therefore access the synaptic cleft. Domain antibodies 
against directionally secreted proteins, such as perforin, would potentially be able to access the 
regions where they are secreted and block their cytolytic action. Diagram not to scale.  
A 
B 
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Previous studies have demonstrated that the inhibitory synapse forms asymmetrically 
without the accumulation of F-actin, as opposed to the F-actin dense, symmetrical 
structure of the activating synapse (123). Receptors, such as LFA-1, are anchored to 
F-actin, which accumulates at the activating synapse, for stabilization of the IS 
structure during sustained signalling. In contrast, signalling at the inhibitory synapse 
inhibits focal adhesions and lacks this structural integrity (70, 416). This is likely to be 
the major determining factor in the exclusion of extracellular molecules. As the NK 
cell contacts its target, the lack of activation may result in little or no spreading and 
no clearance of dextran from the inhibitory synapse, this could be tested directly 
using the cell-spreading assay. This theory is supported by the dependency on actin 
for exclusion of larger dextrans from the activating synapse, demonstrated by actin 
depolymerisation during effector-target conjugation (Figure 3.25 – 3.29). Whilst actin 
integrity is required to exclude dextran, the stabilisation of F-actin filaments following 
synapse formation has no impact on the exclusion of dextran. Therefore, the initial 
reorganisation of F-actin, not seen in inhibitory synapses, along with cell spreading, 
are likely to be required to clear dextran. Without these structural changes, molecules 
remain within the cleft.  
 
6.3 The amount of perforin secreted at the immune synapse 
is ligand type- and density-dependent 
 
Whilst the mechanisms of PFN secretion have been studied in depth, the effects of 
different activating signals and repeated stimulation of NK cells on PFN secretion has 
not yet been directly investigated. NK cell activation is thought to be a binary, or 
digital, process (476). Whilst a threshold of activating signalling over inhibitory 
signalling is required for activation of NK cells, once this threshold is reached, it is 
assumed that NK cells secrete a pre-determined ‘payload’ of cytotoxic proteins 
towards the target cell (525). Data described here establish that NK cell responses, 
mediated by the ligation of activating receptors, induces an analogue, metered 
response, that determine the amount of PFN secreted. In addition, using confocal 
microscopy of captured proteins, the amounts and concentrations of PFN within the 
synaptic cleft were estimated for the first time. 
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Within 3 minutes of exposure to NKG2D or CD16 ligands, in the presence of 
adhesion molecules, NK cells began to degranulate, evidenced by the presence of 
PFN spots on the capture assay slide. Indeed, these spots were not as frequent as 
when cells were incubated for ≥30 minutes, indicating that not all NK cell degranulate 
this rapidly. This highlights that within a population of NK cells, there exists only a 
subset that are capable of rapid responses to the ligation of receptors tested here, 
NKG2D and CD16. This subset may provide an immediate response to a pathogenic 
agent or transformed cell. Indeed, this response may be faster, or slower, following 
ligation of other activating receptors not tested in this study. This phenotype may be 
determined by a specific receptor expression repertoire, gene expression and/or 
previous encounters with other regulatory or target cells. The phenotypes of NK cell 
populations, or that of a clonal expansion from a single NK cell, could be assessed 
prior to the protein capture assay. Determining the PFN secretion kinetics with this 
information could be correlated to determine the expression profiles that predispose 
NK cells to a more rapid response. In this study, PFN secretion was initially greater in 
response to MICA than anti-CD16. However, within 60 minutes, NK cells had 
secreted similar amounts of PFN on either ligand. This suggests that whilst the initial 
signalling pathways downstream of NKG2D and CD16 induce different amounts of 
PFN secretion, activation over a longer period of time results in similar levels of 
secretion. This may be due to the availability of NKG2D receptors on the NK cell 
surface, the distribution of signalling proteins within the NK cells or simply the 
evolution of these pathways that have benefited from a more rapid and greater 
production of PFN in response to NKG2D stimulation, compared to CD16. Further 
elucidation of these factors, in relation to secretion kinetics, would further develop our 
understanding of NK cell PFN secretion. 
 
The amount of perforin secreted is dependent on ligand density 
 
The balance of activating versus inhibitory signalling enables an NK cell to 
discriminate between healthy and diseased cells (526). Whilst this balance of signals 
requires a threshold above inhibition in favour of activation to initiate cell-mediated 
lysis (11, 77, 123), any the effects of further activating receptor ligation have not been 
addressed. NK cell PFN secretion has previously been described as binary, where 
an activating signalling threshold is required to initiate cytolysis (525). Indeed, a 
binary system to initiate NK cell lysis would provide a protective mechanism that 
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would protect autologous cells from aberrant lysis following the expression of low 
numbers of ligand on otherwise healthy cells. The data presented here are 
contradictory to this hypothesis, suggesting that PFN secretion is in fact analogue 
and can be controlled by ligand density. The data suggest that NK cell signalling is 
governed by the amount of ligand a cell interacts with. This has functional 
consequences, with a direct effect on the amount of PFN secreted (Figure 5.4 and 
5.5). Analogue signalling allows a metered response to a stimulus, determined by 
either the amount of receptor expressed or ligand available (Figure 6.5).  
 
 
 
NK cell effector responses can be affected by previous encounters with the 
same or varying ligands 
 
NK cells have been shown to be able to serially lyse target cells (467). However, only 
a small proportion of NK cells have the ability to serially kill targets. An NK cell would 
lose stores of PFN following degranulation, but the ability of NK cells to serially lyse 
target cells suggests that they only lose a certain proportion of stored PFN with each 
Figure 6.5. NK cells secrete greater amounts of perforin in response to increased ligand 
density. NK cell ligation of activating receptors results in the secretion of perforin. However, this 
effector response is analogue, as opposed to digital, and therefore, greater densities of ligand result 
in greater amounts of perforin secreted. (A) A low ligand density causes the secretion of a small 
amount of perforin. (B) A high ligand density results in the secretion of a greater amount of perforin. 
Diagram not to scale. 
A 
B 
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kill. Serial stimulation through either NKG2D or CD16 caused a decrease in the 
amount of PFN secreted by NK cells (Figure 3.5.6 and 5.7). This could have been 
due to either a reduction of PFN stores or the internalisation of receptors. If NK cells 
internalise their receptors, they would be unable to mount as efficient a response 
upon further stimulation. The data support this hypothesis, with PFN secretion 
reduced in response to repeated stimulation with either MICA-Fc proteins or anti-
CD16 antibodies (Figure 5.6 and 5.7). However, these data did not address directly 
whether it was simply a loss of PFN stores that caused the reduction in PFN 
secretion, or a loss of surface expression of receptors. To address this, NK cells 
were stimulated sequentially on different ligands to assess if PFN secretion 
continued to decline, indicating a loss of total PFN stores. 
 
Stimulation through CD16 (ADCC) following initial NKG2D activation triggered PFN 
secretion at levels seen upon initial activation. However, NKG2D signaling following 
CD16 activation was insufficient to restore the PFN response (Figure 5.8 – 5.11). 
This may be due to a downregulation of NKG2D following CD16 ligation. Flow 
cytometric analysis of NKG2D and CD16 expression showed that NKG2D ligation 
had little effect on the percentage of cells expressing CD16. However, the level of 
CD16 expression on the surface of individual NK cells was reduced. CD16 ligation 
decreased both the proportion of cells expressing NKG2D and the overall levels of 
NKG2D expressed on the cell surface.  The minor reduction in CD16 expression did 
not seem to be as stark as the dramatic drop in PFN release. Flow cytometric 
analysis suggested that NK cell size and density was unaffected by the serial 
stimulation assay, indicating that cell viability was not reduced. This indicates that a 
decrease in PFN secretion could not be attributed to a reduction in NK cell health, 
although this can be tested more robustly using a flow stain to directly measure 
alterations in membrane integrity, such as DAPI. This suggests that whilst receptor 
expression may influence the ability of NK cells to serially secrete PFN, it is not the 
only factor. Intracellular signaling is likely to play a role in the degree of PFN 
secretion. Unfortunately, NK cell signalling was not investigated here. Previous 
groups have studied the effects of signalling on NK cell-mediated cytolysis, but have 
yet to show if signalling events are correlated to the amount of PFN secreted. Whilst 
future work can address these outstanding questions (see below), the data here 
establish a direct link between serial ligation of activating receptors and the ability of 
NK cells to secrete PFN.  
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The desensitisation of NK cells to activating ligands may protect the body from 
aberrant cell lysis, whilst allowing NK cells to retain the ability to mount a response to 
opsonised targets. In a tumour setting, repeated stimulation through tumour-
expressed ligands for NKG2D (496), causes a downregulation of the receptor on the 
NK cell surface (504, 527). As a result, NK cells become less efficient, or eventually 
unable, to lyse tumour cells. B cells have been shown to produce antibodies against 
both cancer cell-expressed proteins (528) and viral peptides presented on infected 
cell surfaces (529, 530). Therefore, following the repeated stimulation of NK cells 
through NKG2D, opsonisation of target cells would result in the ligation of CD16, 
possibly enabling further lysis of these targets by previously stimulated NK cells. 
Assessing the NK cell-mediated specific lysis of excess target cells expressing only 
ICAM1 and a ligand for NKG2D could determine the efficacy of this. During a 6-hour 
cytotoxic release assay, the addition of IgG targeted to NKG2D ligands, compared to 
no addition of antibody, would begin to address whether ADCC improved the serial 
lysis of these target cells.  Finally, the inability of NK cells to be re-stimulated 
following serial activation through CD16 may be a defense mechanism protecting the 
body from autoimmunity. B cells can produce a number of autoantibodies, during 
both normal development and in disease (531). The desensitisation of NK cells to 
ADCC may render them hyporesponsive, protecting the body from further autologous 
attack. 
 
The fact that NK cells can be activated through CD16 and continue to release PFN 
following serial stimulation through NKG2D implies that therapeutic antibodies could 
take advantage of this. Hyporesponsive NK cells within a tumour could lead to 
decreased specific lysis and the development of a metastatic tumour. Directing 
antibodies against tumour-specific antigens could reverse NK cell anergy, initiating 
ADCC against these targets, and leading to an enhanced clearance of transformed 
cells. Whilst the downregulation of NK cell activating receptors may be a defense 
mechanism against aberrant autologous cell lysis, the maintained capacity to initiate 
ADCC of opsonised target cells is likely to be beneficial. Data presented here 
indicate that NK cell responses to different ligands can have profound effects on their 
capacity to react to subsequent stimulation. Therefore, therapeutics could take 
advantage of these systems to induce, or improve, the immune response to viral 
infection or transformation (Figure 6.6). 
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Estimation of perforin amounts secreted by NK cells 
 
PFN secretion was quantified as a mean integrated intensity per cell. These 
measurements were used to determine increases or decreases in the amount of PFN 
secreted by NK cells in response to different stimuli. However, this did not address 
the actual amounts of PFN, or the number of molecules released by NK cells. To do 
this, beads coated with known surface densities of antibodies were used to create 
fluorescent beads that could be imaged and quantified using confocal microscopy. 
The antibody binding capacities of the beads were used to define the relationship 
between fluorescence intensity and the number of molecules.  
 
  
Figure 6.6. ADCC-mediated cytolysis could be used to promote NK cell-mediated serial 
lysis efficiency. (A) The ligation of NKG2D and LFA-1 results in the activation and 
degranulation of NK cells, causing lysis of the target cell, but also down regulation of NKG2D 
expression. (B) Receptor internalisation results in fewer receptors available to activate the NK 
cell and therefore less perforin is produced, which may be insufficient to lyse the target cell. (C) 
Following NKG2D ligation, the ligation of CD16 induces a strong effector response where perforin 
secretion remains high, most likely be sufficient to lyse the target cell. Diagram not to scale. 
A 
B C 
Repeated stimualtion
through NKG2D
Subsequent stimualtion
through CD16
Initial stimulation through NKG2D
Reduced perforin secretion Recovered perforin secretion
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Using previously reported measurements of the dimensions of the synapse to 
estimate the volume of liquid it contains, these amounts of protein could then be used 
to estimate the concentration of PFN secreted into the cleft. Following stimulation via 
NKG2D or CD16, PFN reached concentrations of 13 ± 5.7 μM or 12.2 ± 4.3 μM 
respectively. However, these values may be an over-estimation. In a physiological 
cell-cell conjugate setting, PFN binds to the target cell membrane and creates pores 
that cause endocytosis of the damaged membrane, utilising the membrane repair 
response (261, 291, 294). Therefore, whilst PFN is secreted constantly at the 
synapse, the concentration within the synaptic cleft would most likely not exceed 12 
μM. Current data shows that NK cell median time to kill is around 10 minutes, and 
therefore, cytolytic concentrations of PFN may be reached within this time frame. 
After 12 minutes, the concentration of PFN, via NKG2D or CD16 stimulation, reached 
3.6 ± 2.4 μM or 3.3 ± 2.2 μM, respectively. This concentration is consistent with a 
previous study reporting that 5 μM PFN in solution was able to efficiently lyse cells 
(261). 
 
The results of this study have investigated the amount of PFN secreted into the IS. 
PFN secretion varies in response to the density of activating ligand, with increased 
densities inducing greater PFN secretion. Furthermore, NK cells responsiveness to 
repeated activation depends on the nature of the activating signal. In conclusion, NK 
cell signalling and PFN secretion is affected directly by the quality and quantity of 
ligand binding. Further antibody-based modulation of NK cell responses should 
account for these factors to modulate the NK cell response. 
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6.4 Future Perspectives 
 
6.4.1 Clearance and exclusion from the immune synapse 
 
Size-dependent exclusion at the immune synapse 
 
The data presented here show that NK and T cell IS are able to exclude molecules 
above a size threshold. This is likely due to the dimensions of the extracellular 
receptors causing nanometer-sized spacing between the two cell membranes. To 
further investigate this, elongated extracellular domains on the target cell could be 
used. Köhler et al showed that elongating activating or inhibitory ligands abrogated 
signalling, due to size-dependent segregation at the synapse (124). By using a 
similar system, the extracellular domains of the activating receptors could be 
matched to integrin sizes, so that the width of the activating synapse could be 
increased. If the exclusion of molecules were due to the resultant size of the synaptic 
cleft, based on receptor-ligand complex dimensions, the increase of intracellular 
membrane distance would therefore allow larger molecules into the synapse. 
Sufficient extension to accommodate mAb could also be tested using a cytotoxicity 
release assay. If the synapse were able to accommodate mAb within the synapse, a 
mAb against PFN would therefore be able to enter and block killing. This would 
directly test whether the size exclusions imposed by the synapse are due to 
extracellular receptor-ligand complex dimensions and the functional ramifications of 
this. 
 
The inhibitory IS was unable to exclude any of the molecules tested. This suggests 
that the inhibitory synapse is unable to clear molecules from the cell-cell interface 
during synapse formation. This may be due to the absence of F-actin accumulation 
or lack of effector cell spreading, both characteristic of the activating synapse. The 
addition of dextran to pre-formed inhibitory synapses, as was previously done with 
activating synapses, is one method that could be used to address the importance of 
these factors. The formation of inhibitory synapses with target cells or slides coated 
with inhibitory ligands could be utilised for this. Coupled with fluorescent real-time 
cytoskeletal markers such as LifeAct (which can be transfected into cells and used to 
image live actin dynamics), the effect of inhibitory signals on F-actin dynamics, cell 
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spreading, and dextran clearance could be tested. This would determine whether the 
structural differences in the formation of inhibitory and activating synapses 
determines their ability to clear extracellular molecules. 
 
Clearance of molecules from the immune synapse 
 
NK cell spreading, mediated by integrins (532-535), may cause an initial reduction in 
extracellular molecules within the synapse, but the subsequent ligation of smaller 
activating receptors may facilitate the complete exclusion of larger molecules. To test 
whether this is caused by the spreading response initiated by NK cells in contact with 
activating surfaces, the concentration of both integrins and activating ligands could 
be titrated. PNK cells could be plated on increasing amounts of activating ligand with 
a constant amount of ICAM1. This would address whether it is the ligation of 
activating receptors that induces complete clearance of larger molecules from the 
synapse. 
 
Alternatively, the TIRF imaging of smaller 4nm dextran, larger 32 nm dextran and 
actin (using LifeAct) simultaneously could be performed. This would allow imaging of 
actin cytoskeleton dynamics at the cell-slide interface in the presence of different 
dextran sizes, allowing correlative analysis of F-actin reorganisation and the 
clearance of dextran. Furthermore, the use of actin depolymerizing drugs could be 
used alongside this technique to allow real-time imaging of actin degradation at the 
synapse, and how this affects the exclusion of larger dextran from the synaptic cleft. 
 
Antibody blockade of directionally secreted proteins 
 
The results have clearly demonstrated that the pNK cell synapse is able to exclude 
mAb, whereas F(ab’)2 fragments and dAb capably penetrate the IS. Thus, smaller 
sized antibodies would be able to target proteins that are directionally secreted. The 
production of F(ab’)2 fragments and dAb against proteins that are secreted into the 
synapse, such as PFN, would therefore confirm that exclusion of mAb leads to their 
failure to inhibit target cell lysis. These antibodies against PFN should be tested 
using a cytotoxicity release assay in parallel with a degranulation assay (measuring 
surface expression of CD107a). By analysing the lysis of target cells and the extent 
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of degranulation, the importance of size for the efficacy of these targeted therapies 
can be assessed.  
 
The effect of LDL on perforin secreted at the immune synapse 
 
The exclusion of LDL from the pNK cell synapse is consistent with the idea that 
synapse assembly can clear molecules that would otherwise interfere with secreted 
proteins. Previous findings have demonstrated the ability of LDL to bind and inhibit 
PFN and that LDL added to the extracellular solution has little effect on efficient 
killers (449, 450). The addition of LDL to various effector-target conjugates, formed 
by CTLs with a range of killing efficiency, showed that ‘poorer killers’ were more 
susceptible to the inhibitory effects of LDL.  
 
YTS cells elicit a poorer cytolytic response than pNK cells and this may be due to the 
inclusion of LDL within the YTS cell synapse. A cytotoxicity release assay in parallel 
with a degranulation assay in the presence or absence of lipoproteins would address 
this, with the hypothesis that specific lysis by YTS cells would increase when co-
incubation with target cells occurs in lipoprotein-free medium, whereas degranulation 
would remain the same. This would suggest that the presence of LDL within the 
synapse is indeed having a direct effect on the cytolytic capacity of YTS cells.  
 
Further to this, elongation of receptors and ligands at the pNK cell synapse could 
further test this idea. Cytotoxic release assays with targets only expressing ligands 
with extracellular domain sizes matched to integrin receptor-ligand complexes in 
normal and LDL-free medium would address the inclusion of LDL could affect the 
action of secreted PFN. 
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6.4.2. Perforin secretion at the NK cell immune synapse 
 
NK cell activation and degranulation with different ligands and combinations 
 
Current data addresses how repeated CD16 and NKG2D stimulation alters the 
capacity of NK cells to secrete PFN. Future experiments should include activation of 
pNK cells on slides coated with a variety of ligands, including combinations of more 
than one. This would further elucidate how ligation of different receptors affects NK 
cell PFN secretion. Further, investigations of PFN secretion from pNK cells has only 
been addressed under activating conditions. The inclusion of inhibitory ligands on 
slides would also address impact of inhibitory signals on subsequent PFN secretion. 
A previous study showed that titrating antibodies against inhibitory receptors had a 
proportional effect on NK cell-mediated cytolysis (480), which would suggest that 
PFN secretion is indeed metered by inhibitory receptor ligation. Expansion of the 
model used in studies detailed here would allow direct assessment of how negative 
signals alter the PFN response. 
 
Saturation of the capture assay anti-perforin antibodies 
 
Whilst large amounts of anti-PFN antibodies were used to capture PFN, it is possible 
that the slides were saturated, so not all PFN proteins secreted were captured. By 
increasing the amounts of anti-PFN antibodies coated on the slide, this could be 
tested. However, as increasing amounts of PFN was secreted, the proteins would 
have diffused across the slide, leading to the formation of larger spots of PFN, as 
seen in the images. The increase in size of the PFN spots arrested 60 minutes after 
initial stimulation. It could be assumed that no more PFN was secreted, but using 
increasing amounts of anti-PFN antibody would confirm this. 
 
Replication of a target cell surface on an activating slide 
 
The artificial nature of the PFN capture assay is a drawback of this technique. In this 
system, only one integrin and one activating receptor are ligated. Whilst this is 
sufficient to induce a response, the quantity of PFN secreted by the NK cell may 
differ when co-ligation of different activating and inhibitory receptors occurs. The use 
of physiologically relevant amounts of activating ligands would better address the 
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PFN secretion response of NK cells when in contact with a target cell. By flow 
cytometric analysis of tumour cells, virally-infected cells and common cell lines that 
are used as NK cell targets, their surface phenotype could be more closely mimicked 
on a slide. There are other factors, such as cell-cell receptor transfer that are not 
modeled in this assay. Despite these drawbacks, minor tweaks could provide a more 
physiological setting to study NK cell signalling and to unravel how various 
combinations and densities of ligands affect PFN secretion.  
 
The effect of surface tension on perforin secretion 
 
The tension provided by a glass surface is not biomimetic of a cell synapse. 
Specifically, the high tensile forces generated by interaction with glass may influence 
NK cell phenotype. This may result in an altered NK cell response, that is less 
representative of interactions with a conjugated cell, which has a significantly lower 
modulus. This is a particularly important consideration when attempting to simulate 
the substrate modulus of tumour cells. It has been shown that tumour tissues are 
stiffer than non-cancerous tissue (536), and this can enhance their growth (537). It is 
well known that cells are able to sense and respond to the stiffness of a substrate 
(538). Migration kinetics on varying substrate moduli have been investigated. These 
studies demonstrate that increased stiffness is proportionate to increased spreading 
(539, 540). In contrast, cytokine secretion has been shown to decrease on stiffer 
substrates (541). Therefore, the use of the protein capture assay on substrates of 
varying moduli, such as hydrogels (542) or silicone (543), would address how these 
structures can alter the response of NK cells, not only with PFN but other secreted 
factors. 
 
The correlation between perforin secretion and NK cell intracellular signalling 
 
The data here show for the first time that NK cells vary the amount of PFN secreted 
depending on the amount of ligand bound. This may be caused by fluctuations in 
signalling cascades with a direct impact on the number of LG recruited and fusing at 
the synapse. What impact NK cell intracellular signalling, and the specific amount of 
signalling, has on PFN secretion could be directly tested. To do this, propagation of 
activating signals within NK cells should be assessed. Activating signalling pathways 
are kinase cascades of tyrosine phosphorylation. Using Western blotting or flow 
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cytometric analysis, the amounts of phosphorylated proteins, for example Vav1, in 
response to different ligand densities of activating ligand. This would address 
whether greater ligand density results in a greater amount of signalling within the NK 
cell. SiRNA could be used to induce a partial KD of Vav1. These KD cells could then 
be incubated on increasing densities of activating ligand and PFN secretion 
compared to untransfected control cells. If signalling through activating receptors is 
responsible for increased PFN secretion, the KD cells would not be able to release 
comparable amounts. SiRNA could be used to KD a number of proteins and kinases 
within the cascade to fully decipher which proteins control the amount of PFN that is 
released at the synapse. 
 
Comparison of perforin secretion by fresh and IL-2 expanded NK cells 
 
Experiments assessing PFN secretion were performed on pNK cells that had been 
expanded in IL-2 and 6-day rested prior to use. Co-ligation of LFA1 and CD16 
increased the amount of PFN secreted. This is in contrast to a study performed by by 
Bryceson et al, where no change, or even a negative effect, was reported. These 
differences may be due to the use of IL-2 to activate NK cells, which has a significant 
impact on NK cells, altering their receptor profiles (544-546) and gene expression 
(486). To further unravel the effects of IL-2, and how it can alter the responses of NK 
cells, these experiments could be repeated on freshly isolated NK cells and IL-2-
expanded cells from the same donor, providing a direct comparison of how IL-2 
stimulation affects PFN secretion.  
 
The effect of cytokine stimulation on serial NK cell PFN secretion 
 
One of the major obstacles to increasing NK cell-mediated lysis in cancer patients is 
the identification of the most appropriate method to expand NK cells. This can be 
mediated through the addition of IL-2 or IL-15 (302). Stimulation of NK cells to 
improve their ability to serially lyse tumours could provide another mechanism to 
enhance tumour cell clearance. The data presented in this thesis suggest that 
ADCC-mediated lysis, when preceded by natural cytotoxicity, can still efficiently 
induce PFN secretion by NK cells. Previous work has shown that IL-15 increases 
NKG2D-mediated lysis in vitro (547), potentially via upregulating components of the 
cytotoxic machinery. Other studies have also demonstrated the crucial role of IL-15 in 
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vivo. Poly(I:C) activation of NK cells is dependent on interaction with NK cells (548), 
where IL-15 is trans-presented to NK cells (35, 549). In addition, IL-15-unresponsive 
NK cells have been shown to induce reduced NKG2D-mediated cytotoxicity (550, 
551). Collectively, these data demonstrate an important role for IL-15 in NK cell 
mediated cytolysis. For this reason, the effect that cytokine stimulation has on NK cell 
secretion of PFN, and how it may modulate serial secretion of PFN, should be 
investigated. This could reveal how cytokines could be used to enhance target killing. 
The protein capture assay could be used for this purpose. Coupling cytokine 
treatment of NK cells to enhancement of ADCC responses may be a route to 
enhance cytolysis of tumour cells. 
 
Estimation of perforin secreted by NK cells 
 
The methods used to estimate the concentrations of PFN within the synapse use 
reported measurements of the synapse to estimate PFN secretion from the data 
collected following NK cell interaction with an activtaing glass slide. The major 
drawback of this technique is the requirement for some educated guess work. The 
ABC of QSC beads were used to estimate the number of antibodies bound at the 
bead surface. The binding capacity of anti-PFN antibodies and rPFN are assumed to 
be an average of one. Therefore, to obtain a more accurate reading of PFN, different 
approaches are required. This could include the use of radioactive isotypes. The 
measurement of radioactivity is significantly more accurate than fluorescence 
intensity of a fluorophore. This would significantly reduce the error in the system. By 
using radioactively labelled antibodies and rPFN, the amounts of PFN that binds to 
beads and antibodies could be quantified in a step-wise manner. Radioactive anti-
PFN antibodies would be incubated with QSC beads then assessed by scintillation. 
These values could be compared against those obtained with a known number of 
antibodies in solution to give accurate numbers bound per bead. Once these ABC 
are known, radioactively labelled rPFN would be incubated with anti-PFN-loaded 
beads (using the same clone but unlabelled) and measured by scintillation. Again, 
readings could be compared to known concentrations of rPFN in solution and thus, 
the amount of PFN bound could be calculated per bead. Finally, the amount of rPFN 
bound to the beads could be determined by the incubation of radioactively labelled 
antibodies against the captured PFN. This could be either correlated to previously 
measured fluorescence intensity or, radioactively labelled anti-PFN could be used to 
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stain captured PFN in the protein capture assay. This could provide a more accurate 
estimation of the number of PFN molecules secreted by NK cells. 
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6.5 Long Term Developments 
 
Blockade of proteins secreted across the immune synapse in vivo 
 
The data in this thesis have revealed a novel role of the NK cell IS. Most significantly, 
the data demonstrate that small domain antibodies, dAbs, are able to penetrate the 
synaptic cleft. A dAb targeted to proteins directly secreted across the IS could act to 
block their function. Whilst the effects of specifically targeted dAbs could be tested in 
vitro (cytotoxic release assays, etc.), administering them to an model organism would 
directly address the systemic effects of blocking proteins secreted by NK cells, and 
would test whether such an antibody-based therapeutic could have an effect 
physiologically. 
 
The development of the non-obese diabetic (NOD) mouse model (552, 553) has 
enabled the dissection of many molecular pathways involved in the development of 
autoimmune diabetes. Within 3 – 4 weeks of neonatal development, T cells, B cells, 
NK cells and DC infiltrate the islets of Langerhans and attack the tissues, resulting in 
the development of type 1 DM. Importantly, studies have shown that PFN-deficient 
NOD mice have a delayed onset of diabetes, suggesting that PFN plays a significant 
role in disease progression (554). Therefore, the infusion of dAb against PFN could 
begin to address whether or not such therapies can be used as an alternative to – or 
in combination with – traditional therapies to reduce destruction of healthy tissues.  
 
The production of dAb against a specific target is both time consuming and complex, 
requiring a number of stages of affinity maturation (390). However, the use of a 
phage-display library enables the production of dAb against a large number of 
antigens. Using this system, a dAb against PFN, or a specific cytokine, could be 
developed. This dAb could then used to treat a number of conditions. For instance, 
autoimmunity is initiated by a number of factors, including aberrant signalling and the 
recognition of ‘self’ antigens as ‘foreign’. This promotes disease onset and 
progression. This is not only controlled by T cells, but involves interactions between a 
number of immune cells (555). The progression of these diseases is a combination of 
both cytokine secretion and autologous cell-mediated lysis. Whilst therapies to bind 
soluble secreted factors can ameliorate some diseases, these therapies do not target 
proteins secreted across the IS during intercellular communication. It is in this setting 
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that dAb may offer a novel treatment, with their ability to access the IS and proteins 
within it. Targets that conventional therapies are unable to reach. 
 
The data in this thesis have laid groundwork demonstrating that the IS can be 
accessed by dAb. The development of dAb against proteins directly secreted across 
the synapse may provide a novel tool to prevent the destruction of autologous tissue. 
By using such models as the well-established NOD mouse, dAb could be 
investigated to determine whether or not they are effective and the extent of their 
efficacy. 
 
Directing the cytolysis of NK cells and promoting serial killing 
 
The data show that NK cells are able to respond to increased ligand density by 
secreting enhanced amounts of PFN (Figure 5.4 and 5.5). In addition, PFN secretion 
could be restored to initial amounts by CD16 ligation following serial stimulation 
through NKG2D (Figure 5.8 and 5.10). This phenomenon may be used to improve 
NK cell-mediated lysis of tumour cells. Previous work has shown that antibodies can 
be used to direct the NK cell-mediated lysis of tumour cells (320, 466, 556). This can 
be done using ‘dumbbell’ antibodies (such as two dAb connected by a linker peptide 
chain) that bind both tumour surface targets and NK cell receptors, such as NKG2D 
(472). Another approach involves redirected NK cell-mediated lysis, binding 
antibodies against NK cell receptors to the Fc receptors of target cells (557). 
 
Whilst these studies have demonstrated that antibodies can be successfully used to 
mediate NK cell lysis of tumour cells, the data in this thesis highlight the effects that 
receptor ligation can have on PFN secretion. Therefore, to develop novel strategies 
to improve tumour cell clearance, various antibody combinations, or serial binding of 
antibodies, can be investigated to determine which approach provides the most 
effective response from NK cells. Specifically, data here show that CD16 ligation can 
trigger increased PFN secretion after NKG2D ligation. Thus, the application of 
antibodies that bind tumour-specific targets and trigger lysis through NKG2D could 
be administered initially. Next, antibodies that bind the same tumour targets, but 
ligate the ADCC receptor CD16, could then be administered. This may improve the 
NK cell cytotoxic response to tumour cells, increasing serial lysis of target cells. 
These experiments could be trialled first in vitro; assessing the ability of NK cells to 
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lyse a number of target cells with an antibody ligating NKG2D, then using a second 
antibody that targets such as CD16, as used in studies detailed here. A range of 
antibody combinations in tandem with different activating receptors could be tested to 
determine the most effective regimen to maintain maximum PFN secretion following 
serial lysis of tumour cells. 
 
Once the most successful combinations have been determined, these antibodies 
could be administered to murine cancer models to assess their efficacy in vivo. Of 
course, for these studies murine cells must be first used in the in vitro screening 
process. There are a number of techniques to model cancer in the mouse (e.g. 
microinjection of foreign DNA, endogenous gene locus disruption, Cre-loxP inducible, 
RNA interference and virus-mediated gene delivery) that could be useful in this 
setting (558). The protein capture assay demonstrated here could be used in 
combination with in vivo mouse studies to determine the efficacy of antibody-based 
therapies for increasing cell-mediated lysis of tumour cells. These therapies do not 
have to be restricted to NK cells, as CTL-mediated lysis could also be exploited to 
increase the clearance of tumour cells further. 
 
Repeated stimulation of NK cells has revealed that the receptors ligated has a 
profound effect on the ability of an NK cell to serially secrete PFN. These findings 
can inform future studies using mouse models to study their efficacy in vivo. This 
may lead to the development of novel therapies to increase cell-mediated lysis of 
tumour cells. 
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6.6 Concluding Remarks 
 
The NK cell IS is a dynamic cell-cell interface essential for detecting and lysing virally 
infected or transformed cells. Confocal microscopy has demonstrated the sensitivity 
of this interaction to receptor-ligand complex formation, during both the secretion of 
cytotoxic mediators and the clearance of extracellular molecules contained within the 
synaptic cleft. The development of a range of innovative, multidisciplinary techniques 
discussed here has facilitated a greater understanding of how NK cells respond to 
extracellular factors. Future work will further enhance our understanding of the 
cellular mechanisms, such as structural assembly, and the complex nature of 
signalling at the IS.  This has the potential to contribute to enhanced therapeutic 
manipulation of NK cell function, providing improved efficacy in the prevention or 
eradication of disease. 
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